Collaborative Testing Services, Inc
FORENSIC TESTING PROGRAM

P.O. Box 650820
Sterling, VA 20165-0820
e-mail: forensics@cts-interlab.com
Telephone: +1-571-434-1925
Web site: www.cts-forensics.com

Blood Drug Analysis
Test No. 22-5661 Summary Report

Each sample set contained blood samples from three individual cases with unique case scenarios. Participants were requested to analyze the blood samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used. Data were returned from 140 participants and are compiled into the following tables:

This report contains the data received from the participants in this test. Since these participants are located in many countries around the world, and it is their option how the samples are to be used (e.g., training exercise, known or blind proficiency testing, research and development of new techniques, etc.), the results compiled in the Summary Report are not intended to be an overview of the quality of work performed in the profession and cannot be interpreted as such. The Summary Comments are included for the benefit of participants to assist with maintaining or enhancing the quality of their results. These comments are not intended to reflect the general state of the art within the profession.

Participant results are reported using a randomly assigned "WebCode". This code maintains participant's anonymity, provides linking of the various report sections, and will change with every report.

Manufacturer's Information

Each sample set contained blood samples from three cases, each with an individual case scenario. Each case sample consisted of two grey-topped vials containing human blood. Participants were asked to analyze the blood samples and report the presence of any drugs/metabolites and quantitative data obtained (including uncertainty).

SAMPLE PREPARATION:
The human blood used in this test was from different lots, the blood used for item 2 tested positive for THC and its metabolites prior to being obtained from the commercial supplier.

A stock solution of each drug was used to spike specific items. These solutions were obtained in sealed ampoules and were not opened until needed for production. Items were prepared at separate times using the following procedure.

ITEMS 1, 2, and 3 (PREPARATION):
Item preparation consisted of adding a predetermined amount of drug stock solution to human whole blood. It was stirred before pipetting the mixture into each of the pre-labeled vials, which contained Potassium Oxalate and Sodium Fluoride. The vials were sealed and inverted multiple times to mix the preservatives in the vials with the blood solution. All vials were placed in a refrigerator immediately after production and stored there until the sample sets were prepared.

SAMPLE SET ASSEMBLY:
Each sample set contained two vials of each of the three items and placed into a Department of Transportation regulated shipping container. The sample packs were then returned to the refrigerator until shipment.

VERIFICATION:
The laboratories that conducted predistribution testing reported results for all three items through either screening methods and/or confirmatory methods that correlated with production data and consensus responses.

Item 1 Drug (Concentration)	Item 2 Drug (Concentration)	Item 3 Drug (Concentration)
MDMA (360 ng/mL)	Methadone (400 ng/mL)	Heroin (150 ng/mL)
MDA (55 ng/mL)	EDDP (5.8 ng/mL**)	6-MAM (40 ng/mL**)
	THC (1.1 ng/mL**)	Morphine (1,050 ng/mL)
	Carboxy THC (45 ng/mL**)	
	Hydroxy THC (0.9 ng/mL**)	

Please note that the preparation concentration is the value used for calculations during the test preparation phase and may not necessarily represent the final concentration of the samples. It is advised to wait for the Grand Mean statistics available in the Summary and Individual Reports before evaluating performance.

**These analytes were not added to the sample during production by CTS, but were either present in the original blood matrix, or are a natural metabolite of the analyte added during production. Quantitative results were reported for these analytes by at least 10 participants, the Grand Mean of those results is presented here.

Summary Comments

This test was designed to allow participants to assess their proficiency in the examination for the presence and concentration of drugs and/or metabolites in blood. The sample sets provided to participants contained blood samples from three individual cases with unique scenarios. Each case sample consisted of two vials containing 10mL human blood (20mL total). Participants were requested to analyze the blood samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used (Refer to the Manufacturer's Information for preparation details).

There were 139 participants who reported screening results for Item 1 with 84 reporting the presence of MDMA and 68 participants reporting the presence of MDA. Of the 132 participants who reported confirmatory results for Item 1, 125 (94.7%) reported the presence of MDMA and 119 (90.2%) reported the presence of MDA.

There were 139 participants who reported screening results for Item 2 with 111 reporting the presence of Methadone and 144 reporting the presence of Cannabinoids. THC and its metabolites were not added to the sample by CTS during production, but were present in the original blood matrix. Of the 134 participants who reported confirmatory results for Item 2, 127 (94.8%) reported the presence of Methadone, 25 (18.7%) reported the presence of EDDP, 63 (47.0%) reported the presence of THC, 110 (82.1%) reported the presence of Carboxy THC and 14 (10.4%) reported the presence of Hydroxy THC.

There were 139 participants who reported screening results for Item 3. Most commonly reported was the presence of Opiates/Opioids by 77 participants, 70 participants reported the presence of 6-MAM and 69 reported presence of Morphine. 6-MAM was not added to the sample by CTS during production, it is a natural metabolite of the analyte Heroin added during production. Of the 128 participants who reported confirmatory results for Item 3, 124 (96.9%) reported the presence of 6-MAM, and 126 (98.4%) reported the presence of Morphine.

For all three items, immunoassay was the most common screening method. For Item 2 and 3, LC/MS/MS was the most common confirmatory method used to analyze the samples. For Item 1, GC/MS was the most common confirmatory method used to analyze the samples.

If a participant indicated that the confirmatory quantitative result was a single determination and reported in ng/mL, the conclusive quantitative result was included in the raw data table. The raw data was used to calculate the grand mean and standard deviation for each item and are supplied to assist the participants and accrediting bodies in determining the acceptability of results. There were a total of seven participants determined to have “extreme” data (±3 STD from grand mean) within the statistical analyses: five participants in Item 1, three for MDMA and two for MDA, two participants in Item 2, one for Methadone and one for THC.

Screening Results - Item 1

TABLE 1A

Item Scenario:

Case 1: A 22 year-old female was pulled for running a red light. A Drug Recognition Expert arrived and noticed that the individual had dilated pupils and seemed disorientated. The result of a breath alcohol test was 0.00%. Blood was collected 90 minutes later.

Item Contents and Preparation Concentration: MDMA (360 ng/mL)
MDA (55 ng/mL)

WebCode	Screening Results
2A9FUZ	MDMA (BuAC drug screen) MDA (SMA confirmation 1st test)
2DWHAM	MDA- MDMA
2JJHF2	SMA
2XGFQD	Methamphetamine
2Z3DTA	MDMA
32ZWJG	ELISA screening negative, GC-MS screen detected MDMA (methylenedioxymethamphetamine). Confirmed MDMA on GC-MS SMA confirmation, also detected MDA (methylenedioxyamphetamine). Confirmed both MDMA and MDA on second GC-MS SMA confirmation.
384XJC	Methamphetamine
3PLWPA	MDA, MDMA, citalopram, diphenhydramine
48GQV6	methylenedioxymethamphetamine (MDMA) methylenedioxyamphetamine (MDA)
48L4J2	Methamphetamine and amphetamine
4BHXCW	amphetamine, methampethamine
4D2WJY	Cannabinoid
4GLYB6	3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine
4TY2W3	MDA, MDMA
4XXDWA	Methamphetamine
6ED9K2	Methylenedioxymethamphetamine, Methylenedioxyamphetamine
6QPB7Y	MDA MDMA
6ZE2TR	MDMA MDA Zolpidem Diphenhydramine Citalopram

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
73XK23	SMA class, THC class
7DZVHQ	atenolol, citalopram, citalopram metabolite (norcitalopram), MDMA, MDA, paracetamol, zolpidem
7NV3EA	3,4- METHYLENEDIOXYMETHAMPHETAMINE (MDMA) 3,4-METHYLENEDIOXYAMPHETAMINE (MDA)
7RX64B	Methylenedioxyamphetamine (MDA) Methylenedioxymethamphetamine (MDMA)
7W827Z	MDA MDMA
7WPAVU	Methamphetamine and Amphetamine
83E82W	Methamphetamine class
8E3B78	MDA 3, 4-Methylenedioxymethamphetamine (MDMA)
8X2ATA	MDMA- 3,4 METHYLENEDIOXYAMPHETAMINE
8YE38N	MDMA, MDA, Carvedilol, citalopram, diphenhydramine, topiramate, zolpidem
94Y64T	amphetamine, MDMA/methamphetamine
99WWZW	methamphetamine
9LYHDU	MDA MDMA
9QXMGZ	Methamphetamine class
9T3E8R	3,4-Methylenedioxymethamphetamine (MDMA) 3,4-Methylenedioxyamphetamine (MDA)
AAN8KX	MDA MDMA
AD6HL9	Methylenedioxyamphetamine (MDA), Methylenedioxymethamphetamine (MDMA)
AH24FW	Methamphetamine
AMTEPV	Methamphetamine
ATKL94	Methamphetamine
AUF4A6	Methamphetamine (ELISA) MDMA MDA Diphenhydramine Citalopram

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
AV6JBZ	SMA
AX96AX	3,4-methylenedioxyamphetamine 3,4-methylenedioxymethamphetamine
B8Z4FX	Amphetamine, Methamphetamine
BG3H2V	Amphetamine/MDA, Methamphetamine/MDMA, MDMA
BRK67Q	Methylenedioxyamphetamine (MDA) Methylenedioxymethamphetamine (MDMA)
C6NP8U	MDA MDMA
CHA3KP	Methamphetamines, Amphetamines
DFZA93	Methamphetamine Amphetamine
DZNWQ6	methamphetamine/MDMA, amphetamine
E9WNVT	class: Amphetamine/MDA class: Methamphetamine/MDMA
EBYZ3T	MDMA MDA Zolpidem; Zolpidem Metabolite; Citalopram; desmethyl-citalopram
EJUN9X	Methamphetamine, Zolpidem, Amphetamine
EYPBEP	Methamphetamine ELISA
FCP9XF	MDMA MDA Diphenhydramine
FNAJNU	MDA, MDMA, Citalopram
G4F3ZR	MDA (Methylenedioxyamphetamine), MDMA (methylenedioxy-methamphetamine)
GBEU4E	Amphetamines: 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxymethylamphetamine
GBZ8TR	3,4-Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), Zolpidem, Chlorpheniramine, Citalopram, Diphenhydramine
GMBXAU	MDMA MDA

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
GNH4MU	MDMA, MDA
GV3BAT	Methamphetamine, Zolpidem, Amphetamine
GX9PTT	Citalopram/Escitalopram 3.4-Methylenedioxyamphetamine (MDA) 3,4-Methylenedioxymethamphetamine (MDMA) Zolpidem
HAVBCT	Amphetamine, Methamphetamine
HHQ8KP	Methylenedioxyamphetamine, Methylenedioxymethamphetamine
HNC8RP	[Although participant indicated that drugs were identified through screening, none were reported.]
HPN7NJ	Symphathomimetic Amines (SMA)
HX9XMX	MDA MDMA
JVBAFM	3,4-Methylenedioxyamphetamine 3,4-Methylenedioxymethamphetamine
JYTD4J	AMPHETAMINES MDMA/METHAMPHETAMINE
K9V49R	Methamphetamine
KBF2CN	Methamphetamine, Amphetamine
KCVE6R	Methamphetamine (Elisa)
KCWY4N	Amphetamines Methamphetamine/MDMA
KFBVAP	Amphetmaines
KQXJUR	Methamphetamines (ELISA) MDA MDMA Diphenhydramine
KQZDDX	SMA
KZKK8G	3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyamphetamine
L2C3MM	Citalopram, Diphenhydramine, MDA, MDMA, Topiramate
LCDNTL	MDA MDMA
LEFD8N	3,4-Methylenedioxymethamphetamine (MDMA)

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
LL2JQG	Amphetamines class
M6VE6P	Benzodiazepines, methamphetamine, zolpidem, amphetamine
M7FD9L	zolpidem
MDJ6PW	Methylenedioxymethamphetamine (MDMA)
NFFK3C	amphetamine methamphetamine/MDMA
NKERRF	MDMA, MDA
NRZMTK	3,4-methylenedioxymethamphetamine 3,4-methylenedioxyamphetamine
P6ZTCG	Amphetamine Methamphetamine
P96AXR	Methylenedioxymethamphetamine (MDMA)
PUMLNU	(es)citalopram MDA MDMA diphenhydramine
PXV4JF	MDA, MDMA
Q7WJ9N	Methamphetamine
QHJQ2H	Amphetamines
QVTNPJ	MDA, MDMA, citalopram
R3R9RE	Methamphetamine
R776WF	Amphetamine and Methamphetamine
RBG2Y6	citalopram/, diphenhydramine, MDA, MDMA, zolpidem and acetaminophen
RKZJ8H	Possible Amphetamine Class; Possible MDMA
RZXJ9J	Methamphetamine Amphetamine
T4R3JF	3,4-methylenedioxyamphetamine 3,4-methylenedioxymethamphetamine
TCB9H9	3,4-methylenedioxyamphetamine 3,4-methylenedioxymethamphetamine Zolpidem Citalopram Diphenhydramine

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
TDHL6F	Amphetamine Methamphetamine
TG6ZTQ	Methylenedioxyamphetamine (MDA) Methylenedioxymethamphetamine (MDMA)
TLBUML	Methamphetamine & MDMA
TMTPBE	MDA, MDMA
TTC34L	Methamphetamine/Amphetamine class
TV2HHN	Methylenedioxyamphetamine (MDA) Methylenedioxymethamphetamine (MDMA)
TXM4BC	Methylenedioxymethamphetamine (MDMA), Methylenedioxyamphetamine (MDA)
TYY2KM	No drugs detected utilizing screening methods.
U97X4J	methamphetamine
UECQXF	Methamphetamine Amphetamine
UKXLVD	MDA MDMA
UNHCLG	MDMA MDA
UTD3UE	Amphetamine class Methamphetamine class
UWBMVC	Methamphetamine
V7VEG8	amphetamine, methamphetamine
VEMV6C	3,4-methylenedioxymethamphetamine (MDMA) 3,4-methylenedioxyamphetamine (MDA)
VENQTN	No drugs detected utilizing screening methods.
W7DN8N	MDMA
WK8BDF	Methamphetamine
WQBGNC	MDA (3,4-Methylenedioxyamphetamine), MDMA (3,4-Methylenedioxymethamphetamine)
XA7AAA	3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA)
XC8AA8	MDA, MDMA
XL2F8E	Methamphetamine

TABLE 1A: Screening Results - Item 1

WebCode	Screening Results
XNLEBB	Methylenedioxymethamphetamine (MDMA)
XTF8T7	MDA and MDMA
XWGAH8	MDMA MDA Topiramate Citalopram Diphenhydramine Cannabinoids
XXPKB6	Methylenedioxymethamphetamine (MDMA)
XZXJLD	MDMA MDA Zolpidem Diphenhydramine
Y689P8	Methamphetamine
Y8VMDG	MDA MDMA
YETEH6	MDA and MDMA
YPEHP4	MDMA, Zolpidem
YTERZ7	Amphetamine and methamphetamine
YVYP33	No drugs detected utilizing screening methods.
YX7XE9	3,4-Methylenedioxymethamphetamine (MDMA), 3,4-Methylenedioxyamphetamine (MDA)
Z9PR8G	Zolpidem, 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-methamphetamine (MDMA).
ZBUHCB	methamphetamine/MDMA, amphetamine
ZCJXD7	Methamphetamine Amphetamine MDMA
ZM8KVM	No drugs detected utilizing screening methods.

Screening Response Summary for Item 1	Participants: 139
MDMA:	84
MDA	68
Methamphetamine/Amphetamine	72
Diphenhydramine	12
Other drugs/metabolites detected:	46
No drugs/metabolites detected Utilizing Screening Methods:	4

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 1

TABLE 1B

Item Scenario:

Case 1: A 22 year-old female was pulled for running a red light. A Drug Recognition Expert arrived and noticed that the individual had dilated pupils and seemed disorientated. The result of a breath alcohol test was 0.00%. Blood was collected 90 minutes later.

Item Contents and Preparation Concentration: MDMA (360 ng/mL)
MDA (55 ng/mL)

What drugs/metabolites were detected in Item 1?

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2A9FUZ	MDMA	✓			
	MDA	✓			
2DWHAM	MDMA	✓			
	MDA	✓			
2JJHF2	MDMA (methylenedioxymethamphetamine)	✓			
	MDA (methylenedioxyamphetamine)	✓			
2XGFQD	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Diphenhydramine	✓			
2Z3DTA	MDMA	✓			
	MDA	✓			
32ZWJG	MDMA (methylenedioxymethamphetamine)	✓			
	MDA (methylenedioxyamphetamine)	✓			
384XJC	MDMA	✓	Positive		ug/mL
	MDA	✓	Positive		ug/mL
	Additional Analyte(s) Reported				
	Diphenhydramine	✓	Positive		ug/mL
3PLWPA	MDMA		301.89	36.22	ng/mL
	MDA		52.68	12.64	ng/mL
	Additional Analyte(s) Reported				
	Citalopram		5.49	0.98	ng/mL
48GQV6	methylenedioxymethamphetamine (MDMA)	✓			
	methylenedioxyamphetamine (MDA)	✓			
48L4J2	3,4-Methylenedioxymethamphetamine (MDMA)		0.34	± 0.06	µg/mL
	3,4-Methylenedioxyamphetamine (MDA)		52	± 9	ng/mL

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
4BHXCW	methylenedioxymethamphetamine		0.384	0.060	mcg/ml
	methylenedioxyamphetamine		0.056	0.009	mcg/ml
4D2WJY	Methylenedioxymethamphetamine (MDMA)	✓			
	Methylenedioxyamphetamine (MDA)	✓			
4GLYB6	3,4-methylenedioxymethamphetamine		0.35	0.11	mg/L
	3,4-methylenedioxyamphetamine		70	21	µg/L
4TY2W3	MDMA	✓			
	MDA	✓			
4XXDWA	3,4-methylenedioxymethamphetamine (MDMA)		0.35	+/-0.03	ug/ml
	3,4-methylenedioxyamphetamine (MDA)		0.06	+/-0.01	ug/ml
6ED9K2	Methylenedioxymethamphetamine	✓			
	Methylenedioxyamphetamine	✓			
6QPB7Y	MDMA		328.7	19.7	ng/mL
	MDA		61.8	9.3	ng/mL
6ZE2TR	MDMA		388	43	ng/mL
	MDA		58	6	ng/mL
	Additional Analyte(s) Reported				
	Zolpidem	✓			
73XK23	MDMA - Methylenedioxymethamphetamine	✓			
	MDA - Methylenedioxyamphetamine	✓			
7DZVHQ	MDMA		0.37	+/- 15%	mg/L
	MDA		0.05	+/- 15%	mg/L
	Additional Analyte(s) Reported				
	atenolol	✓			
	citalopram	✓			
	citalopram metabolite (norcitalopram)	✓			
	paracetamol	✓			
	zolpidem	✓			
7NV3EA	MDMA	✓			
	MDA	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
7RX64B	Methylenedioxymethamphetamine	✓			
	Methylenedioxyamphetamine	✓			
7W827Z	MDMA	✓			
	MDA	✓			
7WPAVU	Methylenedioxymethamphetamine		0.379	0.059	mcg/mL
	Methylenedioxyamphetamine		0.056	0.009	mcg/mL
83E82W	MDMA	✓			
	MDA	✓			
8E3B78	3,4-Methylenedioxymethamphetamine (MDMA)		377.86	41.56	ng/mL
	MDA		56.84	7.38	ng/mL
8X2ATA	MDMA	✓			
	MDA	✓			
8YE38N	Methylenedioxymethamphetamine (MDMA)		360	72	ng/mL
	Methylenedioxyamphetamine (MDA)		66	13	ng/mL
94Y64T	MDMA	✓			
	MDA	✓			
99WWZW	methylenedioxymethamphetamine	✓			
	methylenedioxyamphetamine	✓			
9LYHDU	MDMA		356	19,9%	ng/mL
	MDA		51,0	17,0%	ng/mL
9QXMGZ	MDMA		0.37	0.05	mg/L
	MDA		0.057	0.007	mg/L
9T3E8R	3,4-Methylenedioxymethamphetamine		560	170	ng/mL
	3,4-Methylenedioxyamphetamine (MDA)		55	17	ng/mL
AAN8KX	MDMA		316.1	69.5	ng/mL
	MDA		48.8	11.7	ng/mL
AD6HL9	Methylenedioxymethamphetamine (MDMA)	✓			
	Methylenedioxyamphetamine (MDA)	✓			
AH24FW	MDMA	✓			
	MDA	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
AMTEPV	MDMA	✓	Positive		
	MDA	✓	Positive		
ATKL94	MDMA		0.37	+/-0.04	ug/ml
	MDA		0.06	+/- 0.01	ug/ml
AUF4A6	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Citalopram	✓			
	Diphenhydramine	✓			
AV6JBZ	MDMA	✓			
	MDA	✓			
AX96AX	3,4-methylenedioxymethamphetamine		0.31	0.09	mg/L
	3,4-methylenedioxyamphetamine		58	17	mcg/L
B8Z4FX	3,4-Methylenedioxymethamphetamine (MDMA)		0.36	0.07	µg/mL
	3,4-Methylenedioxyamphetamine (MDA)		56	10	ng/mL
BG3H2V	MDMA	✓			
	MDA	✓			
BRK67Q	Methylenedioxymethamphetamine (MDMA)		270	84	ng/mL
	Methylenedioxyamphetamine (MDA)		58	18	ng/mL
C6NP8U	MDMA	✓			
	MDA	✓			
CHA3KP	3,4-methylenedioxymethamphetamine (MDMA)		374	37	ng/mL
	3,4-methylenedioxyamphetamine (MDA)		62	9	ng/mL
DZNWQ6	MDMA	✓			
	MDA	✓			
E9WNVT	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Cotinine	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
EBYZ3T	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	CITALOPRAM	✓			
	DESMETHYL-CITALOPRAM	✓			
	ZOLPIDEM	✓			
	ZOLPIDEM Metabolite	✓			
EJUN9X	3,4-Methylenedioxymethamphetamine		445	130	ng/mL
	3,4-Methylenedioxyamphetamine		67	19	ng/mL
	Additional Analyte(s) Reported				
	Diphenhydramine		4.1	1.4	ng/mL
EYPBEP	MDMA	✓			
	MDA	✓			
FCP9XF	Methylenedioxymethylamphetamine		0.37	20%	mg/L
	Methylenedioxyamphetamine		0.068	9.4	mg/L
	Additional Analyte(s) Reported				
	Diphenhydramine	✓			
FNAJNU	MDMA		308.86	37.06	ng/mL
	MDA		55.02	13.20	ng/mL
	Additional Analyte(s) Reported				
	Citalopram		5.72	1.02	ng/mL
G4F3ZR	MDMA		411.16	102.79	ng/mL
	MDA		69.68	17.42	ng/mL
GBEU4E	3,4-Methylenedioxymethylamphetamine		370		ng/mL
	3,4-Methylenedioxyamphetamine		50		ng/mL
GBZ8TR	3,4-Methylenedioxymethamphetamine (MDMA)		0.43	0.13	mg/L
	3,4-Methylenedioxyamphetamine (MDA)		76	23	µg/L
GMBXAU	MDMA		253	30	ng/ml
	MDA		55	30	ng/ml
GNH4MU	MDMA	✓			
	MDA	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
GV3BAT	3,4-methylenedioxymethamphetamine (MDMA)		360	98	ng/mL
	3,4 Methylenedioxyamphetamine (MDA)		53	15	ng/mL
	Additional Analyte(s) Reported				
	Diphenhydramine		3.1	1.1	ng/mL
GX9PTT	3,4-Methylenedioxymethamphetamine (MDMA)	✓			
	3,4-Methylenedioxyamphetamine (MDA)	✓			
	Additional Analyte(s) Reported				
	Citalopram/Escitalopram	✓			
HHQ8KP	Methylenedioxymethamphetamine	✓			
	Methylenedioxyamphetamine	✓			
HNC8RP	**Additional Analyte(s) Reported**				
	Citalopram	✓			
	Norcitalopram	✓			
	Paracetamol	✓			
	Zolpidem	✓			
HPN7NJ	Methylenedioxymethamphetamine	✓			
	Methylenedioxyamphetamine (MDA)	✓			
HX9XMX	MDMA		395.0		ng/mL
	MDA		62.4		ng/mL
JYTD4J	3,4-MDMA	✓			
K9V49R	Methylenedioxymethamphetaine(MDMA)	✓			
	Methylenedioxyamphetamine(MDA)	✓			
KBF2CN	MDMA		0.34	+/-16%	ug/ml
	MDA		54	+/-13%	ng/ml
KCVE6R	MDMA	✓			
	MDA	✓			
KFBVAP	MDMA (3,4-Methylenedioxy methamphetamine)	✓			
KQXJUR	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Diphenhydramine	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
KQZDDX	Methylenedioxymethamphetamine (MDMA)	✓			
	Methylenedioxyamphetamine (MDA)	✓			
KZKK8G	3,4-methylenedioxymethamphetamine		0.31	0.09	mg/L
	3,4-methylenedioxyamphetamine		58	17	µg/L
L2C3MM	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Topiramate	✓			
LCDNTL	Methylenedioxyamphetamine	✓			
LEFD8N	3,4-Methylenedioxymethamphetamine (MDMA)	✓			
	3,4-Methylenedioxyamphetamine (MDA)	✓			
LL2JQG	MDMA	✓			
	MDA	✓			
M6VE6P	3,4-Methylenedioxymethamphetamine		323	88	ng/mL
	3,4-Methylenedioxyamphetamine		50	14	ng/mL
	Additional Analyte(s) Reported				
	Diphenhydramine		3.0	1.1	ng/mL
M7FD9L	**Additional Analyte(s) Reported**				
	zolpidem	✓			
MDJ6PW	Methylenedioxymethamphetamine (MDMA)	✓			
	Methylenedioxyamphetamine (MDA)	✓			
NFFK3C	3,4-methylenedioxymethamphetamine	✓			
	3,4-methylenedioxyamphetamine	✓			
	Additional Analyte(s) Reported				
	Citalopram	✓			
NKERRF	MDMA		341.3	20.5	ng/mL
	MDA		62.9	9.4	ng/mL
NRZMTK	3,4-methylenedioxymethamphetamine		0.58	+/-0.17	mg/L
	3,4-methylenedioxyamphetamine		<0.05		mg/L
P6ZTCG	Methylenedioxymethamphetamine	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
P96AXR	Methylenedioxymethamphetamine (MDMA)	✓			
PUMLNU	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	(es)citalopram	✓			
	diphenhydramine	✓			
PXV4JF	MDMA	✓			
	MDA	✓			
Q7WJ9N	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Diphenhydramine	✓			
QHJQ2H	3,4-methylenedioxymethamphetamine		605		ng/mL
	3,4-methylenedioxyamphetamine		91		ng/mL
QVTNPJ	MDMA		300.11	36.01	ng/ml
	MDA		52.56	12.61	ng/ml
	Additional Analyte(s) Reported				
	Citalopram		5.45	0.98	ng/ml
R3R9RE	3,4-methylenedioxymethamphetamine	✓			
	3,4-methylenedioxyamphetamine	✓			
R776WF	3,4-Methylenedioxymethamphetamine (MDMA)		0.37	0.07	µg/mL
	3,4-Methylenedioxyamphetamine (MDA)		55	10	ng/mL
RBG2Y6	MDMA		360	-/+ 50	ng/mL
	MDA		70	-/+ 8	ng/mL
RKZJ8H	MDMA	✓			
	MDA	✓			
RZXJ9J	No drugs/metabolites detected utilizing confirmatory methods.				
T4R3JF	3,4-methylenedioxymethamphetamine		390 ng/mL	120	ng/mL
	3,4-methylenedioxyamphetamine		54 ng/mL	16	ng/mL
TCB9H9	3,4-methylenedioxymethamphetamine		0.36	0.11	mg/L
	3,4-methylenedioxyamphetamine		66	20	µg/L

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
TDHL6F	methylenedioxymethamphetamine	✓			
	methylenedioxyamphetamine	✓			
TG6ZTQ	MDMA	✓			
	MDA	✓			
TLBUML	MDMA		0.43	30%	ug/mL
	MDA		0.06	30%	ug/mL
TMTPBE	3,4 methylenedioxymethamphetamine		0.37	0.11	mg/L
	3,4 methylenedioxyamphetamine		LLC 50		µg/L
TTC34L	Methylenedioxymethamphetamine	✓			
	Methylenedioxyamphetamine	✓			
TV2HHN	MDMA	✓			
	MDA	✓			
TXM4BC	Methylenedioxymethamphetamine (MDMA)		0.388	0.069	mg/L
	Methylenedioxyamphetamine (MDA)		0.059	0.019	mg/L
TYY2KM	No drugs/metabolites detected utilizing confirmatory methods.				
U97X4J	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Diphenhydramine	✓			
UECQXF	No drugs/metabolites detected utilizing confirmatory methods.				
UKXLVD	MDMA	✓			
	MDA	✓			
UTD3UE	Methylenedioxymethamphetamine (MDMA)		0.32	0.12	mg/L
	Methylenedioxyamphetamine (MDA)		0.050	0.017	mg/L
UWBMVC	3,4-Methylenedioxymethamphetamine (MDMA)	✓			
	3,4-Methylenedioxyamphetamine (MDA)	✓			
V7VEG8	3,4-Methylenedioxymethamphetamine	✓			
	Methylenedioxyamphetamine	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
VEMV6C	3,4-methylenedioxymethamphetamine		0.40	0.12	mg/L
	3,4-methylenedioxyamphetamine		57	17	µg/L
VENQTN	Methylenedioxymethamphetamine	✓			
	Methylenedioxyamphetamine	✓			
W7DN8N	Methylenedioxymethamphetamine (MDMA)	✓			
	Methylenedioxyamphetamine (MDA)	✓			
WK8BDF	MDMA	✓	Positive		
	MDA	✓	Positive		
WQBGNC	mdma (3,4-Methylenedioxy methamphetamine)		0.42	0.13	mg/L
	mda (3,4-Methylenedioxyamphetamine)		lower than the lowest calibrator of 50 micrograms/liter		
XA7AAA	3,4-methylenedioxymethamphetamine (MDMA)		0.40	0.12	mg/L
	3,4-methylenedioxyamphetamine (MDA)		lower than the lowest calibrator of 50 ng/ml		
XC8AA8	MDMA	✓			
	MDA	✓			
XL2F8E	Methylenedioxymethamphetamine		0.38	0.04	ug/mL
	Methylenedioxyamphetamine		0.06	0.006	ug/mL
XNLEBB	Methylenedioxymethamphetamine (MDMA)	✓			
	Methylenedioxyamphetamine (MDA)	✓			
XTF8T7	MDMA		331.3	19.9	ng/mL
	MDA		60.6	9.1	ng/mL
XWGAH8	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Topiramate	✓			
XXPKB6	Methylenedioxymethamphetamine (MDMA)	✓			

TABLE 1B: Confirmatory Results - Item 1

What drugs/metabolites were detected in Item 1?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
XZXJLD	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Diphenhydramine	✓			
	Zolpidem	✓			
Y689P8	MDMA	✓			
	MDA	✓			
Y8VMDG	MDMA		297	8.81	ng/mL
	MDA		45	3,9	ng/mL
YETEH6	MDMA		349.7	21.0	ng/mL
	MDA		58.8	8.8	ng/mL
YPEHP4	MDMA	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
YTERZ7	3,4-methylenedioxymethamphetamine (MDMA)		0.35	±0.07	µg/ml
	3,4-methylenedioxyamphetamine (MDA)		50	±9	ng/mL
YVYP33	N-Methyl-3,4-methylenedioxyamphetamine	✓			
Z9PR8G	3,4-methylenedioxy-methamphetamine (MDMA)	✓			
	3,4-methylenedioxyamphetamine (MDA)	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
ZBUHCB	MDMA	✓			
	MDA	✓			
	Additional Analyte(s) Reported				
	Diphenhydramine	✓			
ZM8KVM	No drugs/metabolites detected utilizing confirmatory methods.				

Confirmatory Response Summary for Item 1	Participants: 132
MDMA:	125 (94.7%)
MDA:	119 (90.2%)
Other Identified Drugs/Metabolites:	41 (31.1%)
No Drugs/Metabolites Detected Utilizing Confirmatory Methods:	4 (3.0%)

Raw Data - Item 1

TABLE 1C

Item 1 Raw Data - MDMA
Preparation concentration: 360 ng/mL

WebCode	List of Raw Data determinations (ng/mL)					
3PLWPA	301.89				301.90	
48L4J2	345.49				345.50	
4BHXCW	384.00				384.00	
4GLYB6	360.30	346.60			353.50	
4XXDWA	355.00				355.00	
6QPB7Y	328.70				328.70	
6ZE2TR	395.92	380.40			388.10	
7DZVHQ	364.00	368.00			366.00	
7WPAVU	379.00				379.00	
8E3B78	377.86				377.90	
8YE38N	378.00	326.00	375.00		359.70	
9LYHDU	356.00				356.00	
9QXMGZ	394.00	395.00	350.00	336.00	368.80	
9T3E8R	583.57	534.40			559.00	X
AAN8KX	316.17				316.20	
ATKL94	372.00				372.00	
AX96AX	348.61	269.80			309.20	
B8Z4FX	360.70				360.70	
BRK67Q	270.00				270.00	
CHA3KP	373.55				373.60	
EJUN9X	445.00	499.00			472.00	
FCP9XF	362.00	375.00			368.50	
FNAJNU	308.86				308.90	
G4F3ZR	411.16				411.20	
GBEU4E	366.00	367.00			366.50	
GBZ8TR	392.28	476.20			434.20	
GMBXAU	253.22				253.20	
GV3BAT	360.00	365.00			362.50	
HX9XMX	395.00				395.00	
KBF2CN	344.01				344.00	
KZKK8G	267.29	348.30			307.80	
M6VE6P	323.00	334.00			328.50	

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - MDMA
Preparation concentration: 360 ng/mL

WebCode	List of Raw Data determinations (ng/mL)							
NKERRF	341.30						341.30	
NRZMTK	497.80	667.30					582.60	X
QHJQ2H	605.00						605.00	X
QVTNPJ	300.11						300.10	
R776WF	370.49						370.50	
RBG2Y6	355.53	364.60					360.00	
T4R3JF	380.38	396.00					388.20	
TCB9H9	447.92	276.60					362.30	
TLBUML	427.00						427.00	
TMTPBE	380.71	363.30					372.00	
TXM4BC	418.26	357.80					388.00	
UTD3UE	322.40						322.40	
VEMV6C	449.97	355.10					402.50	
WQBGNC	399.45	432.60					416.00	
XA7AAA	359.51	442.40					401.00	
XL2F8E	386.00						386.00	
XTF8T7	331.30						331.30	
Y8VMDG	296.00	305.00	289.00	281.00	301.00	307.00	296.50	
YETEH6	349.70						349.70	
YTERZ7	354.02						354.00	

Statistical Analysis for Item 1 - MDMA

Grand Mean	358.91	Number of Participants Included	49	Number of Participants without Raw Data or Data that was not reported in ng/mL	0
Standard Deviation	41.75	Number of Participants Excluded	3		

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - MDA
Preparation concentration: 55 ng/mL

WebCode	List of Raw Data determinations (ng/mL)					
3PLWPA	52.680				52.680	
48L4J2	52.024				52.020	
4BHXCW	56.000				56.000	
4GLYB6	84.590	54.500			69.550	
4XXDWA	610.00				610.00	X
6QPB7Y	61.800				61.800	
6ZE2TR	59.230	56.630			57.930	
7DZVHQ	51.000	50.000			50.500	
7WPAVU	56.000				56.000	
8E3B78	56.840				56.840	
8YE38N	70.000	59.000	70.000		66.330	
9LYHDU	51.000				51.000	
9QXMGZ	64.100	58.900	46.400	56.700	56.530	
9T3E8R	56.890	53.770			55.330	
AAN8KX	48.820				48.820	
ATKL94	63.000				63.000	
AX96AX	64.010	51.980			58.000	
B8Z4FX	56.171				56.170	
BRK67Q	58.000				58.000	
CHA3KP	62.170				62.170	
EJUN9X	67.000	73.000			70.000	
FCP9XF	70.000	67.000			68.500	
FNAJNU	55.020	55.470			55.250	
G4F3ZR	69.687				69.690	
GBEU4E	53.000	52.000			52.500	
GBZ8TR	69.860	82.120			75.990	
GMBXAU	55.390				55.390	
GV3BAT	53.000	57.000			55.000	
HX9XMX	62.400				62.400	
KBF2CN	53.717				53.720	
KZKK8G	52.630	63.020			57.830	
M6VE6P	50.000	52.000			51.000	
NKERRF	62.900				62.900	

TABLE 1C: Raw Data - Item 1

Item 1 Raw Data - MDA
Preparation concentration: 55 ng/mL

WebCode	List of Raw Data determinations (ng/mL)						Participant Mean	
NRZMTK	49.780	62.010					55.900	
QHJQ2H	91.000						91.000	X
QVTNPJ	54.240	52.560					53.400	
R776WF	55.758						55.760	
RBG2Y6	68.718	70.230	71.930				70.290	
T4R3JF	52.020	56.380					54.200	
TCB9H9	79.360	53.290					66.330	
TLBUML	58.000						58.000	
TMTPBE	37.580	32.550					35.070	
TXM4BC	61.730	56.040					58.890	
UTD3UE	50.100						50.100	
VEMV6C	63.270	50.220					56.750	
WQBGNC	37.780	42.550					40.170	
XA7AAA	35.070	43.970					39.520	
XL2F8E	63.000						63.000	
XTF8T7	60.600						60.600	
Y8VMDG	46.000	49.000	44.000	42.000	44.000	47.000	45.330	
YETEH6	58.800						58.800	
YTERZ7	50.196						50.200	

Statistical Analysis for Item 1 - MDA

Grand Mean	57.02	Number of Participants Included	50	Number of Participants without Raw Data or Data that was not reported in ng/mL	0
Standard Deviation	8.00	Number of Participants Excluded	2		

Reporting Procedures - Item 1

TABLE 1D - Item 1

WebCode	Quantitative Reporting Procedures *If quantitative analysis was performed, the reported concentrations are:*
3PLWPA	A single determination.
48GQV6	A single determination.
48L4J2	A single determination.
4BHXCW	A single determination.
4GLYB6	The mean of duplicate/several determinations.
4XXDWA	A single determination.
6ED9K2	A single determination.
6QPB7Y	A single determination.
6ZE2TR	The mean of duplicate/several determinations.
7DZVHQ	The mean of duplicate/several determinations.
7WPAVU	A single determination.
8E3B78	A single determination.
8YE38N	The mean of duplicate/several determinations.
9LYHDU	A single determination.
9QXMGZ	The mean of duplicate/several determinations.
9T3E8R	The mean of duplicate/several determinations.
AAN8KX	A single determination.
AMTEPV	A single determination.
ATKL94	A single determination.
AX96AX	The mean of duplicate/several determinations.
B8Z4FX	A single determination.
BRK67Q	A single determination.
CHA3KP	A single determination.
EJUN9X	Lowest of duplicate samples, truncated
FCP9XF	The mean of duplicate/several determinations.
FNAJNU	Sample was screened and confirmed on a quantitative method, the lower of the two values is the reported concentration
G4F3ZR	A single determination.
GBEU4E	The mean of duplicate/several determinations.
GBZ8TR	The mean of duplicate/several determinations.
GMBXAU	A single determination.
GV3BAT	Lower of the duplicate injections
HX9XMX	A single determination.

TABLE 1D: Reporting Procedures - Item 1

Quantitative Reporting Procedures	
WebCode	***If quantitative analysis was performed, the reported concentrations are:***
KBF2CN	A single determination.
KZKK8G	The mean of duplicate/several determinations.
M6VE6P	The lowest of the duplicate
NKERRF	A single determination.
NRZMTK	MDMA-duplicate mean, MDA-single
QHJQ2H	A single determination.
QVTNPJ	A quantitative method was utilized for screening, therefore, the lowest of the two determinations is utilized as the reported value
R776WF	A single determination.
RBG2Y6	MDMA: single; MDA: mean of duplicate
T4R3JF	The mean of duplicate/several determinations.
TCB9H9	The mean of duplicate/several determinations.
TLBUML	A single determination.
TMTPBE	The mean of duplicate/several determinations.
TXM4BC	The mean of duplicate/several determinations.
UTD3UE	A single determination.
VEMV6C	The mean of duplicate/several determinations.
WQBGNC	The mean of duplicate/several determinations.
XA7AAA	The mean of duplicate/several determinations.
XL2F8E	A single determination.
XTF8T7	A single determination.
Y8VMDG	The mean of duplicate/several determinations.
YETEH6	A single determination.
YTERZ7	A single determination.

Response Summary for Item 1	Participants: 55
A single determination:	29 (52.7%)
The mean of duplicate/several determinations:	19 (8.5%)
Other:	7 (12.7%)

Methods of Analysis - Item 1

TABLE 1E - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
2A9FUZ	Immunoassay	✓		
	GC/MS	✓	✓	
2DWHAM	GC/MS		✓	
2JJHF2	Immunoassay	✓		
	GC/MS	✓	✓	
2XGFQD	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	
2Z3DTA	Immunoassay	✓		
	LC/MS/MS		✓	
32ZWJG	Immunoassay	✓		
	GC/MS	✓	✓	
384XJC	Immunoassay	✓		
	GC/MS		✓	
	GC/FID		✓	✓
3PLWPA	LC/MS/MS	✓	✓	✓
48GQV6	LC/MS/MS	✓	✓	
48L4J2	Immunoassay	✓		
	LC/MS/MS		✓	✓
4BHXCW	Immunoassay	✓		
	GC/MS		✓	✓
4D2WJY	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS			✓
4GLYB6	LC-HRMS/MS	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
4TY2W3	LC/MS/MS	✓		
	GC/MS		✓	
4XXDWA	Immunoassay	✓		
	GC/MS		✓	✓
6ED9K2	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
6QPB7Y	LC/MS/MS	✓	✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
6ZE2TR	Immunoassay	✓		
	LC-QTOF	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
73XK23	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS		✓	
7DZVHQ	LC/MS	✓		
	LC/MS/MS		✓	
	GC/MS	✓		
	Immunoassay	✓		
	HPLC/DAD	✓		
7NV3EA	LC/MS	✓	✓	
7RX64B	GC/MS	✓	✓	
7W827Z	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
7WPAVU	Immunoassay	✓		
	GC/MS		✓	✓
83E82W	GC/MS		✓	
	GC/FID		✓	
	Immunoassay	✓		
8E3B78	LC/MS/MS	✓	✓	✓
8X2ATA	GC/MS		✓	
8YE38N	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	LC-TOFMS	✓		
94Y64T	Immunoassay	✓		
	GC/MS		✓	
	GC/MS with MBTFA			
99WWZW	Immunoassay	✓		
	GC/MS		✓	✓
9LYHDU	LC/MS/MS	✓		
	GC/MS		✓	✓
	LC/HRMS		✓	
9QXMGZ	Immunoassay	✓		
	LC-QTOF	✓	✓	
	LC/MS/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
9T3E8R	LC-HRMS/MS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	
AAN8KX	LC/MS/MS	✓	✓	✓
	Immunoassay	✓		
AD6HL9	GC/MS	✓	✓	
AH24FW	Immunoassay	✓		
	GC/MS		✓	
AMTEPV	Immunoassay	✓		
	GC/MS		✓	
	GC/FID		✓	
ATKL94	Immunoassay	✓		
	GC/MS		✓	✓
AUF4A6	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	
AV6JBZ	Immunoassay	✓		
	GC/MS	✓	✓	
AX96AX	GC/MS		✓	
	LC/MS/MS		✓	
	LC-HRAMS/MS	✓		
B8Z4FX	Immunoassay	✓		
	LC/MS/MS		✓	
BG3H2V	Immunoassay	✓		
	LC/MS/QTOF	✓		
	GC/MS		✓	
BRK67Q	LC/MS/MS	✓	✓	✓
	Immunoassay	✓		
C6NP8U	LC/MS/MS	✓		
	GC/MS		✓	
CHA3KP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS			✓
DFZA93	Immunoassay	✓		
DZNWQ6	Immunoassay	✓		
	GC/MS		✓	
E9WNVT	Immunoassay	✓		
	LC-QTOF-MS	✓		
	GC/MS		✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
EBYZ3T	LC-QTOF	✓		
	GC/MS		✓	
EJUN9X	Immunoassay	✓		
	LC/MS/MS		✓	✓
EYPBEP	Immunoassay	✓		
	GC/MS		✓	
FCP9XF	LC/MS/MS	✓	✓	✓
FNAJNU	LC/MS/MS	✓	✓	✓
G4F3ZR	LC/MS/MS	✓	✓	
GBEU4E	Immunoassay	✓		
	UPLC-QTOF MS	✓	✓	
	LC/MS/MS		✓	✓
GBZ8TR	LC-High resolution MS/MS	✓		
	GC/MS		✓	✓
	LC/MS		✓	✓
GMBXAU	GC/MS	✓	✓	✓
	LC/MS/MS	✓		
GNH4MU	GC/MS	✓		
	LC/MS/MS	✓	✓	
GV3BAT	Immunoassay	✓		
	LC/MS/MS		✓	✓
GX9PTT	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
	LC/QTOF-MS	✓		
HAVBCT	Immunoassay	✓		
HHQ8KP	LC/MS/MS	✓		
	GC/MS		✓	
HNC8RP	LC MS QTOF		✓	
	GC/MS		✓	
HPN7NJ	GC/MS	✓	✓	
	ELISA	✓		
HX9XMX	Immunoassay	✓		
	LC/MS/MS		✓	✓
JVBAFM	LC/MS/MS	✓		
	Immunoassay	✓		
JYTD4J	Immunoassay	✓		
	GC/MS	✓	✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
K9V49R	Immunoassay	✓		
	GC/MS		✓	✓
KBF2CN	Immunoassay	✓		
	LC/MS/MS		✓	✓
KCVE6R	GC/MS	✓		
	GC/FID		✓	
	Immunoassay	✓		
KCWY4N	Immunoassay	✓		
KFBVAP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
KQXJUR	Immunoassay	✓		
	GC/MS	✓		
	GC/FID		✓	
KQZDDX	Immunoassay	✓		
	GC/MS	✓	✓	
KZKK8G	LC-HRMS/MS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
L2C3MM	LC/MS/MS	✓	✓	
LCDNTL	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
LEFD8N	Immunoassay	✓		
	GC/MS	✓	✓	
LL2JQG	Immunoassay	✓		
	GC/MS	✓	✓	
M6VE6P	Immunoassay	✓		
	LC/MS/MS		✓	✓
M7FD9L	LC/MS/MS	✓	✓	
MDJ6PW	Immunoassay	✓		
	GC/MS	✓	✓	
NFFK3C	Immunoassay	✓		
	GC/MS	✓	✓	
NKERRF	LC/MS/MS	✓	✓	✓
NRZMTK	LC-HRMSMS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
P6ZTCG	Immunoassay	✓		
	LC-QTOF MS		✓	
P96AXR	LC/MS/MS	✓	✓	
PUMLNU	LC/MS/MS	✓		
	GC/MS		✓	
PXV4JF	LC/MS/MS	✓		
	GC/MS		✓	
Q7WJ9N	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	
QHJQ2H	Immunoassay	✓		
	LC/MS/MS		✓	✓
QVTNPJ	LC/MS/MS	✓	✓	
R3R9RE	Immunoassay	✓		
	GC/MS		✓	
R776WF	Immunoassay	✓		
	LC/MS/MS		✓	✓
RBG2Y6	LC-QTOF-MS	✓		
	LC/MS/MS	✓	✓	✓
	Immunoassay	✓		
RKZJ8H	Immunoassay	✓		
	GC/MS	✓	✓	
RZXJ9J	Immunoassay	✓		
	LC/MS/MS		✓	✓
T4R3JF	LC-High Resolution Tandem Mass Spectrometry	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	
TCB9H9	LC-HRMS/MS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
TDHL6F	Immunoassay	✓		
	GC/MS		✓	
TG6ZTQ	Immunoassay	✓		
	GC/MS	✓	✓	
TLBUML	Immunoassay	✓		
	GC/MS		✓	✓

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
TMTPBE	LC-HRMS/MS	✓		
	LC/MS/MS		✓	
	GC/MS		✓	✓
TTC34L	Immunoassay	✓		
	GC/MS		✓	
TV2HHN	Immunoassay	✓		
	GC/MS	✓	✓	
TXM4BC	LC/MS/MS		✓	✓
	LC QTOF	✓		
TYY2KM	GC/MS		✓	
U97X4J	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	
UECQXF	Immunoassay	✓		
	LC/MS/MS		✓	✓
UKXLVD	LC/MS/MS	✓		
	GC/MS		✓	
UNHCLG	LC/MS/MS	✓		
UTD3UE	Immunoassay	✓		
	GC/MS		✓	✓
UWBMVC	Immunoassay	✓		
	GC/MS		✓	
	GC/FID		✓	
V7VEG8	Immunoassay	✓		
	LC/MS/MS		✓	
VEMV6C	LC-HRMS/MS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	
VENQTN	Immunoassay	✓		
	GC/MS	✓	✓	
W7DN8N	Immunoassay	✓		
	GC/MS	✓	✓	
WK8BDF	Immunoassay	✓		
	GC/MS		✓	
WQBGNC	GC/MS	✓	✓	✓
	LC/MS/MS	✓	✓	
	LC-HRMS/MS	✓		

TABLE 1E: Methods of Analysis - Item 1

WebCode	Method	Screening	Confirmatory	Quantitation
XA7AAA	LC-HRMS/MS	✓		
	LC/MS		✓	
	GC/MS		✓	✓
XC8AA8	LC/MS/MS	✓		
	GC/MS		✓	
XL2F8E	Immunoassay	✓		
	GC/MS		✓	✓
XNLEBB	Immunoassay	✓		
	GC/MS	✓	✓	
XTF8T7	LC/MS/MS	✓	✓	✓
XWGAH8	LC/MS/MS	✓	✓	
XXPKB6	LC Q TOF	✓	✓	
XZXJLD	Immunoassay	✓		
	LC/QTOF-MS	✓		
	GC/MS		✓	
	LC/MS		✓	
Y689P8	Immunoassay	✓		
	GC/MS		✓	
Y8VMDG	LC/MS/MS	✓	✓	✓
YETEH6	LC/MS/MS	✓	✓	✓
YTERZ7	Immunoassay	✓		
	LC/MS/MS		✓	✓
YVYP33	GC/MS		✓	
YX7XE9	LC/MS/MS	✓		
	Immunoassay	✓		
Z9PR8G	GC-MSD /LS-MS-MS	✓	✓	
ZBUHCB	Immunoassay	✓		
	GC/MS		✓	
ZCJXD7	Immunoassay	✓		
ZM8KVM	GC/MS	✓	✓	

Response Summary for Item 1 - Methods of Analysis			Participants: 138
	Screening	**Confirmatory**	**Quantitation**
Immunoassay:	85	0	0
GC/MS:	32	86	21
LC/MS:	2	5	1
LC/MS/MS:	37	52	32
Other:	27	17	1

Additional Comments for Item 1

TABLE 1F

WebCode	Item Comments
2A9FUZ	Promazine used as internal standard in Drug Screen.
2JJHF2	The internal standard used for the drug screen was promazine.
2Z3DTA	Cut-off value for MDMA and MDA in blood is 30 ng/mL, for the LC-MS-MS confirmatory assay
32ZWJG	Promazine used as internal standard for GC-MS drug screen.
384XJC	MDA/MDMA can cause a false positive on the ELISA screen for methamphetamine.
3PLWPA	MDMA quantitative value was >Linear Range 100.00ng/mL on first extraction. Dilution was performed for reported value. MDA LOQ 5ng/mL; ISTD MDA-D5 MDMA LOQ 5ng/mL; ISTD MDMA-D6 Citalopram LOQ 5ng/mL; ISTD Citalopram-D6
48GQV6	The directions specified "The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly." Topiramate was also confirmed in this sample.
48L4J2	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive amphetamine and/or methamphetamine screen, confirmation/quantitation of amphetamine (AMP), 3,4-methylenedioxyamphetamine (MDA), methamphetamine (mAMP), and 3,4-methylenedioxymethamphetamine (MDMA) is performed using AMP-D5, MDA-D5, mAMP-D11, and MDMA-D5 as internal standards, respectively. LOD for each target drug is 4 ng/mL; LOQ for each target drug is 10 ng/mL.
4D2WJY	Resubmission of Predistribution results. Originally submitted on 4/5/22.
4GLYB6	Mepivacaine used for internal standard; limit of report for above is 12.5 µg/L
6QPB7Y	MDA/MDA-D5, LLOQ 10ng/mL, working range 10-500ng/mL ; MDMA/MDMA-D5, LLOQ 10ng/mL, working range 10-500ng/mL.
6ZE2TR	limit of detection on confirmation/quantitation for diphenhydramine: 6.25 ng/mL. Limit of detection on confirmation/quantitation for citalopram: 12.5 ng/mL
73XK23	Delta-9 THC and Delta-9 THC-COOH not detected/confirmed.
7DZVHQ	LC/MS above refers to LC-QTOF-MS. Internal standard for MDMA quantitation was D5-MDMA. Internal standard for MDA quantitation was D5-MDA.
7NV3EA	ESTAZOLAM WAS USED AS INTERNAL STANDARD
7WPAVU	Immunoassay: Methamphetamine and Amphetamine cutoff: 20ng/mL. GC/MS: Meth, AMP, MDA, MDMA LOQ: 0.020mcg/mL; Internal standards: Meth-D11, AMP-D11, MDA-D5, and MDMA-D5.
8YE38N	Zolpidem - too low to quantitate date 21 June 2022. Carvedilol, citalopram, diphenhydramine - too low to quantitate date 22 June 2022. Topiramate, paracetamol, metformin - too low to quantitate date 20 June 2022.
94Y64T	mbtfa lot [Serial Number] used phenyltoloxamine lot [Serial Number], heptabarbital lot [Serial Number] no amphetamine-tfa detected
9QXMGZ	LOQ = 10 ng/mL, MDA-D5 and MDMA-D5 used as internal standards.
9T3E8R	Internal standard - mepivacaine Limit of report for MDMA & MDA - 12.5 ng/mL
AMTEPV	Note: There was a small amount of diphenhydramine present below LOQ. Not reported.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
AV6JBZ	Promazine was used as ISTD for blood drug screen.
AX96AX	Internal Standards- amphetamine-d11, methamphetamine-d11, mepivacaine, gabapentin-d4. olanzepine-d8, bupropion-d9, diazepam-d5, clonazepam-d4, mephobarbital. Limit of Detection-12.5mcg/L, Lowest calibrator-50mcg/L, Highest calibrator-800mcg/L.
B8Z4FX	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive amphetamine and/or methamphetamine screen, confirmation/quantitation of amphetamine (AMP), 3,4-methylenedioxyamphetamine (MDA), methamphetamine (mAMP), and 3,4-methylenedioxymethamphetamine (MDMA) is performed using AMP-D5, MDA-D5, mAMP-D11, and MDMA-D5 as internal standards, respectively. LOD for each target drug is 4 ng/mL; LOQ for each target drug is 10 ng/mL.
BG3H2V	Citalopram, Diphenhydramine, Zolpidem indicated, did not meet reporting criteria. Internal standards- Mepivacaine, Amphetamine-D11, Methamphetamine-D11.
C6NP8U	MDA detected by LC-MS/MS and confirmed by GC/MS. MDMA detected by LC-MS/MS and confirmed by GC/MS.
CHA3KP	Acetaminophen indicated but not confirmed.
DZNWQ6	Confirmatory ISTD GC/MS: [Initials] and [Initials]
E9WNVT	Immunoassay: ELISA. Internal standard: Mepivacaine LOD - 12.5 ng/mL for MDA and MDMA.
EJUN9X	Lab currently does not have confirmation method for zolpidem. Use deuterated controls for internal standards
FCP9XF	trace amounts of zolpidem, carvedilol, paracetamol and citalopram also detected
FNAJNU	MDA LOQ 5ng/mL; ISTD MDA-D5 MDMA LOQ 5ng/mL; ISTD MDMA-D6 Citalopram LOQ 5ng/mL; ISTD Citalopram-D6 First extraction for MDMA quantitative value was >Linear Range 100.00ng/mL; dilution was performed for reported value
GBEU4E	Screening: Immunoassay and UPLC-QTOF MS (Waters). For UPLC-QTOF MS - Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone MDA & MDMA Confirmation & Quantitaion: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Multiple Reaction Monitoring (MRM) mode. Internal Standard: D5-Methylamphetamine, D3-Ephedrine & D4-Pethidine LOD for MDA & MDMA: 0.5 ng/mL
GBZ8TR	Mepivacaine was internal standard for each testing modality used to report. MDA and MDMA are required to be reported as the average of two determinations acquired from the same extraction. Citalopram and chlorpheniramine were detected in the screen but not reported due to being below our LOR in confirmatory testing. LOR = 25 μg/L Diphenhydramine was detected in the screen but not reported due to being below our LOR in confirmatory testing. LOR = 10 μg/L
GNH4MU	Topirmate (>10ng/ml) and traces of Zolpidem (<10ng/ml) were also detected in the sample.
GV3BAT	Zolpidem hit presumptive positive, however our laboratory is not able to confirm or quantitate these classes/types of drugs. We are only able to quantitate and/or confirm the following: amphetamine, diphenhydramine, ephedrine/pseudoephedrine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, psilocin, LSD, THC, Carboxy-THC, Hydroxy-THC.
HAVBCT	Amphetamine screening cut off is 20ng/mL. Methamphetamine screening cut off is 20ng/mL. Analysts are not certified to perform confirmation testing on Amphetamines/Methamphetamines. Cases that are positive for Amphetamines/Methamphetamines are sent to a reference laboratory.
HPN7NJ	Promazine- Internal Standard for the Drug Screen

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
JYTD4J	The internal reference materials used were Phenyltoloxamine for the base fraction and Hexobarbital for the acid fraction. Unconfirmed MDA detected in the base fraction. Possible Caffeine noted in both the base and acid fractions.
KBF2CN	ELISA Immunalysis Amphetamine kit used is 133.3% cross reactive with MDA. ELISA Immunalysis Methamphetamine kit used is 100% cross reactive with MDMA. Also observed, Zolpidem - 3.068 ng/ml (LLOQ for reporting is 5.0ng/ml)
KFBVAP	Methamphetamine-D9 is used as an internal standard
KQXJUR	MDA and MDMA cross react with the Methamphetamine ELISA Assay
KZKK8G	mepivacaine used as internal standard for MDMA and MDA
L2C3MM	Confirmation cutoff for MDA, Citalopram, Diphenhydramine, Topiramate, and MDMA was 5ng/mL
LEFD8N	Promazine used as internal standard for blood drug screen. ELISA used for immunoassay. MDA detected when performing confirmatory testing for MDMA. Performed confirmation procedure twice on different GC/MS columns to provide two separate tests for reporting MDA.
LL2JQG	Internal standard used for the qualitative assay is prazepam for the screening and MDPA for the qualitative confirmation. At the time of this proficiency test, the laboratory temporarily suspended the reporting of quantitative results for methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA). Therefore, no quantitative results will be reported for this proficiency test. Only qualitative results will be reported.
M6VE6P	Item 1 also screened presumptive positive for benzodiazepines and zolpidem. The [Laboratory] does not yet have confirmatory methods for these compounds so confirmation testing was not performed.
NFFK3C	Phenyltoloxamine and hexobarbital internal reference materials utilized. Possible trace amount of zolpidem was found in the GC/MS screen; however the ELISA zolpidem screening result was negative but somewhat elevated.
NKERRF	ISTD (Method LLOQ - ULOQ): MDMA-D5 (10.0 - 500.0 ng/mL), MDA-D5 (10.0 - 500.0 ng/mL). [Initials] 06/22/2022
NRZMTK	3,4-methylenedioxymethamphetamine Internal standard-mepivacaine, LOD-12.5 ng/mL. 3,4-methylenedioxymethamphetamine Internal standard-mepivacaine, LOD-12.5 ng/mL
QVTNPJ	Extract 1 and Extract 2 for MDMA quantitative value was >Linear Range 100.00 ng/ml; dilution was performed for reported value MDA-d5 ISTD; LOD5ng/ml MDMA-d6 ISTD; LOD 5ng/ml Citalopram-d6 ISTD; LOD 5ng/ml
R776WF	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Amphetamine and Methamphetamine confirmation/quantitation panel includes: Amphetamine, Methamphetamine, MDA, and MDMA. The following internal standards are used: Amphetamine D-5, Methamphetamine D-11, MDA D-5, and MDMA D-5. LOD for all analytes in this panel is 4 ng/mL. The LOQ for all analytes in this panel is 10 ng/mL.
RKZJ8H	Promazine used as Internal Standard for Butyl Acetate

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
RZXJ9J	Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL): Fentanyl 0.5 – 50, Norfentanyl 0.5 – 50, Codeine 5.0 – 500, Hydrocodone 5.0 – 500, Morphine 5.0 – 500, Hydromorphone 5.0 – 500, Oxycodone 5.0 – 500, Oxymorphone 5.0 – 500, Methadone 20 – 2000, EDDP 20 – 2000, Methamphetamine 20 – 2000, Amphetamine 20 – 2000, Cocaine 20 – 2000, Benzoylecgonine 20 – 2000. Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses. Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 1, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10. * Results within 20% of these concentrations are also reported as preliminarily positive.
T4R3JF	Internal standard used: Mepivacaine * The following analytes were also detected above the limit of detection but below the limit of report: citalopram, diphenhydramine, and zolpidem.
TCB9H9	Internal Standard: Mepivacaine, MDA, and MDMA use duplicate testing on the same run with the average being reported. Zolpidem, Citalopram, and Diphenhydramine were detected in the screening and confirmatory method but were below our reporting LOR of 0.025mg/L. Sertraline was detected in the confirmatory method but was below the reporting LOR of 0.025mg/L
TMTPBE	internal standard: mepivacaine citalopram found, qualitative only (LC/MS/MS, LC-HRMS/MS)
TYY2KM	[From Table 1B: Confirmatory Results Item 1- "Not Detected", Dates Analysis performed "2022-05-18 / 2022-06-15"]
UECQXF	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 1, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10. * Results within 20% of these concentrations are also reported as preliminarily positive. Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL): Fentanyl 0.5 – 50, Norfentanyl 0.5 – 50, Codeine 5.0 – 500, Hydrocodone 5.0 – 500, Morphine 5.0 – 500, Hydromorphone 5.0 – 500, Oxycodone 5.0 – 500, Oxymorphone 5.0 – 500, Methadone 20 – 2000, EDDP 20 – 2000, Methamphetamine 20 – 2000, Amphetamine 20 – 2000, Cocaine 20 – 2000, Benzoylecgonine 20 – 2000. Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses.
VEMV6C	LC-HRMS/MS Screening Internal Standard: mepivacaine & mephobarbital. LC/MS/MS Testing Internal Standard: mepivacaine. GC/MS Confirmation/Quantitation Internal Standard: mepivacaine, amphetamine-d11, methampetamine-d11. Limit of Reporting for analytes reported: MDMA & MDA = 12.5 μg/L
WQBGNC	Internal standard for quantitation: Mepivacaine Lowest Calibrator: 50 ng/mL LOR: 12.5 ng/mL
XA7AAA	The lowest calibrator of our calibration curve for MDA is 50 ng/mL. The quantitation was below 50 ng/mL, and therefore the result is reported as lower than the lowest calibrator of 50 ng/mL.
XNLEBB	Promazine was used as an internal standard for GC/MS screening
XWGAH8	Cannabinoid response on the screen was suspected as an interfering peak. A confirmation analysis was run to confirm the results. Limit of confirmation for citalopram and diphenhydramine was 5ng/mL.
YETEH6	MDA LLOQ was 10 ng/mL with a working range was 10 - 500 ng/mL. The internal standard used was MDA-D5. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. MDMA LLOQ was 10 ng/mL with a working range was 10 - 500 ng/mL. The internal standard used was MDMA-D5. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration.
YPEHP4	The specific methodology utilized for both the screening and confirmatory analysis was HRMS by LC-QTOF.

TABLE 1F: Additional Comments for Item 1

WebCode	Item Comments
YTERZ7	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Amphetamine confirmation panel includes amphetamine, methamphetamine, MDA and MDMA. LOD is 4ng/ml and LOQ is 400ng/ml. Amphetamine-D5, methamphetamine-D11, MDMA-D5 and MDA-D5 were used as internal standards.
YVYP33	Internal standard: flurazepam LOD N-methyl-3,4-methylenedioxyamphetamine 550 ng / mL
Z9PR8G	In item 1, citalopram was also detected.
ZBUHCB	Confirmatory ISTD GC/MS: [Initials] and [Initials]
ZCJXD7	Cutoff used: Methamphetamine: >60 ng/mL Amphetamine: >50 ng/mL MDMA: >50 ng/mL

Screening Results - Item 2

TABLE 2A

Item Scenario:

Case 2: A 39 year-old male called 911 complaining of hallucinations and trouble breathing. He was rushed to the hospital and blood samples were collected

Item Contents and Preparation Concentration: Methadone (400 ng/mL)
EDDP (5.8 ng/mL)**
THC (1.1 ng/mL)**
Carboxy THC (45 ng/mL)**
Hydroxy THC (0.9 ng/mL)**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	Screening Results
2A9FUZ	Methadone, THC (class)
2DWHAM	Methadone
2JJHF2	THC Methadone
2XGFQD	THC
2Z3DTA	Methadone Cannabinoids
32ZWJG	ELISA screen was THC (tetrahydrocannabinol) positive. GC-MS drug screen detected methadone. Methadone confirmed on second GC-MS drug screen, delta-9 carboxy tetrahydrocannabinol confirmed on LC-MSMS.
384XJC	THC
3PLWPA	EDDP, Methadone, THC, THC-COOH
48GQV6	Cannabinoids Methadone EDDP
48L4J2	Methadone and cannabinoids
4BHXCW	cannabinoids, methadone
4D2WJY	Cannabinoid
4GLYB6	methadone, delta-9-tetrahydrocannabinol (THC), 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH), lamotrigine
4TY2W3	Cannabinoids and Methadone
4XXDWA	cannabinoids
6ED9K2	THC, Methadone
6QPB7Y	THC-COOH Methadone

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
6ZE2TR	Methadone EDDP Trazodone Lamotrigine Cannabinoids
73XK23	Methadone, THC class
7DZVHQ	lamotrigine, methadone, tetrahydrocannabinol
7NV3EA	METHADONE
7RX64B	Delta-9 Carboxy Tetrahydrocannabinol (THC metabolite) Methadone
7W827Z	Cannabinoids, Methadone
7WPAVU	Methadone and Tetrahydrocannabinol.
83E82W	Cannabinoids class
8E3B78	Methadone THC-COOH
8X2ATA	METHADONE
8YE38N	Lamotrigine, EDDP, methadone
94Y64T	methadone, thcc
99WWZW	cannabiniods
9LYHDU	THC THC-COOH methadone EDDP
9QXMGZ	Cannabinoids
9T3E8R	delta-9-tetrahydrocannabinol (THC) 11-nor-9-carboxy-tetrahydrocannabinol (THC-COOH) methadone 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) lamotrigine
AAN8KX	Delta 9 THC Delta 9 Carboxy THC Methadone Trazodone

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
AD6HL9	Methadone, Delta-9 Carboxy THC
AH24FW	Cannabinoids
AMTEPV	Cannabinoids
ATKL94	Cannabinoids
AUF4A6	Cannabinoids (ELISA) Methadone
AV6JBZ	THC, Opiates
AX96AX	delta-9-tetrahydrocannabinol 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid Methadone
B8Z4FX	Cannabinoids, Methadone
BG3H2V	Cannabinoids
BRK67Q	Cannabinoids Methadone
C6NP8U	THC Methadone
CHA3KP	Methadone Cannabinoids
DFZA93	Methadone THC
E9WNVT	Cannabinoids/11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA) Methadone
EBYZ3T	METHADONE EDDP LAMOTRIGINE CANNABINOIDS
EJUN9X	Cannabinoids, Benzodiazepines, Methadone
EYPBEP	Cannabinoids ELISA
EZLLAR	Cannabinoids/THCA Methadone
FCP9XF	Lamotrigine Methadone EDDP 11-nor-9-carboxy-delta-9-THC

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
FNAJNU	EDDP, Methadone, THC, THC-COOH
G4F3ZR	METHADONE, EDDP, DELTA-9-THC, OH-THC, COOH-THC, LAMOTRIGINE
GBEU4E	Cannabinoids - Delta-9-tetrahydrocannabinol, Delta-9-THC Acid Lamotrigine and Methadone
GBZ8TR	Lamotrigine, Trazodone, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDP), Methadone, Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH), 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH)
GMBXAU	methadone, EDDP THC-COOH
GNH4MU	Methadone, THC-COOH
GV3BAT	Benzodiazepines, Methadone, Cannabinoids
GX9PTT	Cannabinoids EDDP Methadone
HAVBCT	THC, Methadone
HHQ8KP	THC, Methadone
HNC8RP	[Although participant indicated that drugs were identified through screening, none were reported.]
HPN7NJ	Cannabinoid Methadone
HX9XMX	Trazodone Lamotrigine Methadone EDDP
JVBAFM	11-nor-9-Carboxy-Delta-9-THC Methadone
JYTD4J	METHADONE THCC
K9V49R	Cannabinoids
KBF2CN	Methadone Cannabinoids
KCVE6R	Cannabinoids Methadone

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
KCWY4N	Cannabinoids Methadone/Metabolite
KFBVAP	Methadone
KQXJUR	Cannabinoids (ELISA) Methadone
KQZDDX	Cannabinoids
KZKK8G	methadone, lamotrigine, delta-9-THC
L2C3MM	Cannabinoids, EDDP, Lamotrigine, Methadone, Trazodone
LCDNTL	THC Methadone
LEFD8N	Cannabinoids, Methadone
LL2JQG	Cannabinoids class
M6VE6P	Benzodiazepines, Cannabinoids, Methadone
M7FD9L	methadone, EDDP, and EMDP
MDJ6PW	Methadone Cannabinoids
NFFK3C	Methadone THC (Tetrahydrocannabinol)
NKERRF	Methadone, THC-COOH
NRZMTK	THC (delta-9-tetrahydrocannabinol) THC metabolite (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid, a metabolite of THC) methadone 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)
P6ZTCG	Methadone Tetrahydrocannabinol
P96AXR	Lamotrigine, Trazodone, EDDP, and Methadone
PUMLNU	lamotrigine (below cutoff) methadone THC-COOH
PXV4JF	THC, Methadone
Q7WJ9N	Cannabinoids
QHJQ2H	Methadone Cannabinoids

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
QVTNPJ	THC, THC-COOH, EDDP, Methadone
R3R9RE	Cannabinoids
R776WF	Cannabinoids and Methadone
RBG2Y6	cannabinoid metabolites (tetrahydrocannabinol, carboxytetrahydrocannabinol), methadone, lamotrigine
RKZJ8H	Delta-9-THC Methadone
RZXJ9J	Methadone Cannabinoids
T4R3JF	methadone, delta-9-tetrahydrocannabinol, and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid.
TCB9H9	Lamotrigine Trazodone EDDP Methadone delta-9-tetrahydrocannabinol (THC) 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH) 11-nor-delta-tetrahydrocannabinol-9-carboxylic acid (THC-COOH)
TDHL6F	methadone cannabinoids
TG6ZTQ	Cannabinoids Methadone
TLBUML	Marijuana: 11-nor-Delta-9-Carboxy-THC, Methadone
TMTPBE	methadone, 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid
TTC34L	Cannabinoids, Methadone
TV2HHN	Methadone Delta-9 Carboxy THC (THC metabolite)
TXM4BC	Carboxy-THC, THC, Methadone, Caffeine
TYY2KM	No drugs detected utilizing screening methods.
U97X4J	Cannabinoids
UECQXF	Cannabinoids Methadone
UKXLVD	Methadone 11-nor-9-Carboxy-Delta-9-THC

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
UNHCLG	Methadone THC-COOH
UTD3UE	Cannabinoid class Methadone
UWBMVC	THC (Cannabinoids)
V7VEG8	Cannabinoids, Methadone
VEMV6C	delta-9-tetrahydrocannabinol (THC) 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) methadone lamotrigine
VENQTN	Delta-9 Tetrahydrocannabinol
W7DN8N	cannabinoids methadone
WK8BDF	Cannabinoid
WQBGNC	methadone THC-COOH (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid)
XA7AAA	THC (delta-9-tetrahydrocannabinol), THCOOH (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid), lamotrigine, methadone, EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine)
XC8AA8	THC, Methadone
XL2F8E	Cannabinoids
XNLEBB	Cannabinoids, Methadone
XTF8T7	Methadone and THCA
XWGAH8	Cannabinoids Lamotrigine Methadone Trazodone
XXPKB6	Lamotrigine Methadone Trazodone
XZXJLD	Cannabinoids Methadone EDDP
Y689P8	THC

TABLE 2A: Screening Results - Item 2

WebCode	Screening Results
Y8VMDG	METHADONE TRAZODONE
YETEH6	Methadone and THC-COOH
YPEHP4	Lamotrigine, Methadone, Trazodone
YTERZ7	Cannabinoids and methadone
YVYP33	No drugs detected utilizing screening methods.
YX7XE9	THC, Methadone
Z9PR8G	Methadone and 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)
ZBUHCB	Methadone, cannabinoids
ZCJXD7	Methadone Cannabinoids (THC)
ZM8KVM	Opiates

Screening Response Summary for Item 2	Participants: 139
Methadone:	111
Cannabinoids	144
EDDP	21
Other drugs/metabolites detected:	38
No drugs/metabolites detected Utilizing Screening Methods:	2

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 2

TABLE 2B

Item Scenario:

Case 2: A 39 year-old male called 911 complaining of hallucinations and trouble breathing. He was rushed to the hospital and blood samples were collected

Item Contents and Preparation Concentration: Methadone (400 ng/mL)
EDDP (5.8 ng/mL)**
THC (1.1 ng/mL)**
Carboxy THC (45 ng/mL)**
Hydroxy THC (0.9 ng/mL)**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

What drugs/metabolites were detected in Item 2?

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2A9FUZ	Methadone	✓			
	Delta-9 Carboxy THC (THC metabolite)	✓			
2DWHAM	Methadone	✓			
2JJHF2	Methadone	✓			
	Delta-9-Carboxy-Tetrahydrocannabinol (delta-9-THC metabolite)	✓			
2XGFQD	Methadone		0.25	13.75%	ug/mL
	THC		1	13.24%	ng/mL
	THCCOOH		49	11.72%	ng/mL
	THCOH		1	15.18%	ng/mL
2Z3DTA	Methadone	✓			
	Delta 9 Carboxy THC	✓			
32ZWJG	Methadone	✓			
	Delta-9 carboxytetrahydrocannabinol	✓			
384XJC	Methadone		0.26	-/+13.75%	ug/mL
	THC		1	-/+13.24%	ng/mL
	THC-COOH		52	-/+11.72%	ng/mL
3PLWPA	Methadone		378.67	37.86	ng/mL
	EDDP		6.55	1.57	ng/mL
	THC		1.10	0.15	ng/mL
	THC-COOH		43.93	7.90	ng/mL
48GQV6	Methadone		394.97	+/- 118.49	ng/ml
	THC		1.29	+/- 0.30	ng/ml
	Carboxy-THC	✓			

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
48L4J2	Methadone		0.48	± 0.09	µg/mL
	Δ9-tetrahydrocannabinol (THC)		present, < 1	N/A	ng/mL
	11-nor-9-carboxy-Δ9-tetrahydrocannabinol (carboxy-THC)		45	± 7	ng/mL
	11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC)		present, < 1	N/A	ng/mL
4BHXCW	carboxy-THC		33.6	5.8	ng/ml
4D2WJY	Methadone	✓			
	Delta-9-THC-COOH	✓			
4GLYB6	methadone		0.42	0.13	mg/L
	delta-9-tetrahydrocannabinol		1.2	0.2	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid	✓			
	Additional Analyte(s) Reported				
	lamotrigine		lower than lowest calibrator of 0.5 mg/L		
4TY2W3	Methadone		417		ng/ml
	11-nor-9-Carboxy-Delta-9-THC		47		ng/ml
4XXDWA	methadone		0.21	+/-0.03	ug/ml
	Carboxy-THC		57	+/-7	ng/ml
6ED9K2	Methadone		390		ng/mL
	11-nor-9-Carboxy-Delta-9-THC		36		ng/mL
6QPB7Y	Methadone		390.8	66.4	ng/mL
	THC		0.8	0.2	ng/mL
	THC-COOH		40.5	6.9	ng/mL
	11-OH-THC		1.1	0.2	ng/mL
6ZE2TR	methadone		400	34	ng/mL
	EDDP	✓			
	THC		1.1	0.1	ng/mL
	Hydroxy-THC		<1		ng/mL
	Additional Analyte(s) Reported				
	Trazodone		<50		ng/mL
73XK23	Methadone	✓			
	Delta 9 Carboxy THC	✓			

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
7DZVHQ	methadone		0.3	+/-15%	mg/L
	tetrahydrocannabinol		<1	+/-15%	ug/L
	Additional Analyte(s) Reported				
	lamotrigine		0.1	+/-15%	mg/L
7NV3EA	METHADONE	✓			
7RX64B	Methadone	✓			
	Delta-9 Carboxy Tetrahydrocannabinol	✓			
7W827Z	methadone		366		ng/ml
	11-nor-9-Carboxy-Delta-9-THC		40		ng/mL
7WPAVU	Tetrahydrocannabinol		1.87	0.48	ng/mL
	Carboxy-Tetrahydrocannabinol		38.9	6.7	ng/mL
83E82W	Methadone		0.24	13.75%	ug/mL
	THC		1	13.24%	ng/mL
	THC-COOH		62	11.72%	ng/mL
8E3B78	Methadone		443.78	53.25	ng/mL
8X2ATA	METHADONE	✓			
8YE38N	Methadone		360	108	ng/mL
94Y64T	methadone	✓			
	thcc-tms	✓			
99WWZW	Methadone		0.20	13.75%	ug/ml
	Carboxy THC		57	11.72%	ng/ml
9LYHDU	methadone		289		ng/mL
	EDDP	✓			
	THC		1,01	8,7%	ng/mL
	THC-COOH		42,3	7,6%	ng/mL
9QXMGZ	Methadone		0.53	0.06	mg/L

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
9T3E8R	methadone		380	110	ng/mL
	2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)		< 50 ng/mL *		
	delta-9-tetrahydrocannabinol (THC)		1.2	0.2	ng/mL
	11-nor-9-carboxy-tetrahydrocannabinol (THC-COOH)	✓	see note below		
	Additional Analyte(s) Reported				
	lamotrigine		< 125 ng/mL ^		
AAN8KX	Methadone		323.5	67.9	ng/mL
	Delta 9 THC		Less than 2 ng/mL		ng/mL
	Delta 9 Carboxy THC		31.6	6.6	ng/mL
	Additional Analyte(s) Reported				
	Trazodone	✓			
AD6HL9	Methadone	✓			
	Delta-9 Carboxy THC	✓			
AH24FW	methadone		0.28	+/- 13.75%	ug/mL
	THC		1	+/- 13.24%	ng/mL
	THC-COOH		56	+/- 11.72%	ng/mL
AMTEPV	Methadone		0.24	13.75%	ug/mL
	Tetrahydrocannabinol (THC)		1	13.24%	ng/mL
	Carboxy Tetrahydrocannabinol (THC COOH)		65	11.72%	ng/mL
ATKL94	Methadone		0.24	+/-0.03	ug/ml
	Delta-THC		1	0	ng/ml
	THC-COOH		50	+/- 6	ng/ml
AUF4A6	Methadone		0.22	13.75%	ug/mL
	THC		1	13.24%	ng/mL
	THC-COOH		51	11.72%	ng/mL
AV6JBZ	Methadone	✓			
	Delta-9-THC-COOH (THC Metabolite)	✓			
AX96AX	Methadone		0.40mg/L	0.12	mg/L
	delta-9-tetrahydrocannabinol		1.2	0.2	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid	✓			

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
B8Z4FX	Methadone		0.39	0.08	µg/mL
	Δ9-Tetrahydrocannabinol (THC)		1.0	0.2	ng/mL
	11-nor-9-carboxy-Δ9-tetrahydrocannabinol (carboxy-THC)		44	7	ng/mL
	11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC)		present, <1	N/A	ng/mL
BG3H2V	Methadone	✓			
	THCA		36	27	ng/ml
BRK67Q	Methadone		347	108	ng/mL
	Delta-9 Carboxy THC		44	14	ng/mL
C6NP8U	Methadone		415		ng/mL
	11-nor-9-Carboxy-Delta-9-THC		44		ng/mL
CHA3KP	Methadone		396	48	ng/mL
E9WNVT	Methadone	✓			
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA)		39	11	ng/mL
EBYZ3T	METHADONE	✓			
	EDDP	✓			
	Δ-tetrahydrocannabinol (THC)	✓			
	11-nor-9-carboxy-Δ-tetrahydrocannabinol (THC-COOH)	✓			
	11-hydroxy-Δ-tetrahydrocannabinol (THC-OH)	✓			
	Additional Analyte(s) Reported				
	LAMOTRIGINE	✓			
EJUN9X	Tetrahydrocannabinol		1.4	0.5	ng/mL
	11-nor-9-Carboxy-THC		39	9.0	ng/mL
	11-Hydroxy-THC		1.2	0.3	ng/mL
EYPBEP	methadone		0.10	+/- 13.75%	ug/mL
	THC- COOH		69	+/- 11.72%	ng/mL
EZLLAR	Methadone	✓			
	THC		1.0	0.2	ng/ml
	THCA		40	11	ng/ml

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
FCP9XF	Methadone		0.36	21.6%	mg/L
	EDDP	✓			
	11-nor-9-carboxy-delta-9-THC		38	5.8%	ug/L
	Additional Analyte(s) Reported				
	Lamotrigine		0.082	N/A	mg/L
FNAJNU	Methadone		443.57	44.35	ng/mL
	EDDP		7.35	1.76	ng/mL
	THC		1.01	0.14	ng/mL
	THC-COOH		44.54	8.01	ng/mL
G4F3ZR	METHADONE		371.60	111.48	ng/mL
	EDDP		5.00	1.50	ng/mL
	DELTA-9-THC		1.08	0.27	ng/mL
	COOH-THC		45.25	11.32	ng/mL
	OH-THC		1.06	0.27	ng/mL
	Additional Analyte(s) Reported				
	LAMOTRIGINE	✓			
GBEU4E	Methadone		420	110	ng/mL
	Delta-9-tetrahydrocannabinol		1.0	0.4	ng/mL
	Delta-9-THC Acid		40	8	ng/mL
	Additional Analyte(s) Reported				
	Lamotrigine		190	40	ng/mL
GBZ8TR	Methadone		0.39	0.12	mg/L
	2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDP)		LLC of 50		µg/L
	Delta-9-tetrahydrocannabinol (THC)		1.1	0.2	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH)	✓	Positive		
	Additional Analyte(s) Reported				
	Lamotrigine		LLC of 500		µg/L
GMBXAU	methadone		350	30	ng/ml
	EDDP	✓			
	THC-COOH		46	40	ng/ml
GNH4MU	Methadone	✓			
	THC-COOH	✓			

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
GV3BAT	Tetrahydrocannabinol		1.1	0.4	ng/mL
	11-nor-9-Carboxy-THC		37	9	ng/mL
GX9PTT	Methadone	✓			
	EDDP	✓			
	Delta-9 THC	✓			
	Delta-9 Carboxy THC	✓			
HAVBCT	Delta-9-THC		None Detected	N/A	ng/mL
	Delta-9-Carboxy THC		47	7	ng/mL
HHQ8KP	Methadone		398		ng/mL
	11-nor-9-Carboxy-Delta-9-THC		37		ng/mL
HNC8RP	Methadone	✓			
	EDDP, Metabolite of Methadone	✓			
	Additional Analyte(s) Reported				
	Trazadone	✓			
HPN7NJ	Methadone	✓			
	Delta 9-Carboxy THC (THC metabolite)	✓			
HX9XMX	Methadone		400		ng/mL
	EDDP	✓			
	Additional Analyte(s) Reported				
	Lamotrigine		60		ng/mL
	Trazadone		30		ng/mL
JVBAFM	11-nor-9-Carboxy-Delta-9-THC		37	4.44	ng/ml
JYTD4J	Methadone	✓			
	THC-COOH	✓			
	Additional Analyte(s) Reported				
	Lamotrigine	✓			
K9V49R	Methadone		0.24	13.75%	ug/mL
	Carboxy THC		54	11.72%	ng/mL
KBF2CN	Methadone		>0.25	N/A	ug/ml
	11-nor-9-Carboxy-THC (Carboxy-THC)		53	+/-18%	ng/ml
KCVE6R	Methadone		0.24	+/- 13.75%	ug/mL
	THC-COOH		46	+/- 11.72%	ng/mL

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
KFBVAP	methadone	✓			
	methadone EDDP	✓			
	11-nor-9-carboxy-tetrahydrocannabinol	✓			
KQXJUR	Methadone		0.35	13.75%	ug/mL
	THC		1	13.24%	ng/mL
	THC-COOH		50	11.72%	ng/mL
KQZDDX	Methadone	✓			
	Delta-9 Carboxy THC (THC metabolite)	✓			
KZKK8G	methadone		0.38	0.11	mg/L
	delta-9-THC		1.1	0.2	ng/mL
	11-nor-delta-9-THC-9-carboxylic acid	✓			
	Additional Analyte(s) Reported				
	lamotrigine		lower than the lowest calibrator of 0.50 mg/L		
L2C3MM	Methadone		383.55	30%	ng/mL
	EDDP		5.39	16%	ng/mL
	THC-COOH	✓			
	Additional Analyte(s) Reported				
	Lamotrigine	✓			
	Trazodone		25.76	33%	ng/mL
LCDNTL	Methadone		385		ng/mL
	11-nor-9-carboxy-delta-9-THC		41		ng/mL
LEFD8N	Methadone	✓			
	11-nor-9-Carboxy-Delta 9-Tetrahydrocannabinol	✓			
LL2JQG	Methadone	✓			
	Carboxy-THC		44	+/- 7.4	ng/ml
M6VE6P	Tetrahydrocannabinol		1.1	0.4	ng/mL
	11-nor-9-Carboxy-THC		35	9.0	ng/mL
M7FD9L	methadone	✓			
	EDDP	✓			
	EMDP	✓			
MDJ6PW	Methadone	✓			
	Delta-9 Carboxy THC	✓			

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
NFFK3C	Methadone	✓			
	THC-COOH (Tetrahydrocannabinol carboxylic acid)	✓			
	Additional Analyte(s) Reported				
	Lamotrigine	✓			
NKERRF	Methadone		412.3	70.1	ng/mL
	THC-COOH	✓			
NRZMTK	Methadone		0.39	+/-0.12	mg/L
	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)		<0.05		mg/L
	THC (delta-9-tetrahydrocannabinol)		1.1	+/-0.2	ng/mL
	THC metabolite (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid, a metabolite of THC)	✓			
P6ZTCG	Methadone	✓			
P96AXR	Methadone	✓			
	EDDP	✓			
	Additional Analyte(s) Reported				
	Lamotrigine	✓			
	Trazodone	✓			
PUMLNU	methadone	✓			
	THC-COOH		49	+/-24%	ng/mL
	Additional Analyte(s) Reported				
	lamotrigine	✓			
PXV4JF	Methadone		408		ng/mL
	11-Nor-9-Carboxy-Delta-9-THC		47		ng/mL
Q7WJ9N	Methadone		0.25	13.75%	ug/mL
	THC		1	13.24%	ng/mL
	THC-COOH		57	11.72%	ng/mL
QHJQ2H	Methadone		415		ng/mL
	delta-9-tetrahydrocannabinol		1		ng/mL
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		34		ng/mL

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
QVTNPJ	Methadone		389.24	38.92	ng/ml
	EDDP		5.74	1.37	ng/ml
	THC		1.24	0.17	ng/ml
	THC-COOH		44.84	8.07	ng/ml
R3R9RE	Methadone		0.22	+/-13.75%	ug/mL
	Tetrahydrocannabinol		1	+/-13.24%	ng/mL
	carboxy-tetrahydrocannabinol		63	+/-11.72%	ng/mL
R776WF	Methadone		0.46	0.09	µg/mL
	Δ9-Tetrahydrocannabinol (Δ9-THC)		present <1	N/A	ng/mL
	11-nor-9-carboxy-Δ9-Tetrahydrocannabinol (carboxy-THC)		38	6	ng/mL
	11-hydroxy-Δ9-Tetrahydrocannabinol (11-OH-THC)		present <1	N/A	ng/mL
RBG2Y6	methadone		421	-/+ 51	ng/mL
	tetrahydrocannabinol		1.3	-/+ 0.2	ng/mL
	carboxytetrahydrocannabinol		50.1	-/+ 8.3	ng/mL
	Additional Analyte(s) Reported				
	lamotrigine	✓			
RKZJ8H	Methadone	✓			
	Delta-9-Carboxy THC	✓			
RZXJ9J	Methadone		333	38	ng/mL
	Delta-9-THC		0.80	0.14	ng/mL
	11-nor-9-carboxy-Delta-9-THC		32	5	ng/mL
T4R3JF	methadone		380 ng/mL	110	ng/mL
	delta-9-tetrahydrocannabinol		1.1 ng/mL	0.2	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid	✓			
TCB9H9	Methadone		0.36	0.11	mg/L
	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)		LLC of 50		µg/L
	delta-9-tetrahydrocannabinol (THC)		1.1	0.2	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid	✓			

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
TDHL6F	methadone		357	32	ng/mL
	delta-9-tetrahydrocannabinol		1.02	0.20	ng/mL
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		47.1	8.0	ng/mL
TG6ZTQ	Methadone	✓			
	Delta-9-Tetrahydrocannabinol Metabolite	✓			
TLBUML	Methadone		0.38	31%	ug/mL
	Delta-9-THC	✓			
	11-nor-Delta-9-Carboxy-THC	✓			
TMTPBE	methadone		0.41	0.12	mg/L
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid	✓			
TTC34L	Methadone		350		ng/mL
	Ethylidine-dimethyl-diphenylpyrrolidine (EDDP)	✓			
	Delta-9-THC		1.3		ng/mL
	9-carboxy-11-nor-delta-9-THC		60		ng/mL
TV2HHN	Methadone	✓			
	Delta-9 Carboxy THC (THC metabolite)	✓			
TXM4BC	Methadone		0.353	0.041	mg/L
	THC	✓			
	Carboxy-THC		0.0373	0.0051	mg/L
	Additional Analyte(s) Reported				
	Caffeine	✓			
TYY2KM	METHADONE	✓			
U97X4J	Methadone		0.34	13.75%	ug/ml
	THC-COOH		51	11.72%	ng/ml
UECQXF	Methadone		324	37	ng/mL
	Delta-9-THC		0.73	0.12	ng/mL
	11-nor-9-carboxy-Delta-9-THC		29	5	ng/mL
	11-hydroxy-Delta-9-THC		0.57	0.11	ng/mL
UKXLVD	Methadone		401	36.09	ng/mL
	11-nor-9-Carboxy-Delta-9-THC		36	4.32	ng/mL

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
UTD3UE	Methadone		0.442	0.087	mg/L
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol		39.9	8.4	µg/L
UWBMVC	Methadone		0.31	13.75%	ug/mL
	Tetrahydrocannabinol (THC)		1	13.24%	ng/mL
	Carboxy-Tetrahydrocannabinol (THC-COOH)		54	11.72%	ng/mL
V7VEG8	Methadone	✓			
	EDDP	✓			
	11-nor-Delta-9-tetrahydrocannabinol	✓			
	Delta-9-tetrahydrocannabinol	✓			
VEMV6C	Methadone		0.39	0.12	mg/L
	delta-9-tetrahydrocannabinol		1.1	0.2	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid	✓			
VENQTN	Methadone	✓			
	Delta-9 Carboxy THC (THC Metabolite)	✓			
W7DN8N	methadone	✓			
	Delta-9 Tetrahydrocannabinol (THC)		0		
	Delta-9 carboxy THC (THC metabolite)	✓			
WK8BDF	Methadone		0.17	13.75%	ug/ml
	THC-COOH		46	11.72%	ng/ml
WQBGNC	methadone		0.41	0.12	mg/L
	THC-COOH (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid)	✓			
XA7AAA	methadone		0.37	0.11	mg/L
	2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)		lower than the lowest calibrator of 50 ng/mL		
	delta-9-tetrahydrocannabinol (THC)		1.1	0.2	ng/mL
	11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCOOH)	✓			
	Additional Analyte(s) Reported				
	lamotrigine		lower than the lowest calibrator of 0.50 mg/L		
XC8AA8	Methadone		388		ng/mL
	11-nor-9-Carboxy-Delta-9-THC		39		ng/mL

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
XL2F8E	Methadone		0.22	0.03	ug/mL
	Tetrahydrocannabinol		1	0.1	ng/mL
	Carboxy-tetrahydrocannabinol		50	6	ng/mL
XNLEBB	Methadone	✓			
	Delta9-THC-COOH	✓			
XTF8T7	Methadone		376.3	64.0	ng/mL
	THC		0.8	0.2	ng/mL
	THCA		39	6.6	ng/mL
	OH-THC		1.2	0.2	ng/mL
XWGAH8	Methadone		351.82	105.54	ng/mL
	THC		1.05	0.24	ng/mL
	Carboxy THC	✓			
	Additional Analyte(s) Reported				
	Lamotrigine	✓			
	Trazodone		25.74	8.49	ng/mL
XXPKB6	Methadone	✓			
	Additional Analyte(s) Reported				
	Lamotrigine	✓			
	Trazodone	✓			
XZXJLD	Methadone	✓			
	EDDP	✓			
	Delta-9 THC	✓			
	Delta-9 Carboxy THC	✓			
Y689P8	Methadone		0.27	13.75%	ug/mL
	THC		1	13.24%	ng/mL
	THC-COOH		60	11.72%	ng/mL
Y8VMDG	METHADONE		289	7,0	ng/mL
	Additional Analyte(s) Reported				
	TRAZODONE		25	0.8	ng/mL
YETEH6	Methadone		388.3	66.0	ng/mL
	THC		0.8	0.2	ng/mL
	THCA		37	6.3	ng/mL
	OH-THC		1.0	0.2	ng/mL

TABLE 2B: Confirmatory Results - Item 2

What drugs/metabolites were detected in Item 2?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
YPEHP4	Methadone	✓			
	Additional Analyte(s) Reported				
	Lamotrigine	✓			
	Trazodone	✓			
YTERZ7	methadone		0.5	±0.1	µg/ml
	Δ9-tetrahydrocannabinol (THC)		present <1	N/A	ng/mL
	11-nor-9-carboxy-Δ9-tetrahydrocannabinol (COOH-THC)		42	±7	ng/mL
	11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC)		present <1	N/A	ng/mL
YVYP33	Methadone	✓			
Z9PR8G	Methadone	✓			
	2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)	✓			
ZBUHCB	Methadone	✓			
	tetrahydrocannabinols	✓			
	11-nor-9-carboxy-delta-9-tetrahydrocannabinol	✓			
	11-hydroxy-delta-9-tetrahydrocannabinol	✓			
ZM8KVM	Methadone	✓			

Confirmatory Response Summary for Item 2	**Participants: 134**
Methadone:	127 (94.8%)
EDDP:	25 (18.7%)
THC:	63 (47.0%)
Carboxy THC:	110 (82.1%)
Hydroxy THC:	14 (10.4%)
Other Identified Drugs/Metabolites:	31 (23.1%)
No Drugs/Metabolites Detected Utilizing Confirmatory Methods:	0 (0.0%)

Raw Data - Item 2

TABLE 2C

Item 2 Raw Data - Methadone
Preparation concentration: 400 ng/mL

WebCode	List of Raw Data determinations (ng/mL)					
2XGFQD	256.00				256.00	
384XJC	262.00				262.00	
3PLWPA	378.67				378.70	
48GQV6	394.98				395.00	
48L4J2	485.28				485.30	
4GLYB6	382.00	458.90			420.40	
4TY2W3	417.23				417.20	
4XXDWA	215.00				215.00	
6ED9K2	390.22				390.20	
6QPB7Y	390.80				390.80	
6ZE2TR	399.44	400.20			399.80	
7DZVHQ	334.00	352.00			343.00	
7W827Z	366.82				366.80	
83E82W	249.00				249.00	
8E3B78	443.78				443.80	
8YE38N	339.00	374.00	482.00		398.30	
99WWZW	201.00				201.00	
9LYHDU	289.00				289.00	
9QXMGZ	516.00	552.00	507.00	548.00	530.80	
9T3E8R	379.00				379.00	
AAN8KX	323.54				323.50	
AH24FW	283.00				283.00	
AMTEPV	247.00				247.00	
ATKL94	246.00				246.00	
AUF4A6	227.00				227.00	
AX96AX	412.00	390.90			401.50	
B8Z4FX	391.74				391.70	
BRK67Q	347.00				347.00	
C6NP8U	415.11				415.10	
CHA3KP	398.07	393.30			395.70	
EYPBEP	109.00				109.00	X
FCP9XF	359.00				359.00	

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - Methadone
Preparation concentration: 400 ng/mL

WebCode	List of Raw Data determinations (ng/mL)		Participant Mean
FNAJNU	443.57		443.60
G4F3ZR	371.61		371.60
GBEU4E	420.00		420.00
GBZ8TR	387.00		387.00
GMBXAU	349.77		349.80
HHQ8KP	398.75		398.80
HX9XMX	400.00		400.00
K9V49R	248.00		248.00
KBF2CN	416.49		416.50
KCVE6R	244.00		244.00
KQXJUR	359.00		359.00
KZKK8G	383.00		383.00
L2C3MM	383.55		383.60
LCDNTL	385.67		385.70
NKERRF	412.30		412.30
NRZMTK	391.00		391.00
PXV4JF	408.78		408.80
Q7WJ9N	252.00		252.00
QHJQ2H	415.00		415.00
QVTNPJ	389.24		389.20
R3R9RE	220.00		220.00
R776WF	461.81		461.80
RBG2Y6	430.89	410.40	420.60
RZXJ9J	333.29		333.30
T4R3JF	377.00		377.00
TCB9H9	355.00	359.50	357.30
TDHL6F	356.56		356.60
TLBUML	375.00		375.00
TMTPBE	406.06		406.10
TTC34L	397.31	348.30	372.80
TXM4BC	389.15	316.90	353.00
U97X4J	341.00		341.00
UECQXF	323.92		323.90

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - Methadone
Preparation concentration: 400 ng/mL

WebCode	List of Raw Data determinations (ng/mL)						Participant Mean
UKXLVD	401.40						401.40
UTD3UE	442.80						442.80
UWBMVC	311.00						311.00
VEMV6C	387.00						387.00
WK8BDF	177.00						177.00
WQBGNC	407.50						407.50
XA7AAA	372.00						372.00
XC8AA8	388.98						389.00
XL2F8E	226.00						226.00
XTF8T7	376.30						376.30
XWGAH8	351.82						351.80
Y689P8	275.00						275.00
Y8VMDG	283.00	295.00	296.00	292.00	275.00	292.00	288.80
YETEH6	388.30						388.30
YTERZ7	502.79						502.80

Statistical Analysis for Item 2 - Methadone

Grand Mean	358.25	Number of Participants Included	79	Number of Participants without Raw Data or Data that was not reported in ng/mL	0
Standard Deviation	72.86	Number of Participants Excluded	1		

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - EDDP
Preparation concentration: 5.8 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)		Participant Mean
3PLWPA	6.5500		6.5500
9T3E8R	5.0000		5.0000
FNAJNU	7.3500	7.7700	7.5600
G4F3ZR	5.0077		5.0080
GBZ8TR	3.0000		3.0000
L2C3MM	5.3900		5.3900
NRZMTK	14.000		14.000
QVTNPJ	5.8700	5.7400	5.8050
TCB9H9	3.0000		3.0000
XA7AAA	3.0000		3.0000

Statistical Analysis for Item 2 - EDDP

Grand Mean	5.83	Number of Participants Included	10	Number of Participants without Raw Data or Data that was not reported in ng/mL	0
Standard Deviation	3.26	Number of Participants Excluded	0		

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - THC
Preparation concentration: 1.1 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)					Participant Mean	
2XGFQD	1.2300					1.2300	
384XJC	1.1200					1.1200	
3PLWPA	1.1200	1.1000				1.1100	
48GQV6	1.2910					1.2910	
48L4J2	0.9930					0.9930	
4GLYB6	1.1800					1.1800	
6QPB7Y	0.8000					0.8000	
6ZE2TR	1.1200	1.1300				1.1250	
7DZVHQ	0.8200	0.8500				0.8350	
7WPAVU	1.8783					1.8780	X
83E82W	1.1500					1.1500	
9LYHDU	1.0100					1.0100	
9T3E8R	1.2030					1.2030	
AAN8KX	1.3100					1.3100	
AH24FW	1.0400					1.0400	
AMTEPV	1.2200					1.2200	
ATKL94	1.0000					1.0000	
AUF4A6	1.0100					1.0100	
AX96AX	1.1840					1.1840	
B8Z4FX	1.0290					1.0290	
EJUN9X	1.4000	1.5000				1.4500	
EZLLAR	1.0700					1.0700	
FNAJNU	1.1000	1.0100				1.0550	
G4F3ZR	1.0804					1.0800	
GBEU4E	1.0000	1.0000				1.0000	
GBZ8TR	1.0870	1.1650				1.1260	
GV3BAT	1.1000	1.1000				1.1000	
HAVBCT	There is no raw data for this item						
KQXJUR	1.0200					1.0200	
KZKK8G	1.0940	1.1420				1.1180	
M6VE6P	1.1000	1.2000				1.1500	
NRZMTK	1.1600	1.1150				1.1380	

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - THC
Preparation concentration: 1.1 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)		Participant Mean
Q7WJ9N	1.0100		1.0100
QHJQ2H	1.0000		1.0000
QVTNPJ	1.2400	1.2900	1.2650
R3R9RE	1.1300		1.1300
R776WF	0.7160		0.7160
RBG2Y6	1.2653	1.2960	1.2810
RZXJ9J	0.8000		0.8000
T4R3JF	1.0880		1.0880
TCB9H9	1.0650		1.0650
TDHL6F	1.0200		1.0200
TTC34L	1.2500		1.2500
TXM4BC	1.0200		1.0200
UECQXF	0.7300		0.7300
UWBMVC	1.1100		1.1100
VEMV6C	1.0900		1.0900
W7DN8N	0.8600	0.8800	0.8700
XA7AAA	1.1210		1.1210
XL2F8E	1.0700		1.0700
XTF8T7	0.8000		0.8000
XWGAH8	1.0567		1.0570
Y689P8	1.2700		1.2700
YETEH6	0.8000		0.8000
YTERZ7	0.8590		0.8590

Statistical Analysis for Item 2 - THC

Grand Mean	1.07	Number of Participants Included	53	Number of Participants without Raw Data or Data that was not reported in ng/mL	1
Standard Deviation	0.16	Number of Participants Excluded	1		

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - Carboxy THC
Preparation concentration: 45 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)		
2XGFQD	49.080		49.080
384XJC	52.720		52.720
3PLWPA	43.930	44.880	44.410
48L4J2	45.038		45.040
4BHXCW	33.600		33.600
4TY2W3	47.480		47.480
4XXDWA	57.400		57.400
6ED9K2	36.590		36.590
6QPB7Y	40.500		40.500
7W827Z	40.090		40.090
7WPAVU	38.901		38.900
83E82W	62.710		62.710
99WWZW	57.990		57.990
9LYHDU	42.300		42.300
AAN8KX	31.630		31.630
AH24FW	56.800		56.800
AMTEPV	65.600		65.600
ATKL94	50.000		50.000
AUF4A6	51.670		51.670
B8Z4FX	44.364		44.360
BG3H2V	36.560		36.560
BRK67Q	44.000		44.000
C6NP8U	44.050		44.050
E9WNVT	39.240		39.240
EJUN9X	39.000	40.000	39.500
EYPBEP	69.710		69.710
EZLLAR	40.310		40.310
FCP9XF	40.000	37.000	38.500
FNAJNU	44.540	44.990	44.770
G4F3ZR	45.258		45.260
GBEU4E	40.000	40.000	40.000
GMBXAU	46.300		46.300

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - Carboxy THC
Preparation concentration: 45 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)		
GV3BAT	37.000	39.000	38.000
HAVBCT	47.300		47.300
HHQ8KP	37.670		37.670
JVBAFM	37.840		37.840
K9V49R	54.100		54.100
KBF2CN	56.174	49.030	52.600
KCVE6R	46.370		46.370
KQXJUR	50.660		50.660
KZKK8G	39.826	39.780	39.800
LCDNTL	41.460		41.460
LL2JQG	44.170		44.170
M6VE6P	35.000	35.000	35.000
PUMLNU	49.000		49.000
PXV4JF	47.440		47.440
Q7WJ9N	57.550		57.550
QHJQ2H	34.000		34.000
QVTNPJ	46.940	44.840	45.890
R3R9RE	63.000		63.000
R776WF	38.550		38.550
RBG2Y6	50.009	50.260	50.140
RZXJ9J	31.600		31.600
TDHL6F	47.120		47.120
TMTPBE	32.206		32.210
TTC34L	60.470		60.470
TXM4BC	37.520	37.170	37.350
U97X4J	51.570		51.570
UECQXF	29.330		29.330
UKXLVD	36.710		36.710
UTD3UE	39.930		39.930
UWBMVC	54.910		54.910
VEMV6C	39.331		39.330
WK8BDF	46.770		46.770

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - Carboxy THC
Preparation concentration: 45 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)	
WQBGNC	33.698	33.700
XC8AA8	39.740	39.740
XL2F8E	50.700	50.700
XTF8T7	38.900	38.900
Y689P8	60.280	60.280
YETEH6	37.000	37.000
YTERZ7	42.648	42.650

Statistical Analysis for Item 2 - Carboxy THC

Grand Mean	45.04	Number of Participants Included	71	Number of Participants without Raw Data or Data that was not reported in ng/mL	0
Standard Deviation	8.88	Number of Participants Excluded	0		

TABLE 2C: Raw Data - Item 2

Item 2 Raw Data - Hydroxy THC
Preparation concentration: 0.9 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)		Participant Mean
2XGFQD	1.2300		1.2300
48L4J2	0.7700		0.7700
6QPB7Y	1.1000		1.1000
6ZE2TR	There is no raw data for this item		
B8Z4FX	0.7440		0.7440
EJUN9X	1.2000	1.2000	1.2000
G4F3ZR	1.0612		1.0610
R776WF	0.6930		0.6930
UECQXF	0.5700		0.5700
XTF8T7	1.2000		1.2000
YETEH6	1.0000		1.0000
YTERZ7	0.6910		0.6910

Statistical Analysis for Item 2 - Hydroxy THC

Grand Mean	0.93	Number of Participants Included	11	Number of Participants without Raw Data or Data that was not reported in ng/mL	1
Standard Deviation	0.24	Number of Participants Excluded	0		

Reporting Procedures - Item 2

TABLE 2D - Item 2

Quantitative Reporting Procedures	
WebCode	***If quantitative analysis was performed, the reported concentrations are:***
2XGFQD	A single determination.
384XJC	A single determination.
3PLWPA	A single determination was used for both EDDP and Methadone. Sample was screened and confirmed on a quantitative method for THC and THC-COOH, the lower of the two values is the reported concentration.
48GQV6	A single determination.
48L4J2	A single determination.
4BHXCW	A single determination.
4GLYB6	A single determination.
4TY2W3	A single determination.
4XXDWA	A single determination.
6ED9K2	A single determination.
6QPB7Y	A single determination.
6ZE2TR	The mean of duplicate/several determinations.
7DZVHQ	lamotrigine single determination, methadone/THC duplicate
7W827Z	A single determination.
7WPAVU	A single determination.
83E82W	A single determination.
8E3B78	A single determination.
8YE38N	The mean of duplicate/several determinations.
99WWZW	A single determination.
9LYHDU	A single determination.
9QXMGZ	The mean of duplicate/several determinations.
9T3E8R	A single determination.
AAN8KX	A single determination.
AH24FW	A single determination.
AMTEPV	A single determination.
ATKL94	A single determination.
AUF4A6	A single determination.
AX96AX	delta-9-tetrahydrocannabinol-single determination, methadone-the mean of duplicate/several determinations
B8Z4FX	A single determination.
BG3H2V	A single determination.

TABLE 2D: Reporting Procedures - Item 2

WebCode	Quantitative Reporting Procedures *If quantitative analysis was performed, the reported concentrations are:*
BRK67Q	A single determination.
C6NP8U	A single determination.
CHA3KP	The mean of duplicate/several determinations.
E9WNVT	A single determination.
EJUN9X	Lowest of duplicate samples, truncated
EYPBEP	A single determination.
EZLLAR	A single determination.
FCP9XF	Methadone was single determination; lamotrigine and THC-COOH were duplicate determinations
FNAJNU	Sample was screened and confirmed on a quantitative method, the lower of the two values is the reported concentration
G4F3ZR	A single determination.
GBEU4E	The mean of duplicate/several determinations.
GBZ8TR	Quantitative result for THC was the mean of two determinations. All other analytes were single determinations.
GMBXAU	A single determination.
GV3BAT	Lower of the duplicate samples
HAVBCT	A single determination.
HHQ8KP	A single determination.
HX9XMX	A single determination.
JVBAFM	A single determination.
K9V49R	A single determination.
KBF2CN	*See Comments
KCVE6R	A single determination.
KQXJUR	A single determination.
KZKK8G	single for all but delta-9-THC
L2C3MM	A single determination.
LCDNTL	A single determination.
LL2JQG	A single determination.
M6VE6P	The lowest of duplicate
NKERRF	A single determination.
NRZMTK	THC-mean of duplicate, methadone-single, EDDP-single, lamotrigine-single
PUMLNU	A single determination.
PXV4JF	A single determination.
Q7WJ9N	A single determination.

TABLE 2D: Reporting Procedures - Item 2

Quantitative Reporting Procedures	
WebCode	***If quantitative analysis was performed, the reported concentrations are:***
QHJQ2H	A single determination.
QVTNPJ	Screening was performed using a quantitative method, therefore, the lowest of the two determinations is utilized as the reported value.
R3R9RE	A single determination.
R776WF	A single determination.
RBG2Y6	A single determination.
RZXJ9J	A single determination.
T4R3JF	A single determination.
TCB9H9	Methadone quantitation was the mean of duplicate/several determinations. All other analytes were a single determination.
TDHL6F	A single determination.
TLBUML	A single determination.
TMTPBE	A single determination.
TTC34L	Lowest value from duplicate determinations
TXM4BC	The mean of duplicate/several determinations.
U97X4J	A single determination.
UECQXF	A single determination.
UKXLVD	A single determination.
UTD3UE	A single determination.
UWBMVC	A single determination.
VEMV6C	A single determination.
W7DN8N	The mean of duplicate/several determinations.
WK8BDF	A single determination.
WQBGNC	A single determination.
XA7AAA	A single determination.
XC8AA8	A single determination.
XL2F8E	A single determination.
XTF8T7	A single determination.
XWGAH8	A single determination.
Y689P8	A single determination.
Y8VMDG	The mean of duplicate/several determinations.
YETEH6	A single determination.
YTERZ7	A single determination.
Z9PR8G	A single determination.

Response Summary for Item 2	Participants: 94
A single determination:	71 (75.5%)
The mean of duplicate/several determinations:	8 (8.5%)
Other:	15 (16.0%)

Methods of Analysis - Item 2

TABLE 2E - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
2A9FUZ	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
2DWHAM	GC/MS		✓	
2JJHF2	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
2XGFQD	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS	✓	✓	
	GC/FID		✓	✓
2Z3DTA	Immunoassay	✓		
	GC/MS		✓	
32ZWJG	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
384XJC	Immunoassay	✓		
	GC/MS		✓	
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
3PLWPA	LC/MS/MS	✓	✓	✓
48GQV6	LC/MS/MS	✓	✓	✓
48L4J2	Immunoassay	✓		
	LC/MS/MS		✓	✓
4BHXCW	Immunoassay	✓		
	LC/MS/MS		✓	✓
4D2WJY	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS			✓
4GLYB6	LC-HR-MS/MS	✓		
	LC/MS/MS		✓	
4TY2W3	LC/MS/MS	✓	✓	✓
	GC/MS		✓	✓
4XXDWA	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
6ED9K2	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	GC/MS		✓	✓
6QPB7Y	LC/MS/MS	✓	✓	✓
	GC/MS/MS		✓	✓
6ZE2TR	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
	LC-MS-QTOF			
73XK23	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS		✓	✓
7DZVHQ	LC/MS	✓		
	HPLC/DAD	✓		✓
	LC/MS/MS			✓
7NV3EA	LC/MS	✓	✓	
7RX64B	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
7W827Z	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	GC/MS		✓	✓
7WPAVU	Immunoassay	✓		
	LC/MS/MS		✓	✓
83E82W	LC/MS/MS		✓	
	GC/MS		✓	
	GC/FID		✓	
	Immunoassay	✓		
8E3B78	LC/MS/MS	✓	✓	✓
8X2ATA	GC/MS		✓	
8YE38N	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	LC-TOFMS	✓		
94Y64T	Immunoassay	✓		
	GC/MS		✓	
	GC/MS with BSTFA		✓	
99WWZW	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
9LYHDU	LC/MS/MS	✓		
	GC/MS		✓	✓
	LC/HRMS		✓	
9QXMGZ	Immunoassay	✓		
	LC-QTOF	✓	✓	
	LC/MS/MS		✓	✓
9T3E8R	Immunoassay	✓		
	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
AAN8KX	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
AD6HL9	GC/MS	✓	✓	
	LC/MS/MS		✓	
AH24FW	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
AMTEPV	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
	GC/FID		✓	✓
ATKL94	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
AUF4A6	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
AV6JBZ	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
AX96AX	LC/MS/MS		✓	
	LC-HRMS/MS	✓		
B8Z4FX	Immunoassay	✓		
	LC/MS/MS		✓	
BG3H2V	Immunoassay	✓		
	LC/MS/QTOF		✓	
	GC/MS	✓	✓	
	LC/MS/MS		✓	
BRK67Q	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
C6NP8U	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓
CHA3KP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS			✓
DFZA93	Immunoassay	✓		
E9WNVT	Immunoassay	✓		
	LC/MS/MS		✓	
	LC-QTOF-MS	✓		
	GC/MS		✓	
EBYZ3T	LC-QTOF	✓		
	GC/MS		✓	
EJUN9X	Immunoassay	✓		
	LC/MS/MS		✓	✓
EYPBEP	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
	GC/FID			✓
EZLLAR	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
	LC-QTOF-MS	✓		
FCP9XF	LC/MS/MS	✓	✓	✓
FNAJNU	LC/MS/MS	✓	✓	✓
G4F3ZR	LC/MS/MS	✓	✓	
GBEU4E	Immunoassay	✓		
	UPLC-QTOF MS	✓	✓	
	LC/MS/MS		✓	✓
GBZ8TR	LC-High resolution MS/MS	✓		
	LC/MS/MS		✓	✓
GMBXAU	GC/MS	✓	✓	✓
	LC/MS/MS	✓		
GNH4MU	GC/MS	✓		
	LC/MS/MS	✓	✓	
GV3BAT	Immunoassay	✓		
	LC/MS/MS		✓	✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
GX9PTT	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS	✓	✓	
	LC/QTOF-MS	✓		
HAVBCT	Immunoassay	✓		
	GC/MS		✓	✓
HHQ8KP	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	GC/MS		✓	✓
HNC8RP	GC/MS		✓	
	LC MS QTOF		✓	
HPN7NJ	ELISA	✓		
	GC/MS	✓	✓	
	LC/MS		✓	
HX9XMX	UPLC-DAD	✓		
	GC/MS		✓	✓
JVBAFM	Immunoassay	✓		
	LC/MS/MS	✓		
	LC/MS/MS		✓	✓
JYTD4J	Immunoassay	✓		
	GC/MS	✓	✓	
K9V49R	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
KBF2CN	Immunoassay	✓		
	LC/MS/MS		✓	✓
KCVE6R	Immunoassay	✓		
	GC/MS	✓		
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
KCWY4N	Immunoassay	✓		
KFBVAP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
KQXJUR	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
	GC/FID		✓	✓
KQZDDX	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
KZKK8G	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
L2C3MM	LC/MS/MS	✓	✓	
LCDNTL	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
LEFD8N	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
LL2JQG	Immunoassay	✓		
	GC/MS	✓	✓	✓
M6VE6P	Immunoassay	✓		
	LC/MS/MS		✓	✓
M7FD9L	LC/MS/MS	✓	✓	
MDJ6PW	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
NFFK3C	Immunoassay	✓		
	GC/MS		✓	
NKERRF	LC/MS/MS	✓	✓	✓
NRZMTK	LC-HRMSMS	✓		
	LC/MS/MS		✓	✓
P6ZTCG	Immunoassay	✓		
	LC-QTOF MS		✓	
P96AXR	LC/MS/MS	✓	✓	
PUMLNU	LC/MS/MS	✓		
	GC/MS		✓	
PXV4JF	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	✓
	LC/MS		✓	✓
Q7WJ9N	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
QHJQ2H	Immunoassay	✓		
	LC/MS/MS		✓	✓

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
QVTNPJ	LC/MS/MS	✓	✓	
R3R9RE	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
	GC/FID			✓
R776WF	Immunoassay	✓		
	LC/MS/MS		✓	✓
RBG2Y6	LC/MS/MS		✓	✓
	Immunoassay	✓		
	LC-QTOF-MS	✓		
RKZJ8H	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS		✓	✓
RZXJ9J	Immunoassay	✓		
	LC/MS/MS		✓	✓
T4R3JF	LC-High Resolution Tandem Mass Spectrometry	✓		
	LC/MS/MS		✓	✓
TCB9H9	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
TDHL6F	Immunoassay	✓		
	LC/MS/MS		✓	✓
TG6ZTQ	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
TLBUML	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	
	GC/NPD	✓	✓	✓
TMTPBE	LC-HRMS/MS	✓		
	LC/MS		✓	
TTC34L	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
TV2HHN	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
TXM4BC	Immunoassay	✓		
	LC/MS/MS		✓	✓
	LC QTOF	✓		

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
TYY2KM	GC/MS		✓	
U97X4J	Immunoassay	✓		
	GC/MS	✓	✓	
	GC/FID		✓	✓
	LC/MS/MS		✓	✓
UECQXF	Immunoassay	✓		
	LC/MS/MS		✓	✓
UKXLVD	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	GC/MS		✓	✓
UNHCLG	LC/MS/MS	✓		
UTD3UE	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	✓
UWBMVC	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
	GC/FID		✓	✓
V7VEG8	Immunoassay	✓		
	GC/MS/MS		✓	
	LC/MS/MS		✓	
VEMV6C	LC-HRMS/MS	✓		
	LC/MS/MS		✓	✓
VENQTN	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS	✓	✓	
W7DN8N	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	✓
WK8BDF	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
WQBGNC	LC/MS/MS	✓	✓	✓
	LC-HRMS/MS	✓		
XA7AAA	LC-HRMS/MS	✓		
	LC/MS		✓	✓
XC8AA8	Immunoassay	✓		
	LC/MS/MS	✓	✓	
	GC/MS		✓	

TABLE 2E: Methods of Analysis - Item 2

WebCode	Method	Screening	Confirmatory	Quantitation
XL2F8E	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
XNLEBB	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS/MS		✓	
XTF8T7	LC/MS/MS	✓	✓	✓
	GC/MS/MS		✓	✓
XWGAH8	LC/MS/MS	✓	✓	
XXPKB6	LC Q TOF	✓	✓	
XZXJLD	Immunoassay	✓		
	LC/QTOF-MS	✓		
	LC/MS		✓	
	GC/MS		✓	
Y689P8	Immunoassay	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
Y8VMDG	LC/MS/MS	✓	✓	✓
YETEH6	LC/MS/MS	✓	✓	✓
	GC/MS/MS		✓	✓
YTERZ7	Immunoassay	✓		
	LC/MS/MS		✓	✓
YVYP33	GC/MS		✓	
YX7XE9	LC/MS/MS	✓		
	Immunoassay	✓		
Z9PR8G	GC-MSD /LS-MS-MS	✓	✓	
ZBUHCB	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
ZCJXD7	Immunoassay	✓		
ZM8KVM	GC/MS	✓	✓	

Response Summary for Item 2 - Methods of Analysis			Participants: 138
	Screening	**Confirmatory**	**Quantitation**
Immunoassay:	91	0	0
GC/MS:	33	72	22
LC/MS:	2	8	4
LC/MS/MS:	36	102	79
Other:	28	24	16

Additional Comments for Item 2

TABLE 2F

WebCode	Item Comments
2A9FUZ	Promazine used as internal standard in Drug Screen. Limit of Detection is 2ng/mL. Values below LOD are reported as "Not Detected".
2JJHF2	The internal standard used for the drug screen procedure was promazine. The delta-9-THC quantitation method used to quantify delta-9-THC and qualitatively identify delta-9-COOH THC was run. The internal standards used for the delta-9-THC quantitation method were delta-9-THC d3 and delta-9-COOH THC d3. The limit of detection for the delta-9-THC quantitation method is 2ng/mL and any results below this value will be reported as "not detected".
2Z3DTA	Methadone : cut off 30 ng/mL in blood by GC/MS Delta- 9- THC : cut off 15 ng/mL in blood by GC/MS
32ZWJG	Delta-9 tetrahydrocannabinol was below administrative LOD/LOQ and was not reported. Promazine used as internal standard for GC-MS drug screen. Deuterated THC and carboxy THC used as internal standard during LC-MSMS analysis.
384XJC	Methadone analysis was performed using the GC. THC analysis was performed using the LC.
3PLWPA	Methadone quantitative value was >Linear Range 250.00ng/mL on first extraction. Dilution was performed for reported value. EDDP LOQ 5ng/mL; ISTD EDDP-D3 Methadone LOQ 5ng/mL; ISTD Methadone-D9 THC LOQ 1ng/mL; ISTD THC-D3 THC-COOH LOQ 5ng/mL; ISTD THC-COOH-D9
48GQV6	The expanded uncertainty value was calculated at the 99.7 percent confidence level. The directions specified "The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly." Lamotrigine was also confirmed in this sample, additionally trazodone was indicated, the directions said to disregard so confirmatory testing was not pursued.
48L4J2	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive methadone (MDN) screen, confirmation/quantitation of MDN is performed using MDN-D3 as internal standards, respectively. LOD and LOQ for MDN is 5 ng/mL and 10 ng/mL, respectively. Following a positive cannabinoid screen, confirmation/quantitation of Δ9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (carboxy-THC), and 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) is performed using THC-D3, carboxy-THC-D3, and 11-OH-THC-D3 as internal standards, respectively. LOD for THC and 11-OH-THC is 0.5 ng/mL; LOD for carboxy-THC is 2.5 ng/mL. LOQ for THC and 11-OH-THC is 1 ng/mL; LOQ for carboxy-THC is 5 ng/mL. Target drug results quantitating below the LOQ but greater than the LOD are reported as "present, less than [LOQ value]."
4D2WJY	Resubmission of Predistribution results. Originally submitted on 4/5/22.
4GLYB6	Mepivacaine used for internal standard for LC analysis, or deuterated delta-9-tetrahydrocannabinol (THC) and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) for THC analysis. Lamotrigine reported as lower than the lowest calibrator of 0.5 mg/L, but raw data is 0.061 mg/L. Limit of report for methadone and lamotrigine is 0.025 mg/L. Limit of report for THC is 1 ng/mL and for THC-COOH is 5 ng/mL. Due to presence of delta 8 metabolite, quant of THC-COOH could not be reported.
6QPB7Y	LC-MS/MS: Methadone/Methadone-D9, LLOQ 10ng/mL, working range 10-500ng/mL; THC-COOH/THC-COOH-D9, LLOQ 6ng/mL, working range 6-300ng/mL. GC-MS/MS: THC/THC-D3, LLOQ 0.5ng/mL, working range 0.5-20ng/mL; 11-OH-THC/11-OH-THC-D3, LLOQ 0.5ng/mL, working range 0.5-20ng/mL, THC-COOH/THC-COOH-D9, LLOQ 5ng/mL, working range 5-200ng/mL.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
6ZE2TR	Limit of detection for trazodone: 12.5 ng/mL. Limit of detection for hydroxy-THC: 0.5 ng/mL. Lamotrigine not detected on GC-MS screen, no other method for confirmation
73XK23	Limit of detection for Delta-9 THC is 2.0ng/mL. All results under 2ng/mL are reported as not detected.
7DZVHQ	LC/MS above refers to LC-QTOF-MS. Immunoassay was used for presumptive screening of tetrahydrocannabinol. Internal standard for THC quantitation was D3-THC. Internal standard for lamotrigine quantitation was prazepam. Internal standard for methadone quantitation was D3-methadone.
7NV3EA	ESTAZOLAM WAS USED AS INTERNAL STANDARD
7RX64B	Tetrahydrocannabinol (THC) was quantitated but level was below our LOQ.
7WPAVU	Immunoassay: Methadone cutoff: 10ng/mL; Carboxy-Tetrahydrocannabinol cutoff: 10ng/mL. LC/MS/MS: THC and OH-THC LOQ: 1ng/mL, and C-THC cutoff: 5ng/mL; Internal standards: THC-D3, OH-THC-D3, and C-THC-D3.
8E3B78	THC-COOH results not reported due to unacceptable chromatography caused by an interfering peak.
8YE38N	EDDP too low to quantitate date 21 June 2022. Lamotrigine too low to quantitate date of analysis 20 June 2022.
94Y64T	bstfa lot [Serial Number] used phenyltoloxamine lot [Serial Number], heptabarbital lot [Serial Number] 11-OH-THC lot [Serial Number] lamotrigine present but not confirmed
99WWZW	Tetrahydrocanabinol was detected, but not reported as it fell below our lower limit of quantitation of 1 ng/ml. The raw data value was 0.92ng/ml.
9QXMGZ	Sample screened positive for cannabinoids, but we do not confirm these results. LOQ for methadone = 40 ng/mL. Methadone-D3 used for internal standard. Lamotrigine also detected, but not reported.
9T3E8R	11-nor-9-carboxy-tetrahydrocannabinol (THC-COOH) reported qualitatively due to the presence of possible delta-8-tetrahydrocannabinol related metabolites, we currently don't have a validated method for reporting delta-8-tetrahydrocannabinol or its metabolites. THC limit of report 1.0 ng/mL, THC-COOH limit of report 5.0 ng/mL, methadone limit of report 25 ng/mL. Internal standards - mepivacaine, delta-9-THC-d3, delta-9-THC-COOH-d9 * low calibrator for EDDP is 50 ng/mL, limit of report is 3 ng/mL. This sample was reported lower than the lowest calibrator of 50 ng/mL ^ low calibrator for lamotrigine is 125 ng/mL, limit of report is 25 ng/mL, this sample was reported lower than the lowest calibrator of 125 ng/mL
AAN8KX	The lower limit of detection for Delta 9 THC is 2 ng/mL and the concentration for this sample was below that, so it was reported as less than 2 ng/mL.
AD6HL9	Delta-9 THC was detected under our Limit of Detection. Because of this, Delta-9 THC was not reported.
AMTEPV	Note: Hydroxy Tetrahydrocannabinol (THC OH) was present in the sample at a concentration of 1.19ng/mL (uncertainty 15.18%). However, it did not meet reporting criteria due to ion ratio falling acceptance. Not reported.
AV6JBZ	Nalorphine was used as ISTD for opiate confirmation testing. Promazine was used as ISTD for blood drug screen. THC was quantitated for, but below LOD. Metabolite confirmed qualitatively only.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
AX96AX	Internal standards-mephobarbital, mepivacaine, gabapentin-d4, olanzepine-d8, bupropion-d9, diazepam-d5, clonazepam-d4, delta-9-tetrahydrocannabinol-d3, 11-hydroxy-delta-9-tetrahydrocannabinol-d3, 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid-d9 Limit of detection for delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol 1ng/mL Limit of detection for 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid 5ng/mL Calibration range for delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol 1ng/mL-20ng/mL Calibration range for 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid 5ng/mL-100ng/mL 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid reported qualitatively due to what appears to be delta-8-tetrahydrocannabinol co-eluting with the 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid metabolite and cutting off part of the peak. lamotrigine was also found in the sample lower than the lowest calibrator of 0.5mg/L lamotrigine limit of detection 0.5-8.0mg/L trazodone also found. Per CTS, contaminant.
B8Z4FX	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Following a positive methadone (MDN) screen, confirmation/quantitation of MDN is performed using MDN-D3 as internal standards, respectively. LOD and LOQ for MDN is 5 ng/mL and 10 ng/mL, respectively. Following a positive cannabinoid screen, confirmation/quantitation of Δ9-tetrahydrocannabinol (THC), 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (carboxy-THC), and 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) is performed using THC-D3, carboxy-THC-D3, and 11-OH-THC-D3 as internal standards, respectively. LOD for THC and 11-OH-THC is 0.5 ng/mL; LOD for carboxy-THC is 2.5 ng/mL. LOQ for THC and 11-OH-THC is 1 ng/mL; LOQ for carboxy-THC is 5 ng/mL. Target drug results quantitating below the LOQ but greater than the LOD are reported as "present, less than [LOQ value]."
BG3H2V	EDDP and Lamotrigine indicated, did not meet reporting criteria. THC and 11-OH-THC were detected in confirmation testing but concentrations were below limit of quantitation of 1 ng/ml. Internal standards- Mepivacaine, THC-D3, 11-OH-THC-D3, THCA-D3.
C6NP8U	11-nor-9-Carboxy-Delta-9-THC detected by ELISA and confirmed by LC-MS/MS. Methadone detected by LC-MS/MS and confirmed by GC/MS.
CHA3KP	Cannabinoids detected by immunoassay but not confirmed.
E9WNVT	Internal standard: - Mepivacaine - THC-D3 - 11-OH-THC-D3 - THCA-D3 Indicated: - Cotinine - EDDP - Caffeine - THC - quantitation below LOQ - 11-OH-THC - quantitation below LOQ
EJUN9X	Lab does not currently have confirmation method for benzodiazepines and methadone. Deuterated internal standard used. Limit of detection for THC, 11-Hydroxy-THC, and 11-nor-9-Carboxy-THC are 1 ng/mL, 1 ng/mL, and 5 ng/mL respectively.
EZLLAR	Internal Standard: Mepivacaine Indications of Acetaminophen, Cotinine, EDDP, Lamotrigine, Trazodone
FCP9XF	trace amount of trazodone detected
FNAJNU	EDDP LOQ 5ng/mL; ISTD EDDP-D3 Methadone LOQ 5ng/mL; ISTD Methadone-D9 THC LOQ 1ng/mL; ISTD THC-D3 THC-COOH LOQ 5ng/mL; ISTD THC-COOH-D9. First extraction for Methadone quantitative value was >Linear Range 250.00ng/mL; dilution was performed for reported value
GBEU4E	Delta-9-tetrahydrocannabinol, Delta-9-THC Acid Screening: Immunoassay Confirmation & Quantitaion: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) in Multiple Reaction Monitoring (MRM) mode. Internal Standard: Deuterated analogues of THC, and THC Acid LOD for Delta-9-tetrahydrocannabinol: 0.2 ng/mL and Delta-9-THC Acid: 0.5 ng/mL Lamotrigine and Methadone (single determination only) Screening, Confirmation and Quantitation: UPLC-QTOF MS (Waters). Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
GBZ8TR	Mepivacaine, THC-d3, THC-OH-d3, THC-COOH-d9 were used as internal standard. THC-OH was detected in the screen but not reported due to being below our LOR in confirmatory testing. LOR = 1 ng/mL THC-COOH is reported qualitatively only if the presence of a coelutor (possibly delta-8 THC metabolite) is detected upon confirmatory testing. For this case, that coelutor was detected. The lowest calibrator used for the quantitative determination of EDDP is 50 µg/L, the LOR is 3 µ/L Trazodone was not reported due to being identified as an artifact of production.
GNH4MU	Trazodone (>10ng/ml), lamotrigine (>10ng/ml) and traces of EDDP (<10ng/ml) were also detected in the sample.
GV3BAT	Benzodiazepines and methadone hit presumptive positive, however our laboratory is not able to confirm or quantitate these classes/types of drugs. We are only able to quantitate and/or confirm the following: amphetamine, diphenhydramine, ephedrine/psuedoephedrine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, psilocin, LSD, THC, Carboxy-THC, Hydroxy-THC.
HAVBCT	THC screening cut off is 10ng/mL. Methadone screening cut off is 25ng/mL. The quantification result of Delta-9-THC was below the lower reporting limit. The lower reporting limit for Delta-9-THC is 1ng/mL. The lower reporting limit for Delta-9-Carboxy THC is 10ng/mL. Dilutions of samples were prepared for analysis, but not included in the raw data. Extraction was repeated to confirm the THC/COOH correlation. Analysts are not certified to perform confirmation testing on Methadone. Cases that are positive for Methadone are sent to a reference laboratory.
HPN7NJ	Promazine- Internal Standard for Drug Screen Delta 9 - THC-D3 and Delta 9 - Carboxy THC-D3- Internal Standard for Delta 9 - THC procedure Delta 9 - THC Procedure Limit of detection is 2 ng/mL, Values below this value are reported as not detected
JVBAFM	Methadone was detected via LC/MS/MS screening but confirmation/quantitation tests not performed. 11-nor-9-Carboxy-Delta-9-THC was detected via immunoassay screening, and confirmation/quantitation test was performed via LC/MS/MS.
JYTD4J	The internal reference materials used were Phenyltoloxamine for the base fraction, Hexobarbital for the acid fraction, and 11-OH-THC for THC/THCC analysis. Possible Caffeine noted in both the base and acid fractions.
KBF2CN	*Methadone - single determination *Carboxy-THC - the mean of duplicate/several determinations Other confirmed drugs 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), a metabolite of Methadone Qualitative only
KFBVAP	Diazepam D5 is used as an internal standard
KQXJUR	THC-OH was indicated, but below the 1ng/mL LOQ
KQZDDX	Delta-9 Tetrahydrocannabinol (THC) quantitation was performed, quantitated level was below our LOQ/LOD, reported as not detected
KZKK8G	11-nor-delta-9-THC-9-carboxylic acid would normally be reported quantitatively, but due to a coeluting peak that affected integration, it could not be done for this sample. A small amount of EDDP (methadone metabolite) was found that quanted at our limit of report, but was not reported.
L2C3MM	Confirmation cutoff for Trazodone, Methadone, Lamotrigine, EDDP was 5ng/mL THC-COOH confirmation cutoff was 10ng/mL
LCDNTL	Immunoassay : THC positive, LC/MS/MS screen: methadone positive, GC/MS confirmation for methadone, LC/MS/MS confirmation for THC
LEFD8N	Immunoassay used was ELISA. Drug screen internal standard is Promazine. Tetrahydrocannabinol quantitative procedure used which analyzes Delta 9-Tetrahydrocannabinol quantitatively and 11-nor-9-Carboxy-Delta 9-Tetrahydrocannabinol qualitatively. Limit of detection for Delta 9-Tetrahydrocannabinol quantitation is 2 ng/mL. Internal standards used in method were Delta 9-Tetrahydrocannabinol-D3 and 11-nor-9-Carboxy-Delta 9-Tetrahydrocannabinol-D3.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
LL2JQG	internal standard used for delta-9-THC was THC-D3 and Carboxy-THC was Carboxy-THC-D3. Limits of detection for THC is 2 ng/ml and Carboxy-THC is 5 ng/ml. The internal standard for the methadone assay was prazepam.
M6VE6P	Item 2 also screened presumptive positive for benzodiazepines and methadone. The [Laboratory] does not yet have confirmatory methods for these compounds so confirmation testing was not performed.
MDJ6PW	THC Confirmation/Quantitation method via LC/MS/MS has a 2 ng/mL LOQ/LOD
NFFK3C	Phenyltoloxamine and hexobarbital internal reference materials utilized for Acid/Base extraction. 11-OH-THC internal reference material utilized for THC extraction.
NKERRF	ISTD (Method LLOQ - ULOQ): Methadone-D9 (10.0 - 500.0 ng/mL), THC-COOH-D9 (6.0 - 300.0 ng/mL). All THC-COOH results for the LC/MS/MS are reported qualitatively and positive results go forward to Marijuana Confirmation analysis. Criminalist [Name] was not trained or competent to perform Marijuana Confirmation analysis at the time of testing and so only the qualitative results for THC-COOH are reported. [Initials] 06/22/2022
NRZMTK	THC (delta-9-tetrahydrocannabinol) Internal standard -THC-d3, LOD-1 ng/mL THC-COOH Internal standard- THC-COOH-d9, LOD-5 ng/mL. Reporting qualitative due to possible presence of coeluting delta-8-THC, rendering THC-COOH peak integration as unclear. Methadone Internal standard-Mepivacaine, LOD-25 ng/mL EDDP Internal standard-Mepivacaine, LOD-3 ng/mL Lamotrigine detected below the calibration range. Not reporting as it does not fall in the listed classes per section 1308 of Title 21 Code of Federal Regulations.
PXV4JF	Methadone- screened positive LC/MS/MS confirmed GC/MS 11-Nor-9-Carboxy-Delta-9-THC screened immunoassay confirmed LC/MS/MS
QVTNPJ	Extract 1 and Extract 2 for Methadone quantitative value was >Linear Range 250.00 ng/ml; dilution was performed for reported value. THC-d3 ISTD - LOD 1ng/ml THC-COOH - d9 ISTD - LOD 5ng/ml EDDP-d3 ISTD - LOD 5ng/ml Methadone-d9 ISTD - LOD 5ng/ml
R776WF	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. The Cannabinoid confirmation/quantitation panel includes: Δ9-THC, carboxy-THC, and 11-OH-THC. The following internal standards are used: Δ9-THC D3, carboxy-THC D3, and 11-OH-THC D3. The LOD and LOQ for carboxy-THC are 2.5 ng/mL and 5 ng/mL respectively. For the remaining analytes, the LOD and LOQ are 0.5 ng/mL and 1 ng/mL respectively. Opiate confirmation panel includes 6-MAM, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. The following internal standards are used: 6-MAM D-3, codeine D-6, fentanyl D-5, hydrocodone D-6, hydromorphone D-3, methadone D-3, morphine D-3, oxycodone D-3, and oxymorphone D-3. 6-MAM and fentanyl have an LOD of 0.5 ng/mL and an LOQ of 1 ng/mL. The remaining analytes have an LOD of 5 ng/mL and an LOQ of 10 ng/mL.
RBG2Y6	Internal Standard: methadone-D9, THC-D3, THC-COOH-D3, Low Cut Off: methadone 12.5 ng/mL, Low Cut Off: THC 0.5 ng/mL; THC-COOH 3.125 ng/mL, Low Cut Off (LC-MS/MS): lamotrigine 124 ng/mL
RKZJ8H	Promazine used for Internal Standard for Butyl Acetate. Delta-9-THC not detected; below Limit of Detection

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
RZXJ9J	Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Cannabinoids confirmation panel: Analyte Quantitative Range (ng/mL): Delta-9-THC 0.5 – 50, 11-hydroxy-Delta-9-THC 0.5 – 50, 11-nor-9-carboxy-Delta-9-THC 5.0 - 500. Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL): Fentanyl 0.5 – 50, Norfentanyl 0.5 – 50, Codeine 5.0 – 500, Hydrocodone 5.0 – 500, Morphine 5.0 – 500, Hydromorphone 5.0 – 500, Oxycodone 5.0 – 500, Oxymorphone 5.0 – 500, Methadone 20 – 2000, EDDP 20 – 2000, Methamphetamine 20 – 2000, Amphetamine 20 – 2000, Cocaine 20 – 2000, Benzoylecgonine 20 – 2000. Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses. Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Assay Cutoff* (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 1, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10. * Results within 20% of these concentrations are also reported as preliminarily positive.
T4R3JF	Internal standard used: Mepivacaine, nalorphine, and deuterated THC, THC-OH, and THC-COOH * 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid was reported qualitatively because of the possible presence of a co-eluting delta-8-thc metabolite. 11-hydroxy-delta-9-tetrahydrocannabinol (below limit of report, 1 ng/mL) was also detected. Lamotrigine and EDDP were detected but not reported because they are not listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act.
TCB9H9	Internal Standards: Mepivacaine, THC-d3, THC-OH-d3, THC-COOH-d9 THC-OH was detected in the screening method but was below our reporting LOR of 1ng/mL. THC-COOH was reported qualitatively since the co-elutor delta-8-THC metabolite was detected in confirmatory testing. Lamotrigine was found lower than our lowest calibrator of 500µg/L. Trazodone was not reported since it was identified as a production artifact.
TG6ZTQ	THC Quantitation was performed on the sample, but the value observed fell under the LoD/LoQ of 2.0 ng/mL so the result was reported as "no THC detected"
TMTPBE	internal standards: mepivacaine, mephobarbital, THC-COOH d9 lamotrigine also found, qualitative only (LC/MS/MS, LC-HRMS/MS).
TV2HHN	Delta-9 Tetrahydrocannabinol (THC) was quantitated; detected level 0.8 ng/ml was below LLOQ; reported as "Not detected"
TXM4BC	Cannabinoids are screened by Immunoassay and confirmed/quantitated by LCMSMS. It is our laboratory policy to only report a quantitation with the average of 2 replicates. One replicate for THC was 1.02 ng/mL and the 2nd replicate was below our limit of detection (1 ng/mL). Therefore, THC was reported qualitatively. Methadone and caffeine are screened for using the LCQTOF. Methadone was confirmed/quantitated using LCMSMS. Caffeine was confirmed using GCMS.
UECQXF	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 1, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10. * Results within 20% of these concentrations are also reported as preliminarily positive. Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL): Fentanyl 0.5 – 50, Norfentanyl 0.5 – 50, Codeine 5.0 – 500, Hydrocodone 5.0 – 500, Morphine 5.0 – 500, Hydromorphone 5.0 – 500, Oxycodone 5.0 – 500, Oxymorphone 5.0 – 500, Methadone 20 – 2000, EDDP 20 – 2000, Methamphetamine 20 – 2000, Amphetamine 20 – 2000, Cocaine 20 – 2000, Benzoylecgonine 20 – 2000. Cannabinoids confirmation panel: Analyte Quantitative Range (ng/mL): Delta-9-THC 0.5 – 50, 11-hydroxy-Delta-9-THC 0.5 – 50, 11-nor-9-carboxy-Delta-9-THC 5.0 - 500. Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses.
UKXLVD	Methadone used LC-MS/MS for screening and GC/MS for confirmation and quantitation. 11-nor-9-Carboxy-Delta-9-THC used immunoassay for screening and LC-MS/MS for confirmation and quantitation.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
UTD3UE	LC/MS/MS was used to confirm and quantify 11-nor-9-carboxy-delta-9-tetrahydrocannabinol. GC/MS was used to confirm and quantify methadone.
VEMV6C	LC-HRMS/MS Screening Internal Standard: mepivacaine & mephobarbital. LC/MS/MS Testing (for methadone, lamotrigine) Internal Standard: mepivacaine. LC/MS/MS Testing (for cannabinoids) Internal Standard: THC-d3, THC-OH-d3, THC-COOH-d9. Limit of Reporting for analytes reported: methadone, lamotrigine = 25 µg/L; THC & 11-OH-THC = 1.0 ng/mL; THC-COOH = 5 ng/mL. THC-COOH was reported qualitatively only due to a possible Delta-8-THC metabolite or compound co-eluting with it making the quantitation unreliable. Raw data under analyte shows the quantitation result even though only reporting qualitatively. Trazodone was also detected but the testing notes state not to report it. Lamotrigine was also detected lower than our lowest calibrator of 500 µg/L. The level detected was so low that it was far below therapeutic range, and thus while it was detected it was not reported in this form. It also doesn't fall into the classes of drugs that this testing was released for as per the CTS paperwork that came with the test kit.
VENQTN	Delta-9 THC was quantitated but resulted in value lower than the LOD and LOQ (2ng/ml) reported as not detected.
W7DN8N	Delta-9 Tetrahydrocannabinol (THC) quantitative result less than 2 ng/mL reported as not detected, Uncertainty is not calculated on negative cases.
WQBGNC	Methadone internal standard for quantitation: Mepivacaine THC-COOH internal standard for quantitation: THC-COOH-d9.
XA7AAA	EDDP is a metabolite of methadone. The limit of report for EDDP is 3 ng/mL while the lowest calibrator of the calibration curve is 50 ng/mL. Because the quantitative result was 3 ng/mL, it is reported as lower than the lowest calibrator of 50 ng/mL. -The limit of report for lamotrigine is 25 ng/mL while the lowest calibrator is 500 ng/mL. The quantitative result was 66 ng/mL and therefore is reported as lower than the lowest calibrator of 0.50 mg/L. -THCOOH co-eluted with a delta-8-THC-metabolite peak; and therefore it is reported only qualitatively.
XC8AA8	THC: Immunoassay screen, LC/MS/MS confirmation. Methadone: LC/MS/MS screen, GC/MS confirmation
XNLEBB	Promazine used as an internal standard for GC/MS screening and confirmation. Delta9-THC-COOH confirmation performed in part of LC/MS/MS quantitation of delta9-THC. Delta9-THC-COOH-d3 and delta9-THC-d3 were used as internal standards for this analysis. Laboratory limit of detection/quantitation for delta9-THC is 2ng/mL. Values qualitatively detected below that limit are reported as "not detected". Measurement uncertainty data is only included when a quantitative value is reported.
XTF8T7	THCA was screened via LC/MS/MS and confirmed using GC/MS/MS
XXPKB6	There is a note on the scenario screen to disregard the presence of Trazodone on item 2 as an artifact of production. Please it is present in the sample our lab would report it, so I am still listing it as a finding.
Y689P8	THC-OH was inconclusive due to ion ratios being out. Per current policy, analysis was not repeated.
YETEH6	Methadone LLOQ was 10 ng/mL with a working range of 10 - 500 ng/mL. The internal standard used was methadone-D9. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. THCA was screened using the LC/MS/MS method and confirmed using the GC/MS/MS method: THC, OH-THC, and THCA were confirmed using the GC/MS/MS method with a cut off of 0.5 ng/mL for THC and OH-THC; and 5 for THCA. The working range was 0.5 - 20 ng/mL for THC and OH-THC; and 5 - 200 for THCA. The internal standard for THC, OH-THC and THCA were THC-D3, OH-THC-D3 and THCA-D9, respectively. The extraction method used was Liquid/Liquid targeting free, nonconjugated/nonprotein bound, compounds.
YPEHP4	The specific methodology utilized for both the screening and confirmatory analysis was HRMS by LC-QTOF.

TABLE 2F: Additional Comments for Item 2

WebCode	Item Comments
YTERZ7	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Cannabinoid confirmation panel includes THC, carboxy-THC and hydroxy-THC. LOD for THC and hydroxy-THC is 0.5ng/ml and LOQ is 1ng/ml. LOD for carboxy-THC is 2.5ng/ml and LOQ is 5ng/ml. THC-D3, COOH-THC-D3 and 11-OH-THC-D3 used as internal standards. Drug results quantitating below the LOQ but greater than the LOD are reported as present, less than (LOQ value). Opiate confirmation panel includes 6-monoacetylmorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. 6-MAM and fentanyl have a LOD of 0.5ng/ml and a LOQ of 1ng/ml. The remaining analytes have a LOD of 5ng/ml and a LOQ of 10ng/ml. 6-monoacetylmorphine-D3, codeine-D6, fentanyl-D5, hydrocodone-D6, hydromorphone-D3, methadone-D3, morphine-D3, oxycodone-D3, and oxymorphone-D3 were used as internal standards.
YVYP33	Internal standard: flurazepam LOD methadone 75 ng / mL
Z9PR8G	In item 2, lamotrigine was also detected. The metabolite EDDP was identified by GC-MS and LC-MS-MS library match, as to the lab does not have reference material available.
ZBUHCB	Confirmatory ISTD GC/MS: [Initials] and [Initials] Qualitative cannabinoids confirmatory test ISTD LC/MS/MS: delta-9-THC-OH-d3, delta-9-carboxy-THC-d3, delta-9-THC-d3
ZCJXD7	Cutoff: MDONE: >104 ng/mL THC: >10 ng/mL

Screening Results - Item 3

TABLE 3A

Item Scenario:

Case 3: A 45 year-old male was found unresponsive by a nurse at a rehabilitation facility. The male battling drug abuse when he was admitted to the rehab facility. Blood samples were collected at the autopsy.

Item Contents and Preparation Concentration: Heroin (150 ng/mL)
6-MAM (40 ng/mL)**
Morphine (1050 ng/mL)

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	Screening Results
2A9FUZ	Opiates, 6-MAM, Morphine
2DWHAM	Morphine 6-monoacetylmorphine
2JJHF2	Opiate
2XGFQD	Opiates
2Z3DTA	Opiates
32ZWJG	ELISA screen was opiate positive. GC-MS drug screen was negative. GC-MS Opiate confirmation confirmed 6-monoacetylmorphine and morphine.
384XJC	Opiates
3PLWPA	6-MAM, Morphine, Oxymorphone
48GQV6	6-Monoacetylmorphine Morphine
48L4J2	Opioids and zolpidem
4BHXCW	opiates, opioids
4D2WJY	Opiate
4GLYB6	Morphine, 6-monoacetyl-morphine (6-MAM)
4TY2W3	6-monoacetylmorphine, Morphine, and Zolpidem
4XXDWA	opiates
6ED9K2	6-mam, Morphine
6QPB7Y	Morphine 6-MAM
6ZE2TR	morphine 6-monoacetylmorphine sertraline zolpidem
73XK23	Opiates, THC class

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
7DZVHQ	morphine, zolpidem, 6-monoacetylmorphine (MAM)
7NV3EA	MORPHINE 6-MONOACETYLMORPHINE (6-MAM)
7RX64B	6-Monoacetylmorphine (Heroin metabolite) Morphine
7W827Z	6-MAM, Hydromorphone, Morphine, Zolpidem
7WPAVU	Opiates, Opioids, and Zolpidem.
83E82W	Opiate class
8E3B78	6-Acetyl-Morphine (6-MAM) Morphine
8X2ATA	MORPHINE MORPHIN, 6-ACETYL-3-O-TRIMETHYLSILYL
8YE38N	Acetylmorphine, morphine
94Y64T	opiates (general), opiates (synthetic)
99WWZW	opioids
9LYHDU	morphine 6-AM
9QXMGZ	Opiates
9T3E8R	morphine 6-monoacetylmorphine (6-MAM)
AAN8KX	6-monoacetyl morphine Morphine
AD6HL9	Morphine, 6-Monoacetylmorphine
AH24FW	Opiates
AMTEPV	Opiates
ATKL94	Opiates
AUF4A6	Opiates (ELISA)
AV6JBZ	Opiates

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
AX96AX	Morphine 6-monoacetyl-morphine
B8Z4FX	Opiates
BG3H2V	Morphine, 6-acetylmorphine
BRK67Q	6-Monoacetylmorphine Morphine
C6NP8U	6-Monoacetylmorphine Morphine
CHA3KP	Opiates
DFZA93	Opiate 6MAM
DZNWQ6	opiates
EBYZ3T	6MAM MORPHINE GHB
EJUN9X	Opiates, zolpidem
EYPBEP	Opiates ELISA
EZLLAR	6-acetylmorphine Morphine
FCP9XF	Morphine Monoacetylmorphine Hydrochlorthiazide
FNAJNU	6-MAM, Morphine
G4F3ZR	MORPHINE, 6-MAM (6-ACETYLMORPHINE), ZOLPIDEM
GBEU4E	Opiates: 6-Monoacetylmorphine and Morphine
GBZ8TR	Morphine, 6-monoacetyl-morphine (6-MAM), Zolpidem, Sertraline, Delta-9-tetrahydrocannabinol (THC)
GMBXAU	Morphine 6-MAM
GNH4MU	Morphine, 6-acetylmorphine
GV3BAT	Opiates and Zolpidem

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
GX9PTT	Morphine 6-Monoacetylmorphine Oxymorphone Topiramate Zolpidem
HAVBCT	Opiates
HHQ8KP	6-Monoacetylmorphine, Morphine
HNC8RP	[Although participant indicated that drugs were identified through screening, none were reported.]
HPN7NJ	Opiate
HX9XMX	6-Monoacetylmorphine Morphine
JVBAFM	6-Monoacetylmorphine Morphine
JYTD4J	OPIATES SYNTHETIC OPIATES
K9V49R	Opioids
KBF2CN	Opiates
KCVE6R	Opiates (Elisa)
KCWY4N	Opiates
KFBVAP	Opiates
KQXJUR	Opiates (ELISA)
KQZDDX	Opiates
KZKK8G	morphine, 6-monoacetyl-morphine
L2C3MM	6MAM, Morphine, Topiramate
LCDNTL	6-MAM Morphine
LEFD8N	Opiates
LL2JQG	Opiates class
M6VE6P	Opiates, Oxycodone/oxymorphone, Zolpidem
M7FD9L	6-monoacetylmorphine (6-MAM), morphine, and zolpidem
MDJ6PW	Opiates

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
NFFK3C	Opiates (General) Opiates (Synthetic)
NKERRF	Morphine, 6-MAM
NRZMTK	morphine 6-monoacetylmorpine (6-MAM)
P6ZTCG	Opioids Opiates
P96AXR	Morphine and 6-acetylmorphine
PUMLNU	6-acetylmorphine morphine
PXV4JF	6-MAM, Morphine
Q7WJ9N	Opiates
QHJQ2H	Opiates
QVTNPJ	6-MAM; Morphine
R3R9RE	Opiates
R776WF	Opiates
RBG2Y6	morphine, 6-monoacetylmorphine, acetaminophen, sertraline, zolpidem
RKZJ8H	Opiate Class
RZXJ9J	Opiates Generic Opioids
T4R3JF	morphine, 6-monoacetyl morphine
TCB9H9	Morphine 6-monoacetyl-morphine Zolpidem Sertraline
TDHL6F	opiates, oxycodone
TG6ZTQ	Opiates
TLBUML	Opiates
TMTPBE	morphine, 6-MAM
TTC34L	Opiate/Opioids
TV2HHN	Morphine 6-Monoacethylmorphine (Heroin metabolite)

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
TXM4BC	6-monoacetylmorphine, Morphine
TYY2KM	No drugs detected utilizing screening methods.
U97X4J	Opiates
UECQXF	Opiates Opioids Zolpidem
UKXLVD	Morphine 6-Monoacetylmorphine
UNHCLG	Morphine 6MAM
UTD3UE	Opiates class
UWBMVC	Opiates
V7VEG8	Opiates, Opioids
VEMV6C	6-monoacetylmorphine (6-MAM) morphine
VENQTN	Opiates
W7DN8N	opiates
WK8BDF	Opiate
WQBGNC	morphine 6-mam (6-monoacetyl-morphine)
XA7AAA	morphine, 6-monoacetyl-morphine (6-MAM)
XC8AA8	6-MAM, Morphine, Zolpidem
XL2F8E	Opiates
XNLEBB	Opiates
XTF8T7	Morphine and 6-MAM
XWGAH8	Cannabinoids 6-MAM Morphine Topiramate Zolpidem
XXPKB6	6-Monoacetylmorphine (6MAM) Morphine Zolpidem

TABLE 3A: Screening Results - Item 3

WebCode	Screening Results
XZXJLD	6-Monoacetylmorphine Morphine Zolpidem Topiramate
Y689P8	Opiates
Y8VMDG	6-MAM MORPHINE
YETEH6	Morphine and 6-MAM
YPEHP4	6-Monoacetylmorphine, Morphine, Zolpidem
YTERZ7	Opiates
YVYP33	No drugs detected utilizing screening methods.
YX7XE9	6-Monoacetylmorphine (6-MAM), Morphine, Zolpidem
Z9PR8G	Morphine, 6-monoacetylmorphine (6-MAM) and zolpidem
ZBUHCB	opiates
ZCJXD7	OPIATES
ZM8KVM	Morphine, 6-monoacetylmorphine

Screening Response Summary for Item 3	Participants: 139
6-MAM:	70
Morphine:	69
Opioids/Opiates:	77
Other drugs/metabolites detected:	42
No drugs/metabolites detected Utilizing Screening Methods:	2

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

Confirmatory Results - Item 3

TABLE 3B

Item Scenario:

Case 3: A 45 year-old male was found unresponsive by a nurse at a rehabilitation facility. The male battling drug abuse when he was admitted to the rehab facility. Blood samples were collected at the autopsy.

Item Contents and Preparation Concentration: Heroin (150 ng/mL)
6-MAM (40 ng/mL)**
Morphine (1050 ng/mL)

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

What drugs/metabolites were detected in Item 3?

WebCode	Analyte Reported	Qualitative Only	Reported Concentration	Uncertainty	Units
2A9FUZ	6-Monoacetylmorphine	✓			
	Morphine	✓			
2DWHAM	6-monoacetylmorphine	✓			
	Morphine	✓			
2JJHF2	6-Monoacetylmorphine (Heroin Metabolite(	✓			
	Morphine	✓			
2XGFQD	6-Monoacetylmorphine		54	18.69%	ng/mL
	Morphine		1285	15.46%	ng/mL
2Z3DTA	6 monoacetyl morphine	✓			
	Morphine	✓			
32ZWJG	6-monoacetylmorphine	✓			
	Morphine	✓			
384XJC	6-monoacetylmorphine		56	-/+18.69%	ng/mL
	Morphine		1220	-/+15.46%	ng/mL
3PLWPA	6-MAM		52.81	13.73	ng/mL
	Morphine		1277.06	268.18	ng/mL
48GQV6	6-monoacetylmorphine		51.07	+/- 9.19	ng/ml
	Morphine		> 1000		
48L4J2	6-Monoacetylmorphine (6-MAM)		43	± 9	ng/mL
	Morphine		1.0	± 0.2	µg/mL
4D2WJY	6-Monoacetylmorphine	✓			
	Morphine	✓			
4GLYB6	6-monoacetyl-morphine	✓			
	Morphine		1.1	0.3	mg/L

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
4TY2W3	6-monoacetylmorphine		46		ng/ml
	Morphine	✓			
4XXDWA	6-Monoacetylmorphine		50	9	ng/ml
	Morphine		1248	193	ng/ml
6ED9K2	6-monoacetylmorphine		39		ng/mL
	Morphine		Presence Only		
6QPB7Y	6-MAM		>10.0		ng/mL
	Morphine		>300.0		ng/mL
6ZE2TR	6-monoacetylmorphine		22	2	ng/mL
	morphine		1127	108	ng/mL
	Additional Analyte(s) Reported				
	Zolpidem	✓			
73XK23	6-Monoacetylmorphine	✓			
	Morphine	✓			
7DZVHQ	monoacetylmorphine	✓			
	morphine (free)		1.1	+/-15%	mg/L
	Additional Analyte(s) Reported				
	zolpidem		<0.01	+/-15%	mg/L
7NV3EA	6-MAM	✓			
	Morphine	✓			
7RX64B	6-Monoacetylmorphine (Heroin metabolite)	✓			
	Morphine	✓			
7W827Z	6-MAM		26		ng/mL
	Morphine	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
7WPAVU	No drugs/metabolites detected utilizing confirmatory methods.				
83E82W	6-MAM		35	18.69%	ng/mL
	Morphine		1,195	15.46%	ng/mL
8E3B78	6-Acetyl-Morphine (6-MAM)		36.39	4.73	ng/mL
	Morphine		1186.20	130.48	ng/mL

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
8X2ATA	6- ACETYLMORPHIN	✓			
	MORPHINE	✓			
8YE38N	Acetylmorphine		~20		ng/mL
	Morphine		1300	312	ng/mL
94Y64T	6-Monoacetylmorphine	✓			
	morphine	✓			
99WWZW	6-MAM		43	18.69%	ng/ml
	morphine		1180	15.46%	ng/ml
9LYHDU	6-acetyl-morphine (6-AM)		50		ng/mL
	morphine		960		ng/mL
9QXMGZ	6-monoacetylmorphine		0.046	0.004	mg/L
	Morphine		1.0	0.2	mg/L
9T3E8R	6-monoacetylmorphine (6-MAM)	✓			
	morphine		1100	300	ng/mL
AAN8KX	6-Monoacetyl Morphine		30.1	2.4	ng/mL
	Morphine		Greater than 500 ng/mL		
AD6HL9	6-Monoacetylmorphine	✓			
	Morphine	✓			
AH24FW	6-monoacetylmorphine		33	+/- 18.69%	ng/mL
	morphine		1170	+/- 15.46%	ng/mL
AMTEPV	6 monoacetylmorphine		33	18.69%	ng/mL
	Morphine		1111	15.46%	ng/mL
ATKL94	6-Monoacetyl morphine		30	+/- 6	ng/ml
	Morphine		1240	+/- 192	ng/ml
AUF4A6	6-MAM		42	18.69%	ng/mL
	Morphine		1143	15.46%	ng/mL
AV6JBZ	6-Monoacetylmorphine (Heroin Metabolite)	✓			
	Morphine	✓			
AX96AX	6-monoacetyl-morphine	✓			
	Morphine		1.2	0.3	mg/L

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
B8Z4FX	6-monoacetylmorphine		39	8	ng/mL
	Morphine		1.0	0.2	µg/mL
BG3H2V	6-Acetylmorphine	✓			
	Morphine	✓			
BRK67Q	6-Monoacetylmorphine		52	16	ng/mL
	Morphine		890	276	ng/mL
C6NP8U	6-Monoacetylmorphine		38		ng/mL
	Morphine	✓			
CHA3KP	6-monoacetylmorphine	✓			
	Morphine		1154	162	ng/mL
DZNWQ6	6-Acetylmorphine	✓			
	morphine		>1000		
EBYZ3T	6-Monoacetylmorphine (6-MAM)	✓			
	MORPHINE	✓			
	Additional Analyte(s) Reported				
	Gamma Hydroxybutyrate (GHB)	✓			
EYPBEP	6-mono-acetyl-morphine		34	+/- 18.69%	ng/mL
	morphine		1153	+/- 15.46%	ug/mL
EZLLAR	6-acetylmorphine	✓			
	Morphine	✓			
FCP9XF	Monoacetylmorphine	✓			
	Morphine		1.1	20.5%	mg/L
	Additional Analyte(s) Reported				
	Hydrochlorthiazide	✓			
FNAJNU	6-MAM		62.64	16.28	ng/mL
	Morphine		1351.80	283.87	ng/mL
G4F3ZR	6-ACETYLMORPHINE		39.55	11.87	ng/mL
	MORPHINE		1063.63	319.09	ng/mL
GBEU4E	6-Monoacetylmorphine		40	10	ng/mL
	Morphine		1000	210	ng/mL
GBZ8TR	6-monoacetyl-morphine (6-MAM)	✓			
	Morphine		1.2	0.3	mg/L

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
GMBXAU	6-MAM		48	40	ng/ml
	morphine		1147	30	ng/ml
GNH4MU	6-acetylmorphine	✓			
	Morphine	✓			
GX9PTT	6-Monoacetylmorphine	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
HHQ8KP	6-Monoacetylmorphine		35		ng/mL
	Morphine				
HNC8RP	6-Acetylmorphine	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
HPN7NJ	6-monoacetylmorphine (Heroin metabolite)	✓			
	Morphine	✓			
HX9XMX	6-monoacetylmorphine		30		ng/mL
	Morphine		954		ng/mL
JYTD4J	6-Monoacetylmorphine	✓			
	Morphine	✓			
K9V49R	6-Monoacetylmorphine		43	18.69%	ng/mL
	Morphine		1078	15.46%	ng/ml
KBF2CN	6-Monoacetylmorphine	✓			
	Morphine		>1000		ng/mL
KCVE6R	6-Monoacetylmorphine		43	+/- 18.69%	ng/mL
	Morphine		1231	+/- 15.46%	ng/mL
KFBVAP	morphine	✓			
KQXJUR	6-Monoacetylmorphine		40	18.69%	ng/mL
	Morphine		960	15.46%	ng/mL
KQZDDX	6-Monoacetylmorphine (Heroin metabolite)	✓			
	Morphine	✓			

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
KZKK8G	6-monoacetyl-morphine	✓			
	morphine		1.2	0.3	mg/L
L2C3MM	6MAM		39.46	18%	ng/mL
	Morphine		>1000	22%	ng/mL
	Additional Analyte(s) Reported				
	Topiramate	✓			
LCDNTL	6-monacetylmorphine		25		ng/mL
	Morphine		Presence only		
LEFD8N	6-monoacetylmorphine	✓			
	Morphine	✓			
LL2JQG	6-Monoacetylmorphine	✓			
	morphine		1033	+/-278.9	ng/ml
M7FD9L	6-monoacetylmorphine (6-MAM)	✓			
	morphine	✓			
	Additional Analyte(s) Reported				
	zolpidem	✓			
MDJ6PW	6-Monoacetylmorphine	✓			
	Morphine	✓			
NFFK3C	6-monoacetylmorphine	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	Topiramate	✓			
NKERRF	6-MAM		>10.0	4.2	ng/mL
	Morphine		>300.0	112.0	ng/mL
NRZMTK	6-monoacetylmorpine (6-MAM)	✓			
	Morphine		1.2	+/-0.3	mg/L
P6ZTCG	6MAM	✓			
	Additional Analyte(s) Reported				
	Hydromorphone	✓			
P96AXR	6-acetylmorphine	✓			
	Morphine	✓			

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
PUMLNU	6-acetylmorphine	✓			
	morphine	✓			
PXV4JF	6-MAM		19		ng/mL
	Morphine		Presence only		
Q7WJ9N	6-Monoacetylmorphine		44	18.69%	ng/mL
	Morphine		1283	15.46%	ng/mL
QHJQ2H	6-acetylmorphine		57		ng/mL
	Morphine		>500		ng/mL
QVTNPJ	6-MAM		45.25	11.76	ng/ml
	Morphine		1077.73	226.32	ng/ml
R3R9RE	6-Monoacetylmorphine		34	+/-18.69%	ng/mL
	Morphine		1250	+/-15.46%	ng/mL
R776WF	6-Monoacetylmorphine (6-MAM)		40	9	ng/mL
	Morphine		1.0	0.2	µg/mL
RBG2Y6	6-monoacetylmorphine	✓			
	morphine		1199	-/+ 96	ng/mL
RKZJ8H	6-monoacetylmorphine	✓			
	Morphine	✓			
RZXJ9J	Morphine		> ULOQ	N/A	ng/mL
T4R3JF	6-monoacetyl morphine	✓			
	morphine		1300 ng/mL	300	ng/mL
TCB9H9	6-monoacetyl-morphine	✓			
	Morphine		1.0	0.3	mg/L
TDHL6F	6-acetylmorphine		34.2	4.8	ng/mL
	Morphine		>500		ng/mL
TG6ZTQ	6-Acetylmorphine	✓			
	Morphine	✓			
TLBUML	6-Monoacetylmorphine	✓			
	Morphine		1.2	11%	ug/mL
TMTPBE	6-monoacetyl-morphine	✓			
	morphine		1.1	0.3	mg/L

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
TTC34L	6-Monoacetylmorphine		43		ng/mL
	Morphine		1000		ng/mL
TV2HHN	6-Monoacethylmorphine (Heroin metabolite)	✓			
	Morphine	✓			
TXM4BC	6-monoacetylmorphine		0.0247	0.0025	mg/L
	Morphine		1.01	0.11	mg/L
TYY2KM	6-monoacetylmorphine	✓			
	Morphine	✓			
U97X4J	6-Monoacetylmorphine		49	18.69%	ng/ml
	Morphine		1209	15.46%	ng/ml
UECQXF	Morphine		> ULOQ		
UKXLVD	6-Monoacetylmorphine		30	2.7	ng/mL
	Morphine	✓			
UTD3UE	6-Acetylmorphine		0.053	0.022	mg/L
	Morphine		0.78	0.33	mg/L
UWBMVC	6-Monoacetylmorphine		33	18.69%	ng/mL
	Morphine		1221	15.46%	ng/mL
V7VEG8	6-monoacetylmorphine	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	Oxymorphone	✓			
VEMV6C	6-monoacetylmorphine	✓			
	morphine		1.2	0.3	mg/L
VENQTN	6-Monoacetylmorphine	✓			
	Morphine	✓			
W7DN8N	6-monoacetyl morphine (heroin metabolite)	✓			
	morphine	✓			
WK8BDF	6-MAM		44	18.69%	ng/ml
	Morphine		1220	15.46%	ng/ml

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
WQBGNC	6-mam (6-monoacetyl-morphine)	✓			
	morphine		1.1	0.3	mg/L
XA7AAA	6-monoacetyl-morphine (6-MAM)	✓			
	morphine		1.1	0.3	mg/L
XC8AA8	6-MAM		33		ng/mL
	Morphine	✓			
XL2F8E	6-monoacetylmorphine		45	9	ng/mL
	Morphine		1250	193	ng/mL
XNLEBB	6-monoacetylmorphine	✓			
	Morphine	✓			
XTF8T7	6-MAM		> 10		ng/mL
	Morphine		> 300		ng/mL
XWGAH8	6-MAM		23.89	4.30	ng/mL
	Morphine		>1000	220	ng/mL
	Additional Analyte(s) Reported				
	Topiramate	✓			
XXPKB6	6-Monoacetylmorphine (6MAM)	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
XZXJLD	6-Monoacetylmorphine	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
Y689P8	6-Monoacetylmorphine		70	18.69%	ng/mL
	Morphine		1116	15.46%	ng/mL
Y8VMDG	6-MAM		27	1,3	ng/mL
	MORPHINE		682	27.7	ng/mL
YETEH6	6-MAM		>10		ng/mL
	Morphine		>300		ng/mL

TABLE 3B: Confirmatory Results - Item 3

What drugs/metabolites were detected in Item 3?					
WebCode	**Analyte Reported**	**Qualitative Only**	**Reported Concentration**	**Uncertainty**	**Units**
YPEHP4	6-Monoacetylmorphine	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	Zolpidem	✓			
YTERZ7	6-monoacetylmorphine (6-MAM)		47	±10	ng/ml
	Morphine		1.0	±0.2	µg/ml
YVYP33	6 monoacetylmorphine	✓			
	Morphine	✓			
Z9PR8G	6-monoacetylmorphine (6-MAM)	✓			
	Morphine	✓			
	Additional Analyte(s) Reported				
	zolpidem	✓			
ZBUHCB	6-Acetylmorphine	✓			
	morphine		>1000		
ZM8KVM	6-monoacetylmorphine	✓			
	Morphine	✓			

Confirmatory Response Summary for Item 3	**Participants: 128**
6-MAM:	124 (96.9%)
Morphine:	126 (98.4%)
Other Identified Drugs/Metabolites:	17 (13.3%)
No Drugs/Metabolites Detected Utilizing Confirmatory Methods:	1 (0.8%)

Raw Data - Item 3

TABLE 3C

Item 3 Raw Data - 6-MAM
Preparation concentration: 40 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)				
2XGFQD	54.400				54.400
384XJC	56.000				56.000
3PLWPA	52.810				52.810
48GQV6	51.078				51.080
48L4J2	43.329				43.330
4TY2W3	46.250				46.250
4XXDWA	50.000				50.000
6ED9K2	39.110				39.110
6QPB7Y	There is no raw data for this item				
6ZE2TR	21.840	22.440			22.140
7W827Z	26.340				26.340
83E82W	35.000				35.000
8E3B78	36.390				36.390
8YE38N	19.000	19.000	25.000		21.000
99WWZW	43.000				43.000
9LYHDU	50.000				50.000
9QXMGZ	46.000	46.600	44.500	46.400	45.880
AAN8KX	30.120				30.120
AH24FW	33.300				33.300
AMTEPV	33.600				33.600
ATKL94	30.300				30.300
AUF4A6	42.200				42.200
B8Z4FX	39.182				39.180
BRK67Q	52.000				52.000
C6NP8U	38.950				38.950
EYPBEP	34.300				34.300
FNAJNU	62.640				62.640
G4F3ZR	39.551				39.550
GBEU4E	37.000	36.000			36.500
GMBXAU	48.300				48.300
HHQ8KP	35.520				35.520

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - 6-MAM
Preparation concentration: 40 ng/mL**

**This value is the Grand Mean compiled by quantitative results of at least 10 participants (see Manufacturer's Information).

WebCode	List of Raw Data determinations (ng/mL)						
HX9XMX	30.000						30.000
K9V49R	43.800						43.800
KCVE6R	43.650						43.650
KQXJUR	40.700						40.700
L2C3MM	39.460						39.460
LCDNTL	25.150						25.150
NKERRF	22.000						22.000
PXV4JF	19.860						19.860
Q7WJ9N	44.400						44.400
QHJQ2H	57.000						57.000
QVTNPJ	45.250	46.940					46.100
R3R9RE	34.500						34.500
R776WF	40.746						40.750
TDHL6F	34.193						34.190
TTC34L	43.010	50.060					46.540
TXM4BC	25.770	23.630					24.700
U97X4J	49.400						49.400
UKXLVD	30.350						30.350
UTD3UE	53.300						53.300
UWBMVC	33.700						33.700
WK8BDF	44.200						44.200
XC8AA8	33.030						33.030
XL2F8E	45.500						45.500
XTF8T7	There is no raw data for this item						
XWGAH8	23.899						23.900
Y689P8	70.900						70.900
Y8VMDG	26.000	27.000	26.000	28.000	26.000	29.000	27.000
YETEH6	There is no raw data for this item						
YTERZ7	47.828						47.830

Statistical Analysis for Item 3 - 6-MAM

Grand Mean	40.02	Number of Participants Included	57	Number of Participants without Raw Data or Data that was not reported in ng/mL	3
Standard Deviation	10.96	Number of Participants Excluded	0		

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Morphine
Preparation concentration: 1,050 ng/mL

WebCode	List of Raw Data determinations (ng/mL)				
2XGFQD	1,285.0				1,285.0
384XJC	1,220.0				1,220.0
3PLWPA	1,277.1				1,277.1
48GQV6	1,247.3				1,247.3
48L4J2	1,011.7				1,011.7
4GLYB6	1,120.1				1,120.1
4TY2W3	1,053.6				1,053.6
4XXDWA	1,248.0				1,248.0
6ED9K2	922.53				922.50
6QPB7Y	There is no raw data for this item				
6ZE2TR	1,139.8	1,115.0			1,127.4
7DZVHQ	1,145.0	1,128.0			1,136.5
7W827Z	954.18				954.20
83E82W	1,195.0				1,195.0
8E3B78	1,186.2				1,186.2
8YE38N	1,220.0	1,330.0	1,200.0		1,250.0
99WWZW	1,180.7				1,180.7
9LYHDU	960.00				960.00
9QXMGZ	997.00	976.00	1,020.0	993.00	996.50
9T3E8R	1,120.9				1,120.9
AAN8KX	984.82				984.80
AH24FW	1,170.0				1,170.0
AMTEPV	1,111.0				1,111.0
ATKL94	1,240.0				1,240.0
AUF4A6	1,143.1				1,143.1
AX96AX	1,213.8				1,213.8
B8Z4FX	1,075.7				1,075.7
BRK67Q	890.00				890.00
C6NP8U	941.68				941.70
CHA3KP	1,152.8	1,154.3			1,153.6
DZNWQ6	There is no raw data for this item				
EYPBEP	1,153.4				1,153.4
FCP9XF	1,075.0				1,075.0

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Morphine
Preparation concentration: 1,050 ng/mL

WebCode	List of Raw Data determinations (ng/mL)		Participant Mean
FNAJNU	1,351.8		1,351.8
G4F3ZR	1,063.6		1,063.6
GBEU4E	1,000.0	988.00	994.00
GBZ8TR	1,192.3		1,192.3
GMBXAU	1,146.8		1,146.8
HHQ8KP	897.23		897.20
HX9XMX	954.00		954.00
K9V49R	1,078.0		1,078.0
KBF2CN	1,113.1	1,181.1	1,147.1
KCVE6R	1,231.9		1,231.9
KQXJUR	960.10		960.10
KZKK8G	1,182.0		1,182.0
L2C3MM	There is no raw data for this item		
LCDNTL	911.08		911.10
LL2JQG	1,033.6		1,033.6
NKERRF	934.00		934.00
NRZMTK	1,178.3		1,178.3
PXV4JF	936.00		936.00
Q7WJ9N	1,283.9		1,283.9
QHJQ2H	1,095.0		1,095.0
QVTNPJ	1,077.7		1,077.7
R3R9RE	1,250.0		1,250.0
R776WF	1,068.6		1,068.6
RBG2Y6	1,182.6	1,215.8	1,199.2
RZXJ9J	791.75		791.80
T4R3JF	1,332.9		1,332.9
TCB9H9	1,042.3		1,042.3
TDHL6F	946.67		946.70
TLBUML	1,212.0		1,212.0
TMTPBE	1,074.2		1,074.2
TTC34L	1,007.6	1,232.6	1,120.1
TXM4BC	1,037.6	990.90	1,014.2
U97X4J	1,209.9		1,209.9

TABLE 3C: Raw Data - Item 3

Item 3 Raw Data - Morphine
Preparation concentration: 1,050 ng/mL

WebCode	List of Raw Data determinations (ng/mL)						Participant Mean
UECQXF	789.24						789.20
UKXLVD	921.74						921.70
UTD3UE	780.80						780.80
UWBMVC	1,221.5						1,221.5
VEMV6C	1,161.6						1,161.6
WK8BDF	1,220.8						1,220.8
WQBGNC	1,053.7						1,053.7
XA7AAA	1,144.6						1,144.6
XC8AA8	931.69						931.70
XL2F8E	1,250.0						1,250.0
XTF8T7	There is no raw data for this item						
XWGAH8	1,266.2						1,266.2
Y689P8	1,117.0						1,117.0
Y8VMDG	655.00	695.00	703.00	634.00	693.00	714.00	682.30
YETEH6	There is no raw data for this item						
YTERZ7	1,047.7						1,047.7
ZBUHCB	There is no raw data for this item						

Statistical Analysis for Item 3 - Morphine

Grand Mean	1,092.77	Number of Participants Included	77	Number of Participants without Raw Data or Data that was not reported in ng/mL	6
Standard Deviation	139.84	Number of Participants Excluded	0		

Reporting Procedures - Item 3

TABLE 3D - Item 3

WebCode	Quantitative Reporting Procedures *If quantitative analysis was performed, the reported concentrations are:*
2XGFQD	A single determination.
384XJC	A single determination.
3PLWPA	A single determination.
48GQV6	A single determination.
48L4J2	A single determination.
4GLYB6	A single determination.
4TY2W3	A single determination.
4XXDWA	A single determination.
6ED9K2	A single determination.
6QPB7Y	A single determination.
6ZE2TR	The mean of duplicate/several determinations.
7DZVHQ	The mean of duplicate/several determinations.
7W827Z	A single determination.
83E82W	A single determination.
8E3B78	A single determination.
8YE38N	The mean of duplicate/several determinations.
99WWZW	A single determination.
9LYHDU	The mean of duplicate/several determinations.
9QXMGZ	The mean of duplicate/several determinations.
9T3E8R	A single determination.
AAN8KX	A single determination.
AH24FW	A single determination.
AMTEPV	A single determination.
ATKL94	A single determination.
AUF4A6	A single determination.
AX96AX	A single determination.
B8Z4FX	A single determination.
BRK67Q	A single determination.
C6NP8U	A single determination.
CHA3KP	The mean of duplicate/several determinations.
DZNWQ6	duplicate, but above the highest calibrator
EYPBEP	A single determination.

TABLE 3D: Reporting Procedures - Item 3

Quantitative Reporting Procedures	
WebCode	***If quantitative analysis was performed, the reported concentrations are:***
EZLLAR	A single determination.
FCP9XF	A single determination.
FNAJNU	Sample was screened and confirmed on a quantitative method, the lower of the two values is the reported concentration
G4F3ZR	A single determination.
GBEU4E	The mean of duplicate/several determinations.
GBZ8TR	A single determination.
GMBXAU	A single determination.
HHQ8KP	A single determination.
HX9XMX	A single determination.
K9V49R	A single determination.
KBF2CN	The mean of duplicate/several determinations.
KCVE6R	A single determination.
KQXJUR	A single determination.
KZKK8G	A single determination.
L2C3MM	A single determination.
LCDNTL	A single determination.
LL2JQG	A single determination.
NKERRF	A single determination.
NRZMTK	single determination of 1:10 dilution
PXV4JF	A single determination.
Q7WJ9N	A single determination.
QHJQ2H	A single determination.
QVTNPJ	Screening was performed using a quantitative method, therefore, the lowest of the two determinations is utilized as the reported value.
R3R9RE	A single determination.
R776WF	A single determination.
RBG2Y6	A single determination.
RZXJ9J	A single determination.
T4R3JF	A single determination.
TCB9H9	A single determination.
TDHL6F	A single determination.
TLBUML	A single determination.
TMTPBE	A single determination.

TABLE 3D: Reporting Procedures - Item 3

Quantitative Reporting Procedures	
WebCode	***If quantitative analysis was performed, the reported concentrations are:***
TTC34L	Lowest value from least diluted sample
TXM4BC	The mean of duplicate/several determinations.
U97X4J	A single determination.
UECQXF	A single determination.
UKXLVD	A single determination.
UTD3UE	A single determination.
UWBMVC	A single determination.
VEMV6C	A single determination.
WK8BDF	A single determination.
WQBGNC	A single determination.
XA7AAA	A single determination.
XC8AA8	A single determination.
XL2F8E	A single determination.
XTF8T7	A single determination.
XWGAH8	A single determination.
Y689P8	A single determination.
Y8VMDG	The mean of duplicate/several determinations.
YETEH6	A single determination.
YTERZ7	A single determination.
Z9PR8G	A single determination.
ZBUHCB	duplicate, but over the top of the curve

Response Summary for Item 3		Participants: 85
A single determination:	69	(81.2%)
The mean of duplicate/several determinations:	10	(8.5%)
Other:	6	(7.1%)

Methods of Analysis - Item 3

TABLE 3E - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
2A9FUZ	Immunoassay	✓		
	GC/MS	✓	✓	
2DWHAM	GC/MS		✓	
2JJHF2	Immunoassay	✓		
	GC/MS	✓	✓	
2XGFQD	Immunoassay	✓		
	LC/MS/MS		✓	✓
2Z3DTA	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
32ZWJG	Immunoassay	✓		
	GC/MS	✓	✓	
384XJC	Immunoassay	✓		
	LC/MS/MS		✓	✓
3PLWPA	LC/MS/MS	✓	✓	✓
48GQV6	LC/MS/MS	✓	✓	✓
48L4J2	Immunoassay	✓		
	LC/MS/MS		✓	✓
4BHXCW	Immunoassay	✓		
4D2WJY	Immunoassay	✓		
	GC/MS		✓	
4GLYB6	LC-HRMS/MS	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
4TY2W3	LC/MS/MS	✓		
	GC/MS		✓	✓
4XXDWA	Immunoassay	✓		
	LC/MS/MS		✓	✓
6ED9K2	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	✓
6QPB7Y	LC/MS/MS	✓	✓	
6ZE2TR	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
	LC-MS-QTOF	✓		

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
73XK23	Immunoassay	✓		
	GC/MS	✓	✓	
	LC/MS		✓	
7DZVHQ	LC/MS	✓		
	HPLC/DAD	✓		✓
	LC/MS/MS			✓
7NV3EA	LC/MS	✓	✓	
7RX64B	Immunoassay	✓		
	GC/MS		✓	
7W827Z	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
7WPAVU	Immunoassay	✓		
	LC/MS/MS		✓	✓
83E82W	LC/MS/MS		✓	
	Immunoassay	✓		
8E3B78	LC/MS/MS	✓	✓	✓
8X2ATA	GC/MS		✓	
8YE38N	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
	LC-TOFMS	✓	✓	
94Y64T	Immunoassay	✓		
	GC/MS		✓	
	GC/MS with BSTFA		✓	
99WWZW	Immunoassay	✓		
	LC/MS/MS		✓	✓
9LYHDU	LC/MS/MS	✓		
	LC/MS		✓	✓
	LC/HRMS		✓	
9QXMGZ	Immunoassay	✓		
	LC-QTOF	✓	✓	
	LC/MS/MS		✓	✓
9T3E8R	LC-HRMS/MS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	
AAN8KX	Immunoassay	✓		
	LC/MS/MS	✓	✓	✓
AD6HL9	GC/MS	✓	✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
AH24FW	Immunoassay	✓		
	LC/MS/MS		✓	✓
AMTEPV	Immunoassay	✓		
	LC/MS/MS		✓	✓
ATKL94	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
AUF4A6	Immunoassay	✓		
	LC/MS/MS		✓	✓
AV6JBZ	Immunoassay	✓		
	GC/MS	✓	✓	
AX96AX	GC/MS		✓	
	LC/MS/MS		✓	
	LC-HRMS/MS	✓		
B8Z4FX	Immunoassay	✓		
	LC/MS/MS		✓	
BG3H2V	Immunoassay	✓		
	LC/MS/QTOF	✓		
	GC/MS	✓	✓	
BRK67Q	LC/MS/MS	✓	✓	✓
	Immunoassay	✓		
C6NP8U	LC/MS/MS	✓		
	GC/MS		✓	✓
CHA3KP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS			✓
DFZA93	Immunoassay	✓		
DZNWQ6	Immunoassay	✓		
	LC/MS/MS		✓	✓
	GC/MS		✓	
EBYZ3T	LC-QTOF	✓		
	GC/MS		✓	
EJUN9X	Immunoassay	✓		
EYPBEP	Immunoassay	✓		
	LC/MS/MS		✓	✓
EZLLAR	Immunoassay	✓		
	LC-MS-QTOF	✓		
	GC/MS		✓	
FCP9XF	LC/MS/MS	✓	✓	✓

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
FNAJNU	LC/MS/MS	✓	✓	✓
G4F3ZR	LC/MS/MS	✓	✓	
GBEU4E	Immunoassay	✓		
	UPLC-QTOF MS	✓	✓	
	LC/MS/MS		✓	✓
GBZ8TR	LC-High resolution MS/MS	✓		
	GC/MS		✓	✓
	LC/MS		✓	✓
GMBXAU	LC/MS/MS	✓	✓	✓
	GC/MS	✓		
GNH4MU	GC/MS	✓		
	LC/MS/MS	✓	✓	
GV3BAT	Immunoassay	✓		
GX9PTT	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
	LC/QTOF-MS	✓		
HAVBCT	Immunoassay	✓		
HHQ8KP	LC/MS/MS	✓		
	GC/MS		✓	✓
HNC8RP	GC/MS		✓	
	LC MS QTOF		✓	
HPN7NJ	ELISA	✓		
	GC/MS	✓	✓	
HX9XMX	Immunoassay	✓		
	LC/MS/MS		✓	✓
JVBAFM	LC/MS/MS	✓		
	Immunoassay	✓		
JYTD4J	Immunoassay	✓		
	GC/MS	✓	✓	
K9V49R	Immunoassay	✓		
	LC/MS/MS		✓	✓
KBF2CN	Immunoassay	✓		
	LC/MS/MS		✓	✓
KCVE6R	Immunoassay	✓		
	LC/MS/MS		✓	✓
KCWY4N	Immunoassay	✓		

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
KFBVAP	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	
KQXJUR	Immunoassay	✓		
	LC/MS/MS		✓	✓
KQZDDX	Immunoassay	✓		
	GC/MS	✓	✓	
KZKK8G	LC-HRMS/MS	✓	✓	
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
L2C3MM	LC/MS/MS	✓	✓	
LCDNTL	Immunoassay	✓		
	LC/MS/MS	✓		
	GC/MS		✓	
LEFD8N	Immunoassay	✓		
	GC/MS	✓	✓	
LL2JQG	Immunoassay	✓		
	GC/MS	✓	✓	✓
M6VE6P	Immunoassay	✓		
M7FD9L	LC/MS/MS	✓	✓	
MDJ6PW	Immunoassay	✓		
	GC/MS	✓	✓	
NFFK3C	Immunoassay	✓		
	GC/MS	✓	✓	
NKERRF	LC/MS/MS	✓	✓	✓
NRZMTK	LC-HRMSMS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	
P6ZTCG	Immunoassay	✓		
	LC-QTOF MS		✓	
P96AXR	LC/MS/MS	✓	✓	
PUMLNU	LC/MS/MS	✓		
	LC/MS/MS		✓	
PXV4JF	LC/MS/MS	✓		
	GC/MS		✓	✓
Q7WJ9N	Immunoassay	✓		
	LC/MS/MS		✓	✓

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
QHJQ2H	Immunoassay	✓		
	LC/MS/MS		✓	✓
QVTNPJ	LC/MS/MS	✓	✓	
R3R9RE	Immunoassay	✓		
	GC/MS			
	LC/MS/MS		✓	✓
R776WF	Immunoassay	✓		
	LC/MS/MS		✓	✓
RBG2Y6	LC/MS/MS		✓	✓
	LC-QTOF-MS	✓		
	Immunoassay	✓		
RKZJ8H	Immunoassay	✓		
	GC/MS	✓	✓	
RZXJ9J	Immunoassay	✓		
	LC/MS/MS		✓	✓
T4R3JF	LC-High Resolution Tandem Mass Spectrometry	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	
TCB9H9	LC-HRMS/MS	✓		
	GC/MS		✓	✓
	LC/MS/MS		✓	✓
TDHL6F	Immunoassay	✓		
	LC/MS/MS		✓	✓
TG6ZTQ	Immunoassay	✓		
	GC/MS		✓	
TLBUML	Immunoassay	✓		
	GC/MS		✓	✓
TMTPBE	LC-HRMS/MS	✓		
	GC/MS		✓	✓
TTC34L	Immunoassay	✓		
	LC/MS/MS		✓	✓
TV2HHN	Immunoassay	✓		
	GC/MS		✓	
TXM4BC	LC QTOF	✓		
	LC/MS/MS		✓	✓
TYY2KM	GC/MS		✓	
U97X4J	Immunoassay	✓		
	LC/MS/MS		✓	✓

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
UECQXF	Immunoassay	✓		
	LC/MS/MS		✓	✓
UKXLVD	LC/MS/MS	✓		
	GC/MS		✓	✓
UNHCLG	LC/MS/MS	✓		
UTD3UE	Immunoassay	✓		
	GC/MS		✓	✓
UWBMVC	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
	GC/FID		✓	✓
V7VEG8	Immunoassay	✓		
	LC/MS/MS		✓	
VEMV6C	LC-HRMS/MS	✓		
	LC/MS/MS		✓	
	GC/MS			✓
VENQTN	Immunoassay	✓		
	GC/MS	✓	✓	
W7DN8N	Immunoassay	✓		
	GC/MS	✓	✓	
WK8BDF	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
WQBGNC	GC/MS	✓	✓	✓
	LC-HRMS/MS	✓		
XA7AAA	LC-HRMS/MS	✓	✓	
	GC/MS		✓	✓
	LC/MS		✓	
XC8AA8	LC/MS/MS	✓		
	GC/MS		✓	
XL2F8E	Immunoassay	✓		
	GC/MS	✓		
	LC/MS/MS		✓	✓
XNLEBB	Immunoassay	✓		
	GC/MS	✓	✓	
XTF8T7	LC/MS/MS	✓	✓	✓
XWGAH8	LC/MS/MS	✓	✓	
XXPKB6	LC Q TOF	✓	✓	

TABLE 3E: Methods of Analysis - Item 3

WebCode	Method	Screening	Confirmatory	Quantitation
XZXJLD	Immunoassay	✓		
	LC/QTOF-MS	✓		
	LC/MS/MS		✓	
	GC/MS		✓	
Y689P8	Immunoassay	✓		
	LC/MS/MS		✓	✓
Y8VMDG	LC/MS/MS	✓	✓	✓
YETEH6	LC/MS/MS	✓	✓	✓
YTERZ7	Immunoassay	✓		
	LC/MS/MS		✓	✓
YVYP33	GC/MS		✓	
YX7XE9	LC/MS/MS	✓		
	Immunoassay	✓		
Z9PR8G	GC-MSD /LS-MS-MS	✓	✓	
ZBUHCB	Immunoassay	✓		
	GC/MS		✓	
	LC/MS/MS		✓	✓
ZCJXD7	Immunoassay	✓		
ZM8KVM	GC/MS	✓	✓	

Response Summary for Item 3 - Methods of Analysis **Participants: 138**

	Screening	Confirmatory	Quantitation
Immunoassay:	85	0	0
GC/MS:	24	63	19
LC/MS:	2	5	2
LC/MS/MS:	35	74	54
Other:	27	12	2

Additional Comments for Item 3

TABLE 3F

WebCode	Item Comments
2A9FUZ	Nalorphine used as internal standard in Opiate confirmation. Promazine used as internal standard in Drug Screen.
2JJHF2	The internal standard used for the drug screen procedure was promazine. The internal standard used for the opiate confirmation procedure was nalorphine.
2Z3DTA	Morphine: Cut off 50 ng/ml in blood by LC/MS/MS 6monoacetyl morphine: Cut off 25 ng/ml in blood by LC/MS/MS
32ZWJG	Promazine used as internal standard during GC-MS drug screen. Nalorphine used as internal standard during GC-MS opiate confirmation.
3PLWPA	Analyst discretion- Oxymorphone was marked pending on the screen. 6-MAM quantitative value was >Linear Range 25.00ng/mL on first extraction. Dilution was performed for reported value. Morphine quantitative value was >Linear Range 500.00ng/mL on first extraction. Dilution was performed for reported value. 6-MAM LOQ 0.5 ng/mL; ISTD 6-MAM-D6 Morphine LOQ 5 ng/mL; ISTD Morphine-D6
48GQV6	The expanded uncertainty value was calculated at the 99.7 percent confidence level. The value for morphine was outside our quantitative range so the uncertainty was not calculated. The directions specified "The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly." Topiramate was also confirmed in this sample.
48L4J2	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Opiates confirmation/quantitation panel includes 6-monoacetylmorphine (6-MAM), codeine (COD), fentanyl (FENT), hydrocodone (HDC), hydromorphone (HDM), methadone (MDN), morphine (MOR), oxycodone (OXYC), and oxymorphone (OXYM) using 6-MAM-D3, COD-D6, FENT-D5, HDC-D6, HDM-D3, MDN-D3, MOR-D3, OXYC-D3, and OXYM-D3 as internal standards, respectively. LOD for 6-MAM and FENT is 0.5 ng/mL; LOQ is 1 ng/mL. LOD and LOQ for the remaining target drugs is 5 ng/mL and 10 ng/mL, respectively. Following a positive zolpidem screen, confirmation/quantitation of zolpidem (ZOLP) is performed using ZOLP-D7 as an internal standard. LOD and LOQ for zolpidem is 5 ng/mL and 10 ng/mL, respectively. Confirmation/quantitation results below 5 ng/mL are reported as none detected. Laboratory does not routinely analyze postmortem samples.
4D2WJY	Resubmission of Predistribution results. Originally submitted on 4/5/22.
4GLYB6	Mepivacaine used for internal standard in screen and for 6-MAM in confirmation. Nalorphine used as internal standard for confirmation testing of morphine. Limit of report for morphine is 3.1 μg/L.
4TY2W3	Morphine concentration was above the highest calibrator(400ng/ml) and was not reported per our protocol.
6ED9K2	Morphine level is above our current calibration range.
6QPB7Y	Morphine/Morphine-D6, LLOQ 6ng/mL, working range 6-300ng/mL ; 6-MAM/6-MAM-D6, LLOQ 0.2ng/mL, working range 0.2-10ng/mL. Results were above the ULOQ.
6ZE2TR	Limit of detection on confirmatory analysis for sertraline: 12.5 ng/mL. Sample diluted 1:5 for determination of morphine concentration
73XK23	Delta-9 THC and Delta-9 THC-COOH not detected/confirmed.
7DZVHQ	LC/MS above refers to LC-QTOF-MS for screening. Internal standard for mophine was D3-morphine. Internal standard for zolpidem was D6-zolpidem

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
7NV3EA	ESTAZOLAM WAS USED AS INTERNAL STANDARD
7W827Z	Morphine ULOQ is 400ng/mL
7WPAVU	Immunoassay: Opiates - Target: Morphine, cutoff: 10ng/mL; Opioids - Target: Oxycodone, cutoff: 10ng/mL; Zolpidem cutoff: 10ng/mL. LC/MS/MS: Analyte (cutoff) [IS] - Alprazolam (10 ng/ml) [Alprazolam-d5], Aminoclonazepam (5 ng/ml) [Aminoclonazepam-d4], Aminoflunitrazepam (5 ng/ml) [Aminoflunitrazepam-d7], Bromazepam (5 ng/ml) [Bromazepam-d4], Buspirone (5 ng/ml) [Buspirone-d8], Chlordiazepoxide (20 ng/ml) [Chlordiazepoxide-d5], Clobazam (20 ng/ml) [Estazolam-d5], Clonazepam (5 ng/ml) [Clonazepam-d4], Clonazolam (10 ng/ml) [Clonazepam-d4], Delorazepam (10 ng/ml) [Delorazepam-d4], Demoxepam (20 ng/ml) [Demoxepam-d5], Desaklyflurazepam (5 ng/ml) [Desalkylflurazepam-d4], Deschloroetizolam (5 ng/ml) [Deschloroetizolam-d5], Desmethylflunitrazepam (5 ng/ml) Desmethylflunitrazepam-d4], Diazepam (20 ng/ml) [Diazepam-d5], Diclazepam (5 ng/ml) [Diclazepam-d4], Diphenhydramine (20 ng/ml) [Diphenhydramine-d3], Doxylamine (20 ng/ml) [Doxylamine-d5], Estazolam (10 ng/ml) [Estazolam-d5], Etizolam (5 ng/ml) [Etizolam-d3], Flualprazolam (5 ng/ml) [Triazolam-d4], Flubromazepam (10 ng/ml) [Nordiazepam-d5], Flubromazolam (10 ng/ml) [Triazolam-d4], Flunitrazepam (5 ng/ml) [Flunitrazepam-d7], Flurazepam (5 ng/ml) [Flurazepam-d4], Hydroxyalprazolam (10 ng/ml) [Hydroxyalprazolam-d5], Hydroxyetizolam (5 ng/ml) [Bromazepam-d4], Hydroxymidazolam (10 ng/ml) [Hydroxymidazolam-d4], Hydroxyphenazepam (20 ng/ml) [Oxazepam-d5], Hydroxytriazolam (10 ng/ml) [Clonazepam-d4], Hydroxyzine (20 ng/ml) [Hydroxyzine-d8], Lorazepam (10 ng/ml) [Lorazepam-d4], Midazolam (10 ng/ml) [Midazolam-d4], Nitrazepam (20 ng/ml) [Nordiazepam-d5], Nordiazepam (20 ng/ml) [Nordiazepam-d5], Oxazepam (20 ng/ml) [Oxazepam-d5], Phenazepam (20 ng/ml) [Triazolam-d4], Temazepam (20 ng/ml) [Temazepam-d5], Triazolam (5 ng/ml) [Triazolam-d4], Zaleplon (10 ng/ml) [Zaleplon-d4], Zolpidem (10 ng/ml) [Zolpidem-d6], Zopiclone (10 ng/ml) [Zopiclone-d4].
8YE38N	From [Table 3B: Confirmatory Results] Reported Concentration - "Acetylmorphine - no uncertainty, therefore reported as approximate"
94Y64T	bstfa lot [Serial Number] used phenyltoloxamine lot [Serial Number], heptabarbital lot [Serial Number]
9QXMGZ	6-MAM LOQ = 5 ng/mL, morphine LOQ = 10 ng/mL. 6-MAM-D3 and morphine-D3 for internal standards.
9T3E8R	Internal standards - mepivacaine & nalorphine morphine limit of report is 3.1 ng/mL
AAN8KX	The upper limit of quantitation for morphine is 500 ng/mL. The morphine concentration for this sample was above that, therefore it was reported out as greater than 500 ng/mL.
AMTEPV	Note: This sample was submitted as an overdose. It was ran at full volume and was significantly over LOQ. Ran with a dilution factor of 1:10. Data concentration from instrument was multiplied by dilution factor to give reported value. Instrument value was 111.1ng/mL for morphine and 3.36ng/mL for 6 monoacetylmorphine. A basic drug screen was also performed on this sample using GC/MS and GC/FID. Basic drug screen did not detect any drugs.
AV6JBZ	Nalorphine was used as ISTD for opiate confirmation testing. Promazine was used as ISTD for blood drug screen.
AX96AX	Internal standards-Mephobarbital, mepivacaine, BZE-d8 butyl, nalorphine butyl, gabapentin-d4, olanzapine-d8, bupropion-d9, diazepam-d5, clonazepam-d4. Limit of detection for Morphine 3.1 mcg/L. Calibration range 50μg/L-1600μg/L

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
B8Z4FX	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. Opiates confirmation/quantitation panel includes 6-monoacetylmorphine (6-MAM), codeine (COD), fentanyl (FENT), hydrocodone (HDC), hydromorphone (HDM), methadone (MDN), morphine (MOR), oxycodone (OXYC), and oxymorphone (OXYM) using 6-MAM-D3, COD-D6, FENT-D5, HDC-D6, HDM-D3, MDN-D3, MOR-D3, OXYC-D3, and OXYM-D3 as internal standards, respectively. LOD for 6-MAM and FENT is 0.5 ng/mL; LOQ is 1 ng/mL. LOD and LOQ for the remaining target drugs is 5 ng/mL and 10 ng/mL, respectively. Laboratory does not routinely analyze postmortem samples (outside scope of testing).
BG3H2V	Internal standards- Mepivacaine, Nalorphine-diTMS.
C6NP8U	Morphine detected by LC-MS/MS and confirmed by GC/MS. Drug report would say drug level is above the established calibration range. Calibration range is 20-400ng/mL. 6-Monoacetylmorphine detected by LC-MS/MS and confirmed by GC/MS.
CHA3KP	Acetaminophen confirmed.
DZNWQ6	Confirmatory ISTD GC/MS: [Initials] and [Initials] Qualitative opiates confirmatory test ISTD LC/MS/MS: morphine-d6, codeine-d6, hydrocodone-d6 Quant ISTD LC/MS/MS: morphine-d6. 7 point linear curve with range from 10 to 1000 ng/mL. No dropped points. mean of duplicates is truncated, UOM is rounded
EJUN9X	Lab currently does not have confirmation method for opiates and zolpidem
EZLLAR	Internal Standard: Mepivacaine Indications of Acetaminophen, Cotinine, Naproxen, Sertraline
FCP9XF	trace amount of zolpidem detected
FNAJNU	6-MAM LOQ 0.5ng/mL; ISTD 6-MAM-D6 Morphine LOQ 5ng/mL; ISTD Morphine-D6 First extraction for 6-MAM quantitative value was >Linear Range 25.00ng/mL; dilution was performed for reported value. First extraction for Morphine quantitative value was >Linear Range 500.00ng/mL; dilution was performed for reported value
GBEU4E	Screening: Immunoassay and UPLC-QTOF MS (Waters). For UPLC-QTOF MS - Internal Standards: Cyclobarbitone, Prazepam & D3-Methadone 6-Monoacetylmorphine and Morphine confirmation & Quantitaion: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Multiple Reaction Monitoring (MRM) mode. Internal Standard: D3- Morphine LOD for Morphine and 6-Monoacetylmorphine: 2 ng/mL
GBZ8TR	Morphine determination was a result of the extraction of a diluted sample. 500 µL of sample were diluted with 4.5 mL of deionized water to produce a 1:10 dilution. The quantitative result for morphine was 119.23 µg/L. The raw data amount above reflects the calculated result after correcting for dilution. Mepivacaine and nalorphine were used as internal standards. Zolpidem and sertraline were detected in the screen but not reported due to being below our LOR in confirmatory testing. LOR = 25 µg/L THC was detected in the screen but not reported due to being negative in confirmatory testing. LOR = 1 ng/mL
GNH4MU	Topirmate (>10ng/ml) and traces of Zolpidem (<10ng/ml) were also detected in the sample.
GV3BAT	Opiates and zolpidem hit presumptive positive, however our laboratory is not able to confirm or quantitate these classes/types of drugs. We are only able to quantitate and/or confirm the following: amphetamine, diphenhydramine, ephedrine/psuedoephedrine, ketamine, MDA, MDMA, mescaline, methamphetamine, phentermine, psilocin, LSD, THC, Carboxy-THC, Hydroxy-THC.
HAVBCT	The screening cutoff for Opiates is 20ng/mL. Analysts are not certified to perform confirmation testing on Opiates. Cases that are positive for Opiates are sent to a reference laboratory.
HHQ8KP	Morphine was above our calibration range, so it would be reported as presence only with a statement that the value was above the calibration range.
HPN7NJ	Promazine- Internal Standard for Drug Screen Nalorphine- Internal Standard for Opiate Procedure

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
JYTD4J	The internal reference materials used were Phenyltoloxamine for the base fraction and Hexobarbital for the acid fraction. Possible Zolpidem noted in the base fraction. Possible Topiramate noted in the acid fraction. Possible Caffeine noted in both the base and acid fractions.
KFBVAP	Diazepam D5 is used as Internal standard
KQXJUR	Item 3 required a 1:10 dilution based on the ULOQ.
L2C3MM	Confirmation cutoff for Topiramate, 6MAM, Morphine was 5ng/mL
LCDNTL	Immunoassay was negative, LC/MS/MS Screen positive for 6-mam, and morphine GC/MS confirmed 6-MAM and morphine. Morphine is reported as presence only because it is above our calibration curve. Report would read: Drug content of blood: Morphine* *Drug level is above the established calibration range.
LEFD8N	Nalorphine used as internal standard for opiate confirmation. Promazine used as internal standard for blood drug screen. Immunoassay used was ELISA.
LL2JQG	Internal standard for the codeine and morphine assay were Codeine-D3 and Morphine-D3. The internal standard for 6MAM was prazepam.
M6VE6P	The [Laboratory] does not yet have confirmatory methods for these compounds so confirmation testing was not performed.
NFFK3C	Phenyltoloxamine and hexobarbital internal reference materials utilized. Possible trace amount of zolpidem detected in GC/MS screen; however the Zolpidem ELISA screen result was negative but somewhat elevated. Additionally, Sertraline was detected in the GC/MS screen but did not meet the confirmation requirements.
NKERRF	ISTD (Method LLOQ - ULOQ): Morphine-D6 (6.0 - 300.0 ng/mL), 6-MAM-D6 (0.2 - 10.0 ng/mL). Results were reported as greater than the highest calibrator value. [Initials] 06/22/2022
NRZMTK	Morphine LC-HRMSMS internal standard - mepivacaine GCMS, internal standard - nalorphine, LOD-3.1 ng/mL LCMSMS, internal standard -mepivacaine 6-monoacetylmorpine (6-MAM) LC-HRMSMS, internal standard - mepivacaine LCMSMS, internal standard -mepivacaine
PUMLNU	morphine was detected above our highest calibrator of 300 ng/mL
PXV4JF	6-MAM LC/MS/MS screen confirmation GC/MS Morphine LC/MS/MS screen confirmation GC/MS, presence only due to being above range. Report would read: Drug content of blood: Morphine* *Drug level is above the established calibration range.
QVTNPJ	Extract 1 and Extract 2 for 6-MAM quantitative value was >Linear Range 25.00 ng/ml; dilutions were performed for confirmation and reported value. Lowest of the two dilution determinations is the reported value. Extract 1 and Extract 2 for Morphine quantitative value was >Linear Range 500ng/ml; dilution was performed for reported value. 6-MAM-d6 ISTD - LOD 0.5ng/ml Morphine-d6 ISTD - LOD 5ng/ml
R3R9RE	The Basic extraction analyzed on the GC/MS is performed on all samples. While this testing was performed on this sample, no drugs were confirmed nor quantified by this method.
R776WF	ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine, and zolpidem. The laboratory does not routinely analyze postmortem samples (outside scope of testing). Opiate confirmation panel includes 6-MAM, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. The following internal standards are used: 6-MAM D-3, codeine D-6, fentanyl D-5, hydrocodone D-6, hydromorphone D-3, methadone D-3, morphine D-3, oxycodone D-3, and oxymorphone D-3. 6-MAM and fentanyl have an LOD of 0.5 ng/mL and an LOQ of 1 ng/mL. The remaining analytes have an LOD of 5 ng/mL and an LOQ of 10 ng/mL.
RBG2Y6	Only qualitative analysis of 6-MAM is provided by this laboratory.

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
RKZJ8H	Promazine used for Internal Standard for Butyl Acetate. Nalorphine used for Internal Standard for Opiate Confirmation
RZXJ9J	Analysis by high performance liquid chromatography/tandem mass spectrometry in whole blood for: Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL): Fentanyl 0.5 – 50, Norfentanyl 0.5 – 50, Codeine 5.0 – 500, Hydrocodone 5.0 – 500, Morphine 5.0 – 500, Hydromorphone 5.0 – 500, Oxycodone 5.0 – 500, Oxymorphone 5.0 – 500, Methadone 20 – 2000, EDDP 20 – 2000, Methamphetamine 20 – 2000, Amphetamine 20 – 2000, Cocaine 20 – 2000, Benzoylecgonine 20 – 2000. Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses. Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL) Assay Cutoff* (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 1, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10. * Results within 20% of these concentrations are also reported as preliminarily positive.
T4R3JF	Internal standard used: Mepivacaine and nalorphine * The following analytes were also detected above the limit of detection but below the limit of report: zolpidem and sertraline.
TCB9H9	Internal Standards: Mepivacaine, Nalorphine, Morphine was extracted using a 1:10 dilution. The above raw data value is the calculated result after factoring in the dilution. Zolpidem and Sertraline were detected in the screen and confirmatory method but below our limit of report of 25 µg/L.
TMTPBE	internal standards: mepivacaine, nalorphine
UECQXF	Analysis by immunoassay screening in whole blood for: Assay Cutoff* (ng/mL): Meth /Amphetamines 20, Barbiturates 50, Benzodiazepines 10, Buprenorphine 1, Cannabinoids 10, Benzoylecgonine 50, Dextromethorphan 5, Fentanyl 1, Meprobamate 100, Methadone 10, Opiates 10, Opioids 10, Phencyclidine 5, TCA 25, Tramadol 5, Zolpidem 10. * Results within 20% of these concentrations are also reported as preliminarily positive. Opiates, Opioids, and Stimulants confirmation panel: Analyte Quantitative Range (ng/mL): Fentanyl 0.5 – 50, Norfentanyl 0.5 – 50, Codeine 5.0 – 500, Hydrocodone 5.0 – 500, Morphine 5.0 – 500, Hydromorphone 5.0 – 500, Oxycodone 5.0 – 500, Oxymorphone 5.0 – 500, Methadone 20 – 2000, EDDP 20 – 2000, Methamphetamine 20 – 2000, Amphetamine 20 – 2000, Cocaine 20 – 2000, Benzoylecgonine 20 – 2000. Measurement uncertainty is reported at a 95.45% level of confidence for all quantitative blood drug analyses.
UKXLVD	Morphine had a concentration greater than the highest calibrator. Reported as presence only.
VEMV6C	LC-HRMS/MS Screening Internal Standard: mepivacaine & mephobarbital. LC/MS/MS Testing Internal Standard: mepivacaine. GC/MS Testing (morphine) Internal Standard: nalorphine & mepivacaine. Limit of Reporting for analytes reported: morphine = 3.1 µg/L
WQBGNC	Morphine Internal Standard for quantification: Nalorphine
XC8AA8	Morphine level above ULOQ (400 ng/mL). Zolpidem not reportable based on confirmation test GC/MS % match
XNLEBB	Promazine used as an internal standard for GC/MS screening. Nalorphine used as an internal standard for GC/MS opiate confirmation.
XTF8T7	Results which are greater than its working calibration range are reported out as being greater than the concentration of its highest calibrator. - [Initials] 6/8/2022
XWGAH8	Cannabinoid response on the screen was suspected as an interfering peak. A confirmation analysis was run to confirm the results. Uncertainty for morphine was calculated using 1000ng/mL as that is the highest value included in the uncertainty budget and calibration curve. Limit of confirmation for zolpidem was 5ng/mL.

TABLE 3F: Additional Comments for Item 3

WebCode	Item Comments
YETEH6	Morphine LLOQ was 6 ng/mL with a working range was 6 - 300 ng/mL. The internal standard used was morphine-D6. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration. 6-MAM LLOQ was 0.2 ng/mL with a working range of 0.2 - 10 ng/mL. The internal standard used was 6-MAM-D6. The extraction method used was protein precipitation with acetonitrile followed by size exclusion filtration.
YPEHP4	The specific methodology utilized for both the screening and confirmatory analysis was HRMS by LC-QTOF.
YTERZ7	Laboratory does not routinely analyze postmortem samples (outside scope of testing). ELISA screening panel includes: amphetamine, benzodiazepines, buprenorphine, cannabinoids, carisoprodol, cocaine and metabolites, fentanyl, methadone, methamphetamine, opiates, oxycodone/oxymorphone, phencyclidine and zolpidem. Opiate confirmation panel includes 6-monoacetylmorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. 6-MAM and fentanyl have a LOD of 0.5ng/ml and a LOQ of 1ng/ml. The remaining analytes have a LOD of 5ng/ml and a LOQ of 10ng/ml. 6-monoacetylmorphine-D3, codeine-D6, fentanyl-D5, hydrocodone-D6, hydromorphone-D3, methadone-D3, morphine-D3, oxycodone-D3, and oxymorphone-D3 were used as internal standards.
YVYP33	Internal standard: flurazepam LOD morphine 200 ng / mL LOD 6 monoacetylmorphine 75 ng / mL
ZBUHCB	Confirmatory ISTD GC/MS: NPA and SKF Qualitative opiates confirmatory test ISTD LC/MS/MS: morphine-d6, codeine-d6, hydrocodone-d6 Quant ISTD LC/MS/MS: morphine-d6. 7 point linear curve with range from 10 to 1000 ng/mL. No dropped points. mean of duplicates is truncated, UOM is rounded
ZCJXD7	Cutoff: OPIATES: >300 ng/mL

Additional Test Comments

TABLE 4

WebCode	Additional Comments
4D2WJY	Resubmission of results from [Predistribution Results].
4GLYB6	Various low level analytes were detected in the screen for all items; most quanted below or near limit of report, except for lamotrigine. Not reported: 1A: zolpidem, diphenhydramine, citalopram 1B: EDDP (metabolite of methadone), trazodone, THC-OH (metabolite of THC) 1C: zolpidem, sertraline
9QXMGZ	Using LC-QTOF as a screening/confirmatory tool, I observed multiple prescription medications in these items, such as citalopram, desmethylcitalopram, zolpidem, and topiramate, that were below our LOQ and not pursued.
AMTEPV	ELISA - 05/10/22. LC/MS/MS opiate 06/15/22. LC/MS/MS thc 06/15/22. GC/MS GC/FID basic 06/21/22
GBEU4E	Item 1: Diphenylhydramine, Naproxen, Paracetamol, Salicylic Acid, Zolpiderm, Caffeine and Theophylline also detected. They could be artifacts of production and they are not part of controlled substances. Therefore, these drugs were not listed in the result sheets. Item 3: Naproxen, Paracetamol, Salicylic Acid, Caffeine and Theophylline also detected. They could be artifacts of production and they are not part of controlled substances. Therefore, these drugs were not listed in the result sheets.
KCWY4N	Only screening testing is performed.
L2C3MM	Item logged into ILIMS on 4/29/2022 I took custody of the item on 5/10/2022
WQBGNC	Listing the section code of what drugs should be reported to CTS on the scenario page would be helpful instead of just on the website scenario page. Or a list of all drugs in every sample that should not be pursued, not just the one mentioned in Item 2 (Item 1: possible zolpidem, diphenhydramine, citalopram; Item 2: possible lamotrigine, trazodone; Item 3: possible zolpidem). Some labs are able to find more than what CTS is looking for and makes submitting data confusing.
XNLEBB	Reported drugs limited to [Laboratory] Toxicology drug panel.
Y8VMDG	In the quantitative analyses, more determinations were made than reported in the six fields available for each analyte.
YPEHP4	Unsure how the fortified testing blank blood was screened (drug compounds) for, and at what levels.

-End of Report-
(Appendix may follow)

Collaborative Testing Services ~ Forensic Testing Program

Test No. 22-5661: Blood Drug Analysis

DATA MUST BE SUBMITTED BY **June 27, 2022, 11:59 p.m.** TO BE INCLUDED IN THE REPORT

Participant Code: U1234K WebCode: MPGBGA

Scenario:

Investigators have submitted two vials of blood from each of three separate cases for your analysis. Using your laboratory's procedures, analyze each item and report the presence of any drugs and/or metabolites.

Case 1: A 22 year-old female was pulled for running a red light. A Drug Recognition Expert arrived and noticed that the individual had dilated pupils and seemed disorientated. The result of a breath alcohol test was 0.00%. Blood was collected 90 minutes later.

Case 2: A 39 year-old male called 911 complaining of hallucinations and trouble breathing. He was rushed to the hospital and blood samples were collected.

Case 3: A 45 year-old male was found unresponsive by a nurse at a rehabilitation facility. The male battling drug abuse when he was admitted to the rehab facility. Blood samples were collected at the autopsy.

-Verification testing showed a low level of Trazodone in Item 2, please disregard this as well as artifacts of production, methanol and acetonitrile.

***PLEASE NOTE** The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly.*

Items Submitted (Sample Pack BDRG):

Item 1: Two vials of blood from Case 1
Item 2: Two vials of blood from Case 2
Item 3: Two vials of blood from Case 3

Screening Results for Item 1:

1-1). Please indicate the screening results for Item 1.

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 1:

1-2). Was confirmatory analysis performed for this item? ○ Yes ○ No

1-3). What drugs/metabolites were detected in Item 1? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

1-4). If quantitative analysis was performed, are the reported concentrations above

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

1-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

1-6). Additional Comments for Item 1

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

Screening Results for Item 2:

2-1). Please indicate the screening results for Item 2.

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 2:

2-2). Was confirmatory analysis performed for this item? ○ Yes ○ No

2-3). What drugs/metabolites were detected in Item 2? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

2-4). If quantitative analysis was performed, are the reported concentrations above

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

2-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

2-6). Additional Comments for Item 2

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

Screening Results for Item 3:

3-1). Please indicate the screening results for Item 3.

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

Confirmatory Results for Item 3:

3-2). Was confirmatory analysis performed for this item? ○ Yes ○ No

3-3). What drugs/metabolites were detected in Item 3? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.

☐ No drugs/metabolites detected utilizing confirmatory methods.

Analyte	Qualitative Only?	Reported Concentration	Uncertainty	Units
	☐			( )

Date(s) Analysis Performed on Analyte:

Raw Data (ng/mL):

3-4). If quantitative analysis was performed, are the reported concentrations above

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

3-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.

Please list each method only once.

Method Used	Screening	Confirmatory	Quantitation
	☐	☐	☐

3-6). Additional Comments for Item 3

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

Date Samples Received:

Additional Comments on Test

Please note: *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

RELEASE OF DATA TO ACCREDITATION BODIES

The Accreditation Release is accessed by pressing the "Continue to Final Submission" button online and can be completed at any time prior to submission to CTS.

CTS submits external proficiency test data directly to ASCLD/LAB, ANAB, and/or A2LA. Please select one of the following statements to ensure your data is handled appropriately.

○ This participant's data is intended for submission to ASCLD/LAB, ANAB, and/or A2LA. (Accreditation Release section below must be completed.)
○ This participant's data is **not** intended for submission to ASCLD/LAB, ANAB, and/or A2LA.

Have the laboratory's designated individual complete the following steps
only if your laboratory is accredited in this testing/calibration discipline
by one or more of the following Accreditation Bodies.

Step 1: Provide the applicable Accreditation Certificate Number(s) for your laboratory

ANAB Certificate No.
(Include ASCLD/LAB Certificate here)

A2LA Certificate No.

Step 2: Complete the Laboratory Identifying Information in its entirety

Authorized Contact Person and Title

Laboratory Name

Location (City/State)